![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
CV Kol pour Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Statistiques d'influence
Concept | World rank |
---|---|
5q23q31 | #1 |
desr probands siblings | #1 |
higher pdi | #1 |
bpd anx relatives | #1 |
highiq adults | #1 |
exposure clinical features | #1 |
psychiatric comorbidity md | #1 |
adult adhd differences | #1 |
expected growth children | #1 |
rs2272080 | #1 |
subjects lateonset adhd | #1 |
emotional symptoms adhd | #1 |
disorder schizotaxia | #1 |
rs1076560t | #1 |
subthreshold pediatric | #1 |
adhd female individuals | #1 |
cbclbp profile | #1 |
switches bipolar disorder | #1 |
cacng2 gene | #1 |
adhd educational deficits | #1 |
anxiety disorders siblings | #1 |
adhd neuropsychological functioning | #1 |
effects lisdexamfetamine dimesylate | #1 |
robust familiality | #1 |
children disorder | #1 |
notch4 polymorphisms | #1 |
18 items impairment | #1 |
bmi ldx | #1 |
psychiatric comorbidities adhd | #1 |
adhd baseline assessment | #1 |
african children adhd | #1 |
d10s195 | #1 |
selfreport adhd | #1 |
selfreport adhd symptoms | #1 |
families adhd | #1 |
genes association studies | #1 |
nonreferred adults | #1 |
medications adult adhd | #1 |
asds clinical scales | #1 |
differences medications | #1 |
12allele | #1 |
risk comt gene | #1 |
adhd comorbid odd | #1 |
adhd depressed children | #1 |
adhd gene | #1 |
alcohol dependence relatives | #1 |
efs girls | #1 |
studies depressed children | #1 |
snps drd4 gene | #1 |
putamen volume alterations | #1 |
adhd sex | #1 |
5‐generation | #1 |
intelligence additive effects | #1 |
pharmacogenetics predictors | #1 |
adhd adhdtd | #1 |
disorders comorbid mania | #1 |
subthreshold adhd subjects | #1 |
offspring behavioral disinhibition | #1 |
adhd learning | #1 |
adhd african children | #1 |
parents behavioral disinhibition | #1 |
adhd adult disorder | #1 |
memory adults | #1 |
rf025 | #1 |
adhd oxidative stress | #1 |
adhd maoa | #1 |
opd add opd | #1 |
quantitative phenotype snp | #1 |
autistic traits presence | #1 |
treatment moderated | #1 |
innovative sms intervention | #1 |
adhdfamilies | #1 |
variants aggressive behavior | #1 |
sob sob association | #1 |
diagnostic continuity | #1 |
adolescent patients adhd | #1 |
distal genomic region | #1 |
parental sud sud | #1 |
metaanalysis controlled study | #1 |
subjects adhd | #1 |
drd2 disrupts | #1 |
adhddbds adhd | #1 |
rorb bipolar disorder | #1 |
nonmental diseases | #1 |
rs1040399 | #1 |
hyperactivity cognition | #1 |
pain tolerance oih | #1 |
adhd income loss | #1 |
adhd single nucleotide | #1 |
adults stimulant sizes | #1 |
pain tolerance fm | #1 |
referred juveniles | #1 |
schizophrenia families smoking | #1 |
etiology adhd | #1 |
increased adhd symptoms | #1 |
adhd probands relatives | #1 |
linkage wave | #1 |
age stimulant treatment | #1 |
syp female adhd | #1 |
bpi sza | #1 |
adhd seconddegree relatives | #1 |
schizotaxia schizophrenia | #1 |
adhd fam | #1 |
time reproduction children | #1 |
risk opioid dependence | #1 |
onset attention | #1 |
siblings adhd children | #1 |
clinical response orosmph | #1 |
relatives conduct disorder | #1 |
female adhd | #1 |
benefit‐risk ratio | #1 |
lifetime impairment | #1 |
relatives control probands | #1 |
adhd pattern | #1 |
risk tourette spectrum | #1 |
adolescents concurrent adhd | #1 |
vntr haplotype | #1 |
controls rels | #1 |
new psychometric definition | #1 |
fiveminutespeechsample | #1 |
ctcata | #1 |
analysis adhd | #1 |
schizophrenia rs1076560t | #1 |
intellectual delays | #1 |
subtype adhd | #1 |
rate symptoms | #1 |
teenage parents individuals | #1 |
longitudinal outcome boys | #1 |
fbxo33 | #1 |
fhrscz | #1 |
adolescent sud | #1 |
adhd adverse impact | #1 |
neurocognitive traits | #1 |
rare protective allele | #1 |
criteria pdd | #1 |
antisocial disorders risk | #1 |
adhd aud | #1 |
new phenotype definition | #1 |
adhd gender | #1 |
school reliability | #1 |
rs2279805 | #1 |
neuropsychological functioning boys | #1 |
1236a | #1 |
actual motor performance | #1 |
weaknesses comorbidity | #1 |
c759t | #1 |
laboratory driving simulation | #1 |
vulnerability indicators schizophrenia | #1 |
genetic variation nr3c1 | #1 |
galantamine hydrogen bromide | #1 |
2455 controls | #1 |
relatives wm performance | #1 |
preschool comorbidity | #1 |
risk disorder | #1 |
lod213 | #1 |
adhdtd | #1 |
type attention | #1 |
comorbidity major depression | #1 |
p81e06 | #1 |
daily parent rating | #1 |
disorder | #1 |
disorganized symptom dimensions | #1 |
pdi impulsiveness | #1 |
sexdifferentiated effects traits | #1 |
rs41084 | #1 |
severe emotional dysregulation | #1 |
siblings adhd | #1 |
morbidity adhd | #1 |
nonmental diseases adhd | #1 |
downward extension adolescents | #1 |
disorder boys | #1 |
disorders parents | #1 |
repeat allele | #1 |
adhd bipolar studies | #1 |
tic persistence | #1 |
euphoria cardinal symptom | #1 |
adhd psychiatric conditions | #1 |
referred parents | #1 |
pdd criteria | #1 |
greater risk add | #1 |
offspring sud parents | #1 |
zmynd17 genes | #1 |
foursnp | #1 |
adhd prs gwas | #1 |
odd disruptive behavior | #1 |
learning disorders adhd | #1 |
nmu oral | #1 |
genetic heterogeneity adhd | #1 |
vcfs manic symptoms | #1 |
efds youth | #1 |
large controlled study | #1 |
comt odd | #1 |
adhd clinical characteristics | #1 |
rs9610449 | #1 |
parents md | #1 |
git1 association adhd | #1 |
adhd genetic correlation | #1 |
adhd aes | #1 |
patients adhdpi | #1 |
schizophrenia fhrs | #1 |
adhd oppositional | #1 |
rs7124601 | #1 |
persistence childhood adhd | #1 |
children ermph | #1 |
oros methylphenidate orosmph | #1 |
genomesignificance | #1 |
training raters | #1 |
iiv shr | #1 |
rs11568324 | #1 |
sud remittent adhd | #1 |
familial disorders adhd | #1 |
starsadhd | #1 |
shlod | #1 |
amses amrs | #1 |
adhd bipolar comorbidity | #1 |
comorbid problems | #1 |
20183 | #1 |
hyperactivity body | #1 |
asrs scores | #1 |
disorder relatives | #1 |
vivo neuroreceptor imaging | #1 |
aadhd hyperactivity biomarkers | #1 |
cgsq ermph | #1 |
valid diagnosis | #1 |
pdics | #1 |
adhd dsm | #1 |
suggestive linkage | #1 |
methylphenidate efficacy | #1 |
patients adhdct | #1 |
impulsive symptoms | #1 |
symptoms aggregation | #1 |
autism‐associated brain regions | #1 |
relatives diagnoses | #1 |
rs9627183 | #1 |
marijuana cocaine crack | #1 |
adhdoddcd | #1 |
disorder molecular | #1 |
timely renewal | #1 |
snpssnpsa | #1 |
norepinephrine transporter gene | #1 |
relatives children | #1 |
children idiopathic adhd | #1 |
ldx sizes adults | #1 |
parental sud adhd | #1 |
hartsough | #1 |
fhraff | #1 |
rs1633445 | #1 |
efds bpi disorder | #1 |
teachers cbt intervention | #1 |
“forgetfulness | #1 |
mania referred children | #1 |
motor problems adhd | #1 |
drug dependence relatives | #1 |
rf041 | #1 |
new diagnoses age | #1 |
77e08 | #1 |
palau scz | #1 |
rs552655 | #1 |
51 genes | #1 |
smoking wm microstructure | #1 |
stimulant treatment adults | #1 |
locus adhd | #1 |
studies adhd | #1 |
add opd | #1 |
mph controls | #1 |
specific psychopathology children | #1 |
exposure parental adhd | #1 |
slc9a9 adhd | #1 |
adhd disorders comorbidity | #1 |
normal sexual dimorphisms | #1 |
regions age | #1 |
affective symptoms children | #1 |
adolescent psychiatric cohort | #1 |
adhdtd siblings | #1 |
risk subsequent substance | #1 |
scqscore | #1 |
smoking cessation controls | #1 |
“schizotypes | #1 |
trait educational attainment | #1 |
35191 controls | #1 |
genetic frontal schizophrenia | #1 |
maoa impulsivity | #1 |
adverse impact adhd | #1 |
antisocial disorder relatives | #1 |
adhd increased | #1 |
neuropsychological impairments relatives | #1 |
subcortical structure volume | #1 |
relatives add probands | #1 |
genetic correlations schizophrenia | #1 |
cbcl clinical scales | #1 |
faraone | #1 |
proband youth bpdsud | #1 |
tass adhdrs | #1 |
shr iiv | #1 |
adhd findings | #1 |
ldx sizes | #1 |
adhd children ld | #1 |
adhd 5 | #1 |
adhd specific | #1 |
abstinence pharmacological treatment | #1 |
allele adhd | #1 |
connectivity executive control | #1 |
stimulant treatment youth | #1 |
bmi mts | #1 |
efds functional outcomes | #1 |
infas | #1 |
dopamine receptor polymorphism | #1 |
adhd candidate | #1 |
juvenile antisocial traits | #1 |
adhd proband | #1 |
patterns psychiatric comorbidity | #1 |
cohorts age groups | #1 |
lateandmoderate | #1 |
stimulant nmu | #1 |
dao gene schizophrenia | #1 |
quantitative analyses treatment | #1 |
p179e06 | #1 |
stimulant therapy youths | #1 |
motor preference asthma | #1 |
add parent report | #1 |
neurocognitive dysfunctions | #1 |
adhd concurrent sud | #1 |
adhd follow | #1 |
adhd conclusions | #1 |
hyperactivity cross | #1 |
copy organization | #1 |
relation stress exposure | #1 |
peer environmental factors | #1 |
rs550818 | #1 |
cortical thickness adhd | #1 |
21 circadian genes | #1 |
anxiety disorders findings | #1 |
adhd prs rtv | #1 |
conduct disorder probands | #1 |
inattention items | #1 |
a409p | #1 |
pdd mania | #1 |
mania pdd | #1 |
disorder report | #1 |
chronic emotional dysregulation | #1 |
ldx sizes children | #1 |
maternal inattention anxiety | #1 |
anxious depressed subscales | #1 |
key conceptual issues | #1 |
stimulants comorbidity | #1 |
nonreferred adult | #1 |
comorbid psychopathology childhood | #1 |
transient financial stress | #1 |
efficacy medications | #1 |
highiq youths | #1 |
parental adhd sud | #1 |
versus disability | #1 |
disorder familial | #1 |
adolescent attention | #1 |
adhd genetic receptors | #1 |
adhd maternal smoking | #1 |
adherence stimulant medication | #1 |
adhd snps | #1 |
asrs‐v11 | #1 |
hyperactivity disorder adults | #1 |
adoption studies | #1 |
aklt01 adhd | #1 |
female individuals adhd | #1 |
treating adhd | #1 |
stimulant treatment | #1 |
genes hallucinations states | #1 |
rs3027400 | #1 |
adhd girls adhd | #1 |
aklt01 tova api | #1 |
predictors persistence | #1 |
desipraminestimulants | #1 |
female humans inhibition | #1 |
growth outcomes adhd | #1 |
remission definition | #1 |
daonrg1 | #1 |
twin adoption studies | #1 |
psychopharmacologic | #1 |
hyperactivity female | #1 |
unipolar relatives bipolars | #1 |
growth deficits deficits | #1 |
relszs | #1 |
hyperactivity pdi | #1 |
mania manic features | #1 |
c2orf82 | #1 |
persistence adhd | #1 |
gsprss | #1 |
motorendophenotype | #1 |
adhd dbds | #1 |
adhdrs5 | #1 |
adhd sample | #1 |
proband youth bpd | #1 |
schizophrenia code | #1 |
p0499 | #1 |
adhd efds | #1 |
120 normal controls | #1 |
adult samples adhd | #1 |
major depression youth | #1 |
rtv adhd prs | #1 |
anachronisms | #1 |
male adolescents adhdct | #1 |
longacting medications | #1 |
impulsive subtype | #1 |
relatives drug dependence | #1 |
genetic studies sud | #1 |
adult adhd diagnosis | #1 |
bpi disorder sexes | #1 |
depression offspring variables | #1 |
rels persons | #1 |
stimulant treatment risk | #1 |
criteria☆ | #1 |
mania conduct disorder | #1 |
nonreferred samples | #1 |
probands comorbidity | #1 |
desr adhd | #1 |
adhd followup | #1 |
rs1051312 | #1 |
lifetime adhd | #1 |
asrs aisrs | #1 |
genes sexdifferentiated effects | #1 |
opd add | #1 |
adhd genetic variants | #1 |
emotional problems pmee | #1 |
desr siblings | #1 |
genetics adhd | #1 |
adhd druggable genes | #1 |
bipolars unipolar relatives | #1 |
pepple | #1 |
fm pain tolerance | #1 |
diagnostic efficiency analysis | #1 |
rs12843268 | #1 |
deletioncarrier | #1 |
symptoms versus impairment | #1 |
children teaes | #1 |
addh dmi | #1 |
productivity adhd | #1 |
adhd highiq youths | #1 |
n55374 | #1 |
adhd bpi disorder | #1 |
risk childhood onset | #1 |
masxr treatment | #1 |
metabias | #1 |
bpi disorder aspd | #1 |
diagnoses valid | #1 |
psychopathology implications | #1 |
boys social disability | #1 |
oih fm | #1 |
odd affective symptoms | #1 |
predictors adhd | #1 |
adhd | #1 |
pilot study adhd | #1 |
vcfsadhd adhd | #1 |
illness child comorbidity | #1 |
schizophrenia familybased studies | #1 |
bipolar disorder bpprss | #1 |
age 7repeat allele | #1 |
biomarkers adhd | #1 |
83097 | #1 |
229 families | #1 |
mgh studies | #1 |
adhd adoption studies | #1 |
hyperactivity comorbidity humans | #1 |
hamshere | #1 |
tass adhd | #1 |
autistic traits youth | #1 |
qms adult adhd | #1 |
2276tc | #1 |
psud adhd probands | #1 |
4‐year follow‐up study | #1 |
bipolar disorder switches | #1 |
paliperidone monotherapy | #1 |
relatives risk adhd | #1 |
sodasmph | #1 |
hyperactivity biomarkers aadhd | #1 |
attention deficit | #1 |
siblings antisocial families | #1 |
transmission adhd | #1 |
adhd diagnosed | #1 |
akt1 snp markers | #1 |
adhd children depression | #1 |
stress exposure connectivity | #1 |
nonreferred siblings probands | #1 |
p20e04 | #1 |
based association study | #1 |
features adhd | #1 |
htf9c | #1 |
nonaffected siblings children | #1 |
children general psychopathology | #1 |
p446e08 | #1 |
valid psychiatric disorder | #1 |
inattentive subtype adhd | #1 |
individuals attention | #1 |
rs2469770 | #1 |
african‐american pedigrees | #1 |
moderating effects patterns | #1 |
childhood adhd adulthood | #1 |
abnormalities adhd | #1 |
d10s2327 | #1 |
rs3792452 | #1 |
adhd studies | #1 |
dysfunctional gene | #1 |
increased expression methylation | #1 |
24 gm day | #1 |
persons rels | #1 |
adhd genetic exome | #1 |
ptsd familial disorders | #1 |
df39 | #1 |
ermph cgsq | #1 |
genetic studies adhd | #1 |
stimulant treatment profiles | #1 |
adhd community sample | #1 |
sud risk offspring | #1 |
medications adhd | #1 |
adolescent follow youth | #1 |
psychiatric risk vcfs | #1 |
referred samples | #1 |
adults neurodevelopmental disorder | #1 |
levels dysfunction | #1 |
compared adhd | #1 |
neuropsychologic function schizophrenia | #1 |
add antisocial disorders | #1 |
rs3916970 | #1 |
male individuals adhd | #1 |
adhd iiv | #1 |
hyperactive impulsive | #1 |
daorasd2 | #1 |
children pdag parents | #1 |
p97e−03 | #1 |
cbclbp | #1 |
or133 | #1 |
135–526 | #1 |
stimulants childhood | #1 |
deficit hyperactivity | #1 |
loci adhd | #1 |
bpi disorder relatives | #1 |
relbps | #1 |
99item cbs | #1 |
adults adhd subjects | #1 |
oih pain tolerance | #1 |
motor preference adhd | #1 |
pathways adhd | #1 |
familial vulnerability schizophrenia | #1 |
chi28783 | #1 |
fam mothers | #1 |
adhdrsivinv | #1 |
adhd neuropsychological | #1 |
dependence controls | #1 |
comorbidity conduct | #1 |
genetic correlation adhd | #1 |
placebo cgsq | #1 |
parental bpd | #1 |
2327ct | #1 |
idir aversion | #1 |
meaningful anxiety phenotype | #1 |
cadhd aadhd | #1 |
non‐random error | #1 |
hyperactivity child | #1 |
rs2498799 | #1 |
mr005 | #1 |
subcortical volumes adhd | #1 |
siblings adolescent | #1 |
cbcldesr | #1 |
adhd adult adhd | #1 |
endosomal genes asds | #1 |
p758e08 | #1 |
adhd methods | #1 |
sex bpi disorder | #1 |
hypothesized precursors | #1 |
tass internal consistency | #1 |
mania pdd subjects | #1 |
bpd bpdsud | #1 |
risk anxiety disorders | #1 |
paternal smoking conception | #1 |
adhd france | #1 |
adhd responders | #1 |
regulation desr | #1 |
bipolar mdd | #1 |
sud phenotypes | #1 |
anx bpd | #1 |
children bpi disorder | #1 |
onset distributions | #1 |
apol1 schizophrenia | #1 |
bpd anx bpd | #1 |
neurocognitive marker | #1 |
shared endophenotypes | #1 |
adhd predictors | #1 |
sud adolescent patients | #1 |
substance disorders relatives | #1 |
elaborative verbal encoding | #1 |
parental panic disorder | #1 |
neuropsychological testing individuals | #1 |
antisocial disorders bpd | #1 |
adhd community | #1 |
parental panic depression | #1 |
child psychiatry referrals | #1 |
sud bpdsud | #1 |
chronological age age | #1 |
association tph2 | #1 |
mothers fam | #1 |
adhd personality traits | #1 |
adhd comorbid | #1 |
validity adhd | #1 |
adhd prss | #1 |
ptsd adhd probands | #1 |
criteria 14 children | #1 |
chinese outpatient sample | #1 |
non‐adhd children | #1 |
relatives multiplex families | #1 |
notch4 polymorphisms schizophrenia | #1 |
impulsiveness inattention | #1 |
dsmiv subtypes adhd | #1 |
odd relatives | #1 |
risk female relatives | #1 |
impulsive behavioral aggression | #1 |
network‐level assessment | #1 |
31item | #1 |
ldx growth | #1 |
rationaleadhd | #1 |
drd2 risk gene | #1 |
20183 cases | #1 |
adhd gwas | #1 |
controls adhd children | #1 |
rs3746544 rs1051312 | #1 |
cbclbp profile children | #1 |
48basepairrepeat | #1 |
model adult samples | #1 |
risk suds | #1 |
depressed children depression | #1 |
dbds adhd | #1 |
association evidence schizophrenia | #1 |
familial risk gender | #1 |
2 familial factors | #1 |
nasal nmu nmu | #1 |
familial subtype | #1 |
psychiatric conditions adults | #1 |
diagnosis bpi disorder | #1 |
adhd stronger connectivity | #1 |
cardinal symptom mania | #1 |
nonreferred sample | #1 |
hyperactivity disorder | #1 |
adhd smoking risk | #1 |
genetic risk severity | #1 |
familial moderators | #1 |
adhd pdics | #1 |
adult probands siblings | #1 |
adhd medications placebo | #1 |
structured interview mania | #1 |
genetic association rorb | #1 |
efficacy outcome adhd | #1 |
groundskeeper | #1 |
p27e05 | #1 |
lifetime impairment survey | #1 |
longitudinal analysis childhood | #1 |
suds genetic studies | #1 |
hyperactivity databases | #1 |
mania clinical interview | #1 |
impact tic disorders | #1 |
hyperactivity case | #1 |
hyperactivity disorder scores | #1 |
adhd alcohol dependence | #1 |
prss adhd | #1 |
increased methylation genes | #1 |
relatives bpi | #1 |
pdag mdd mdd | #1 |
ermph clinical response | #1 |
9r allele | #1 |
adhd control probands | #1 |
palau early | #1 |
adults ldx sizes | #1 |
aisrs asrs | #1 |
inattention shr | #1 |
manic symptoms vcfs | #1 |
rutters | #1 |
time qualitative review | #1 |
firstdegree relatives children | #1 |
slc9a9 disease associations | #1 |
gene attention | #1 |
acting medications | #1 |
relatives control | #1 |
aggregate cutoff score | #1 |
high‐risk adolescent offspring | #1 |
adhd mdd prss | #1 |
adhd vntr | #1 |
adhde | #1 |
symptoms adult | #1 |
onset chronological age | #1 |
prescription stimulant adults | #1 |
studies attention | #1 |
treatment effects values | #1 |
adhd social disability | #1 |
adhd youth ld | #1 |
association snap25 | #1 |
parental polygenic risk | #1 |
experts abstinence | #1 |
kiaa1292 | #1 |
adhd siblings | #1 |
adhd clinical obesity | #1 |
children motor competence | #1 |
inattentive hyperactive | #1 |
prodromal overt psychosis | #1 |
oral nmu nmu | #1 |
sensitive adhd | #1 |
prevalence attention | #1 |
boys female gender | #1 |
anterior insular lobule | #1 |
bipolar disorder girls | #1 |
children mania diagnosis | #1 |
molecular genetics network | #1 |
adhd adolescent | #1 |
diagnostic criteria adhd | #1 |
greater risk adhd | #1 |
adhd sample model | #1 |
17yearold boys | #1 |
gene comt | #1 |
co‐expression modules | #1 |
adhd scores | #1 |
manic symptoms disorder | #1 |
adhd long term | #1 |
adhd teenage parents | #1 |
stimulant nonmedical | #1 |
morbidity bipolar disorder | #1 |
neuroleptic nonresponse | #1 |
adhd cognition | #1 |
adhd efficacy outcome | #1 |
smd greater severity | #1 |
consensus statement combination | #1 |
gender adhd | #1 |
14 children pdd | #1 |
intron8 | #1 |
youth adhd prss | #1 |
dna methylation adhd | #1 |
late‐onset adhd | #1 |
qms adhd | #1 |
hyperactivity comorbidity | #1 |
hyperactivity child child | #1 |
deficits time | #1 |
adhd brain alterations | #1 |
adolescence longitudinal analysis | #1 |
unfamiliar challenges | #1 |
children adolescents cohorts | #1 |
healthy cortical development | #1 |
predicted clinical response | #1 |
antisocial families | #1 |
pair health | #1 |
adhd symptom counts | #1 |
mr006 | #1 |
adhd children | #1 |
concurrent adhd | #1 |
teacher combined | #1 |
type adhd | #1 |
anxiety disorders relatives | #1 |
desr adult probands | #1 |
2327t | #1 |
relatives adhd girls | #1 |
pediatric panic disorder | #1 |
adult persistence adhd | #1 |
lateonset adhd | #1 |
schizotaxia negative schizotypy | #1 |
adhd obesity overweight | #1 |
transmission parents | #1 |
adhd females | #1 |
hyperactivity child genome | #1 |
adhd mini | #1 |
treatment masxr | #1 |
hyperactivity child humans | #1 |
fsiq comt | #1 |
adhd adolescent patients | #1 |
persistent adhd adults | #1 |
snp quantitative phenotype | #1 |
genetic sexual dimorphism | #1 |
comt fsiq | #1 |
schizotypal relatives | #1 |
adolescents genetic risk | #1 |
anxiousdepressed | #1 |
schizophrenia european samples | #1 |
bipolar disorders psud | #1 |
familial evidence | #1 |
parents sud | #1 |
behaviors substances | #1 |
method authors | #1 |
adhd degree relatives | #1 |
bpd parents | #1 |
disorder versus disability | #1 |
low attention | #1 |
schizophrenia current knowledge | #1 |
adhd context | #1 |
adhd probands | #1 |
adhd children mania | #1 |
female gender boys | #1 |
paternal over‐transmission | #1 |
expected height weight | #1 |
control probands | #1 |
adhd somatosensory functioning | #1 |
anx relatives | #1 |
competitivep | #1 |
2064 trios | #1 |
adhd disorder | #1 |
teacher report | #1 |
qelbree | #1 |
matching fallacy | #1 |
cbt intervention adolescents | #1 |
adhd phenotypes | #1 |
prospective datasets | #1 |
bpi disorder efds | #1 |
tova api aklt01 | #1 |
bpi disorder adhd | #1 |
d15s1012 | #1 |
adults life | #1 |
measurement invariance study | #1 |
criteria mania | #1 |
oih cpt | #1 |
motheronly | #1 |
adhd functional | #1 |
outcome adhd | #1 |
drd4 association | #1 |
iiv hyperactivity behavior | #1 |
stress adhd severity | #1 |
clock genes rorb | #1 |
risk aggressive symptoms | #1 |
potential endophenotypes adhd | #1 |
offspring parental adhd | #1 |
adhd background | #1 |
2276ct | #1 |
molecular psychiatric genetics | #1 |
maoa neuropsychological functioning | #1 |
p44e05 | #1 |
genetic overlap adhd | #1 |
bpd relatives | #1 |
executive functioning adults | #1 |
autism symptoms adhd | #1 |
hypothesis disorders | #1 |
increasing resource demand | #1 |
twin adoption | #1 |
learning disabilities girls | #1 |
adhd clinical trial | #1 |
variance oppositional symptoms | #1 |
ldx bmi | #1 |
maoa adhd | #1 |
mspi allele | #1 |
consensus combination | #1 |
drd4 7repeat allele | #1 |
h2053 | #1 |
ldx growth delays | #1 |
association evidence | #1 |
896 cases | #1 |
142 combined subtype | #1 |
confusability analyses | #1 |
adhd familial disorder | #1 |
gene studies | #1 |
cdbpd | #1 |
age1542 | #1 |
callingalgorithms | #1 |
adult persistence | #1 |
disorders aa | #1 |
motor skills attention | #1 |
adhd structural abnormalities | #1 |
drugplacebo response curve | #1 |
bpi probands | #1 |
adhd dat1 gene | #1 |
druggable genome disorder | #1 |
cognitive endophenotypes adhd | #1 |
probands clinical status | #1 |
bpd firstdegree relatives | #1 |
ainslbl | #1 |
interviews disease humans | #1 |
95 hrr | #1 |
stimulants height | #1 |
height ldx | #1 |
discordant twin study | #1 |
rs6077690 | #1 |
treatment mts | #1 |
subthreshold adhd | #1 |
snps quantitative phenotypes | #1 |
adhd asthma | #1 |
adhd smoking | #1 |
bpd anx | #1 |
rs7118422 | #1 |
disorders hypothesis | #1 |
desr adults | #1 |
patients attentional disorders | #1 |
relatives bpi probands | #1 |
112 80 | #1 |
ats siblings | #1 |
biological schizophrenia stress | #1 |
rs916455 | #1 |
10repeats | #1 |
comorbid odd adhd | #1 |
candidate genes adhd | #1 |
association behavioral inhibition | #1 |
bpd bpd anx | #1 |
nmu nasal nmu | #1 |
relatives alcohol dependence | #1 |
inflation personal satisfaction | #1 |
adhd dyscalculia | #1 |
parental probands | #1 |
add 73 probands | #1 |
htf9c gene | #1 |
adhd desr | #1 |
neuropsychological probes | #1 |
adhd mp | #1 |
unexplored void | #1 |
odd disorders follow | #1 |
earlyandmoderate | #1 |
suds crosssectional studies | #1 |
siblings adhd probands | #1 |
pdd mania mania | #1 |
subsets linkage | #1 |
nonreferred siblings | #1 |
distribution child | #1 |
suggestive linkage signals | #1 |
persistent adhd symptoms | #1 |
adhd volumetric reductions | #1 |
context adhd | #1 |
arch ger psychiatry | #1 |
trait impulsivity adhdct | #1 |
35191 | #1 |
adhd slc6a3 genotype | #1 |
sample adhd | #1 |
adhd higher | #1 |
common genetic risk | #1 |
4q28 | #1 |
symptom burden adults | #1 |
smoking adhd | #1 |
deficits expected growth | #1 |
treatment stimulants | #1 |
discipline problem | #1 |
adhd psychiatric | #1 |
psud controls | #1 |
adhd screening | #1 |
sexes bpi disorder | #1 |
oral nmu | #1 |
behavioral inhibition parents | #1 |
1 relatives | #1 |
adulthood genetic architecture | #1 |
siblings males | #1 |
onset mania | #1 |
adhd attention | #1 |
affs add | #1 |
asd youth adhd | #1 |
groups girls | #1 |
adhd ads | #1 |
visual memory deficit | #1 |
racial heterogeneity | #1 |
comparison subjects participants | #1 |
adhd familial risk | #1 |
substantial genetic component | #1 |
drug frequency variables | #1 |
adhd children exposure | #1 |
desr subjects | #1 |
association maoa | #1 |
authors adhd | #1 |
combination scientific data | #1 |
molecular genetic studies | #1 |
adherence xr | #1 |
probands adhd | #1 |
paternal overtransmission | #1 |
adhd sexes | #1 |
rs9325032 | #1 |
evidence sud phenotypes | #1 |
alphaglx | #1 |
drugplacebo | #1 |
adhd chinese population | #1 |
prescription stimulant nonmedical | #1 |
adhd module | #1 |
adhd genetic studies | #1 |
pdd subjects mania | #1 |
hyperactive impulsive symptoms | #1 |
neurocognitive functions suds | #1 |
diagnosis adhd | #1 |
schizotaxia negative symptoms | #1 |
pooleddata | #1 |
association psychiatric comorbidity | #1 |
adhd risk factors | #1 |
masir | #1 |
suds nicotine dependence | #1 |
adhdi prenatal exposure | #1 |
rs6000200 | #1 |
asthma motor preference | #1 |
clinical controls | #1 |
trypotphan | #1 |
adhd clinical | #1 |
gsprs adhd | #1 |
late onset adhd | #1 |
years adhd | #1 |
adhd linkage | #1 |
findings adhd | #1 |
alcohol disorders offspring | #1 |
stimulant treatment alcohol | #1 |
relatives pediatric probands | #1 |
girls disorder | #1 |
aggressive symptoms risk | #1 |
covariates dopamine receptors | #1 |
mwq inattention items | #1 |
bipolar adhd | #1 |
genes adhd | #1 |
ldx amses | #1 |
pediatric bipolari disorder | #1 |
stable behavioral inhibition | #1 |
association adhd | #1 |
paediatric patients adhd | #1 |
youth adhd | #1 |
familially | #1 |
familial risk analyses | #1 |
adhd stimulant treatment | #1 |
nonreferred | #1 |
dat1 adhd | #1 |
concurrent adhd sud | #1 |
probands add | #1 |
adhd drug dependence | #1 |
parents proband youth | #1 |
onset distribution | #1 |
growth delays weight | #1 |
relatives default network | #1 |
clinically diagnosed obesity | #1 |
palauans maps loci | #1 |
impaired sensorimotor timing | #1 |
nonpsychotic relatives controls | #1 |
adhd risk alleles | #1 |
controls adhd probands | #1 |
adhd subjects controls | #1 |
comorbid oppositional | #1 |
adhd comorbid disorders | #1 |
genes etiology | #1 |
sud adolescent | #1 |
valid disorder | #1 |
parental md | #1 |
nhe inhibitors adhd | #1 |
volumes participants | #1 |
dsm bipolar disorder | #1 |
adhd hyperactivity automobile | #1 |
adhd children bpd | #1 |
diagnostic continuity adhd | #1 |
distinct subtype | #1 |
adhd maternal | #1 |
persistence disorder | #1 |
criteria age | #1 |
report adhd | #1 |
impactnl | #1 |
slc6a4 gene risk | #1 |
followup assessment | #1 |
pdi hyperactivity | #1 |
gene aggressive behavior | #1 |
multi‐stage study | #1 |
adhd treatment treatment | #1 |
rs2449340 | #1 |
adhd african | #1 |
mp adhd | #1 |
disorder meta | #1 |
bpd girls | #1 |
adhd antisocial | #1 |
expression adhd | #1 |
inattentive symptoms adults | #1 |
adhd rat | #1 |
cyp2d6 hypothesis | #1 |
age groups cohorts | #1 |
s034 | #1 |
illness adolescent | #1 |
ptsd bpi disorder | #1 |
asrs | #1 |
adhd candidate genes | #1 |
endophenotypic construct | #1 |
familybased studies association | #1 |
adhd prss adhd | #1 |
daodisc1 | #1 |
familiar disease | #1 |
offspring parental md | #1 |
adhd population | #1 |
mtbi adhd | #1 |
population screen | #1 |
5ht1b receptor gene | #1 |
postmortem brain identifies | #1 |
lobe mri measures | #1 |
add relatives | #1 |
neural network correlates | #1 |
paediatric adhd | #1 |
mitigates stimulant | #1 |
validity diagnosis | #1 |
adhdmethodcurves | #1 |
fidgety philipp | #1 |
risk psud | #1 |
140 adhd probands | #1 |
highiq adults adhd | #1 |
adhd antisocial comorbidity | #1 |
schizophrenic probands1portions | #1 |
drd5 vntr | #1 |
thermenos | #1 |
association dopamine receptors | #1 |
manic children pdd | #1 |
mph adult adhd | #1 |
140 adhd | #1 |
40basepairrepeat | #1 |
adhd valid | #1 |
pharmacological treatment adolescents | #1 |
self‐reported adhd | #1 |
n6979 | #1 |
adhd total score | #1 |
caregiver strain cgsq | #1 |
latrophilin 3 gene | #1 |
mdd pdag mdd | #1 |
aud adhd | #1 |
diagnoses adhd | #1 |
gender familial risk | #1 |
adhd outcome | #1 |
adhd child comorbidity | #1 |
adhd switches | #1 |
187 children | #1 |
cigarette smoking siblings | #1 |
relatives bipolar | #1 |
risk adhd | #1 |
reproducibility adolescent | #1 |
schizotaxia subjects | #1 |
loci asd symptoms | #1 |
cigarette smoking metaanalysis | #1 |
social adjustment inventory | #1 |
disorder follow | #1 |
serotonin genetic | #1 |
nfspds | #1 |
adhd drd4 | #1 |
impairments adults | #1 |
p902e−07 | #1 |
convergent functional genomic | #1 |
9 nhe9 | #1 |
ldx size children | #1 |
hyperactivity | #1 |
nplz | #1 |
dyscalculia adhd | #1 |
conduct disorder aspd | #1 |
bpdsud bpd | #1 |
familial underpinnings | #1 |
motor preference disability | #1 |
ldx expected height | #1 |
rs1482337–rs2252471 | #1 |
expressed emotion children | #1 |
european treatment guideline | #1 |
smaller total brain | #1 |
familial links | #1 |
p647e07 | #1 |
md parents | #1 |
adhd reliability | #1 |
risk factor psud | #1 |
ermph placebo groups | #1 |
phenotype adhd | #1 |
adhd cigarette smoking | #1 |
association slc6a3 | #1 |
bipolar disorder parents | #1 |
17year | #1 |
affective psychosis hraff | #1 |
interaction adhd | #1 |
psychiatric disorders adhd | #1 |
cortical surface adhd | #1 |
druggable genome adhd | #1 |
adhd highly | #1 |
childhood predictors adhd | #1 |
74±77 | #1 |
adolescent response inhibition | #1 |
bpd hypothesis | #1 |
relatives 1 probands | #1 |
nonreferred subjects | #1 |
mania rates | #1 |
depressed children adhd | #1 |
life adult adhd | #1 |
personality traits adults | #1 |
adhd conduct disorder | #1 |
clinical features adhd | #1 |
elevated risk adhd | #1 |
treatment bsd | #1 |
disorder hyperactivity | #1 |
administration marijuana | #1 |
inattention adhd | #1 |
bpprss | #1 |
proband child | #1 |
adults cadhd | #1 |
tdt analysis | #1 |
sob adhd | #1 |
adhd antisocial disorders | #1 |
dat1 vntr | #1 |
disorder attention | #1 |
neuropsychological performance adhd | #1 |
comorbid adult adhd | #1 |
schizophrenia notch4 | #1 |
osa genetic heterogeneity | #1 |
1350t | #1 |
adhddbds | #1 |
disorder adhd | #1 |
tomoxetine adult adhd | #1 |
marijuana smoking metaanalysis | #1 |
aspd youth | #1 |
adhd module mwq | #1 |
“3 | #1 |
adolescents sud treatment | #1 |
clinical interview mania | #1 |
mwq adhd module | #1 |
males overweight obesity | #1 |
treatment stimulant | #1 |
relatives girls | #1 |
sp067 | #1 |
adhd probands adhd | #1 |
pippi longstocking | #1 |
pediatric bpi disorder | #1 |
sud adolescence | #1 |
adults diagnosis | #1 |
dat110 6 | #1 |
adhd euphoria | #1 |
prss psychiatric disorders | #1 |
nonverbal social–emotional cues | #1 |
brain activity flow | #1 |
re‐review | #1 |
adhdassociated alleles | #1 |
relatives multiplex | #1 |
positive peer affiliation | #1 |
etiology disorder | #1 |
impulsive drive | #1 |
depression adhd child | #1 |
mddprss | #1 |
regions lgi | #1 |
adhd psychoactive substance | #1 |
adult samples model | #1 |
childhood genetic background | #1 |
rates relatives | #1 |
siblings control probands | #1 |
overlapping symptoms | #1 |
nimh genetics initiative | #1 |
tourettes syndrome adhd | #1 |
schizophrenia nonpsychotic relatives | #1 |
familial association adhd | #1 |
maf⩾1 | #1 |
rs3776512 | #1 |
subthreshold diagnoses valid | #1 |
relatives adhd status | #1 |
persistence pediatric disorder | #1 |
week treatment response | #1 |
pregnancy adhd | #1 |
temperamental risk factor | #1 |
noninhibited children | #1 |
smoking schizophrenia families | #1 |
23 candidate genes | #1 |
shifting sands | #1 |
hamiltondepression | #1 |
pediatric bipolar spectrum | #1 |
anxiety disorders twins | #1 |
scz palau | #1 |
haplotypes adhd | #1 |
standardized manner | #1 |
severe dysregulation | #1 |
children motor domain | #1 |
children growth delays | #1 |
ldx masir | #1 |
adhd asm snps | #1 |
stimulant misuse | #1 |
schizophrenia bipolar psychoses | #1 |
cdh13 memory performance | #1 |
european treatment guidelines | #1 |
bpi disorder youth | #1 |
comt maoa | #1 |
git1 adhd | #1 |
ld addh children | #1 |
interobserver agreement measures | #1 |
adhd cbcl | #1 |
bpi relatives | #1 |
4q3121 | #1 |
13052159 | #1 |
adhd social class | #1 |
rs1799835 | #1 |
higher adhd | #1 |
rs11133767 | #1 |
falconer3 | #1 |
deficit | #1 |
idir proteins siblings | #1 |
stimulant treatment adhd | #1 |
comt maoa interaction | #1 |
elevated rates adhd | #1 |
behavioral disinhibition offspring | #1 |
pinslbl | #1 |
scales risk | #1 |
major depression share | #1 |
adhd desr probands | #1 |
adhd haplotype block | #1 |
onset criterion adhd | #1 |
matter volumes volumes | #1 |
dbds adhddbds | #1 |
individuals adhd | #1 |
adhd genetic | #1 |
aud alcohol disorders | #1 |
family‐based association test | #1 |
adhd neuropsychological impairments | #1 |
adhd adhd cases | #1 |
higher prevalence girls | #1 |
adhd girls | #1 |
adhd gsprs | #1 |
adhd asd youth | #1 |
girls learning disabilities | #1 |
motorendophenotypes | #1 |
cacng2 genes schizophrenia | #1 |
adolescent outcome adhd | #1 |
psud relatives | #1 |
adhd susceptibility genes | #1 |
bpi disorder children | #1 |
age onset criterion | #1 |
aadhd cadhd | #1 |
schizophrenia hrscz | #1 |
adhd baseline | #1 |
comorbid problems adhd | #1 |
stimulants abuse potential | #1 |
adhd alleles | #1 |
dopamine d4 gene | #1 |
np functioning chr | #1 |
sbrv | #1 |
nfspd | #1 |
diagnoses probands | #1 |
asd weaknesses | #1 |
n122 | #1 |
genetic variants adhd | #1 |
familial transmission adhd | #1 |
association syp | #1 |
educational failure | #1 |
braingenie | #1 |
prescription stimulant nmu | #1 |
larger samples | #1 |
youth informant source | #1 |
adhd comorbid dbds | #1 |
efficacy outcome week | #1 |
orosmph adult adhd | #1 |
risk substance disorders | #1 |
adhd serotonin | #1 |
suds adhd | #1 |
structured interview pdd | #1 |
add aff | #1 |
genes disorder | #1 |
addictive drugs dust | #1 |
odd control | #1 |
gene interaction comt | #1 |
parental children | #1 |
probands rates | #1 |
relatives adhd probands | #1 |
risk factors opd | #1 |
vall66 | #1 |
stimulant treatment differences | #1 |
dsmiiir dsmiv adhd | #1 |
smd higher rates | #1 |
assess adult adhd | #1 |
placebo ldx treatment | #1 |
prs rtv | #1 |
structural differences children | #1 |
interaction adhd severity | #1 |
prs58502974 | #1 |
add pdics | #1 |
efficacy adderall | #1 |
bpi disorder | #1 |
neuroanatomic predictors | #1 |
exposure maternal smoking | #1 |
hyperactivity biomarkers | #1 |
cortical networks attention | #1 |
adhd adhd probands | #1 |
motor preference | #1 |
affective symptoms dbds | #1 |
tidqam | #1 |
conduct bipolar disorders | #1 |
children behavioral inhibition | #1 |
disability asthma | #1 |
odd familial disorders | #1 |
suds neurocognitive functions | #1 |
biased maternal reporting | #1 |
studies adhd children | #1 |
adhd 11 years | #1 |
clinical correlates ocd | #1 |
items 99item cbs | #1 |
sbrv adhd | #1 |
oral methylphenidate treatment | #1 |
children behavioral | #1 |
studies method | #1 |
prsanalyses | #1 |
adherence stimulant treatment | #1 |
fspds | #1 |
sud parents | #1 |
suds relatives | #1 |
sud nicotine dependence | #1 |
volume alterations | #1 |
sob association adhd | #1 |
depression symptoms aggregation | #1 |
highiq youths adhd | #1 |
future dsm | #1 |
insular lobule | #1 |
model ermph | #1 |
masir ldx | #1 |
slc9a9 | #1 |
mania criteria | #1 |
adult adhd | #1 |
chi25762 | #1 |
nr3c1 stress exposure | #1 |
–rs2272080 | #1 |
psychopathology reward dysfunction | #1 |
genotype calling procedures | #1 |
bpd probands | #1 |
unique impairments | #1 |
pdd pdd subjects | #1 |
dat1 untranslated regions | #1 |
parental suds | #1 |
adhd symptoms crf | #1 |
childhoodonset mania | #1 |
ptsd siblings | #1 |
anxiety disorders families | #1 |
children antisocial disorders | #1 |
diagnoses relatives | #1 |
comt intelligence | #1 |
adult adhd treatment | #1 |
aff add | #1 |
relatives greater activation | #1 |
anxiety disorders baseline | #1 |
overweight obesity males | #1 |
trypotphan hydroxylase | #1 |
subjects ldx | #1 |
evidence stimulant treatment | #1 |
dust addictive drug | #1 |
taf9bp2 | #1 |
psychiatric comorbidity girls | #1 |
dsm5 adult adhd | #1 |
youth bpi disorder | #1 |
unaffected siblings volumes | #1 |
rs2469758–rs2461489 | #1 |
onset adult subjects | #1 |
ldx adult adhd | #1 |
multiplex sample | #1 |
adhd familial | #1 |
cases adhd | #1 |
association attention | #1 |
adhd neuroimage study | #1 |
relatives 3 probands | #1 |
15q13 deletions | #1 |
expanded symptom criteria | #2 |
d2s410 | #2 |
dsmiiir adhd | #2 |
adhd conduct | #2 |
cbcl desr | #2 |
morning behavior | #2 |
lgi regions | #2 |
relatives simplex families | #2 |
suggestive linkage loci | #2 |
stimulants adults | #2 |
conjfdr005 | #2 |
families schizophrenia patients | #2 |
child comorbidity illness | #2 |
mood disorders adhd | #2 |
neuroleptic dose reduction | #2 |
deficits sustained attention | #2 |
psychoactive substance disorders | #2 |
deficit sustained attention | #2 |
activation trigger | #2 |
adhd neuropsychological tests | #2 |
consortium neuroscience | #2 |
dsmiv subtypes | #2 |
oral prescription | #2 |
rates adhd | #2 |
adhd choice | #2 |
hyperactivity impulsiveness | #2 |
comorbid conduct problems | #2 |
wwwhapmaporg | #2 |
neuropsychoanalytic treatment | #2 |
parents major depression | #2 |
idiopathic adhd | #2 |
findings children | #2 |
childhood adolescent adhd | #2 |
initial stimulant | #2 |
schizophrenia twin studies | #2 |
ncrl | #2 |
cbcljbd children | #2 |
relatives adhd | #2 |
18 dsm | #2 |
disorder conclusions | #2 |
major depression findings | #2 |
multicenter adhd | #2 |
health organization asrs | #2 |
adhd adults | #2 |
adhd method | #2 |
adhd impact | #2 |
models adhd | #2 |
methodological complexities | #2 |
parents disorder | #2 |
separation attention deficit | #2 |
youth meaningful | #2 |
adhd assessed | #2 |
schizotypy handedness | #2 |
adhd neuropsychological deficits | #2 |
cbcl clinical | #2 |
age onset distributions | #2 |
drug abuse dependence | #2 |
efds | #2 |
6‐year longitudinal study | #2 |
twin studies adhd | #2 |
comorbidity disorder | #2 |
problems adhd | #2 |
adhd height | #2 |
adhd adhd patients | #2 |
preventing schizophrenia | #2 |
wiatii | #2 |
background attention | #2 |
reward‐related activation | #2 |
persistent attention | #2 |
candidate genetic pathways | #2 |
structured diagnostic interviews | #2 |
life social adjustment | #2 |
disorders adhd | #2 |
adhd risk factor | #2 |
rs40184 | #2 |
adhd disability | #2 |
relatives add | #2 |
adhd risk icv | #2 |
qualitative review | #2 |
disorder studies | #2 |
comorbid oppositional defiant | #2 |
diagnosis attention | #2 |
childhoodonset adhd | #2 |
familial risk analysis | #2 |
schizophrenia pedigrees | #2 |
derived diagnosis | #2 |
disorders suds | #2 |
qualitative literature review | #2 |
viloxazine extendedrelease | #2 |
psychotic mood disorder | #2 |
manic children | #2 |
unipolar relatives | #2 |
dsm adhd | #2 |
schizophrenia calcineurin | #2 |
actively reducing severity | #2 |
psychiatric comorbidity | #2 |
informant source | #2 |
treatment sud patients | #2 |
bias child child | #2 |
conners adult adhd | #2 |
expanded versions | #2 |
bidirectional overlap | #2 |
parent rating | #2 |
lallele homozygotes | #2 |
140 girls | #2 |
adhd comorbid problems | #2 |
psychiatrically | #2 |
disorder add | #2 |
schizophrenia genetic studies | #2 |
hyperactivity female humans | #2 |
familybased studies | #2 |
disorder girls | #2 |
adhd bipolar | #2 |
unweighted screener asrs | #2 |
disorders similarities | #2 |
comorbid conduct | #2 |
probands | #2 |
structure adult adhd | #2 |
scale asrs | #2 |
adhdprss | #2 |
≥210 | #2 |
adhd mph response | #2 |
d0·18 | #2 |
bipolar disorder relatives | #2 |
attentional control effects | #2 |
support genetic factors | #2 |
adhd adhd children | #2 |
parental anxiety disorders | #2 |
cbsk | #2 |
sud bpd | #2 |
adhdonly | #2 |
performancemeasures | #2 |
opioid induced hyperalgesia | #2 |
immune disorder | #2 |
adhd comparison | #2 |
risk factor adhd | #2 |
bipolar disorder sud | #2 |
disorder children | #2 |
adhd risk gene | #2 |
comparison probands | #2 |
rs6938431 | #2 |
subjects adults | #2 |
qtl linkage adhd | #2 |
treatment childhood adhd | #2 |
nicotine substance | #2 |
snp12snp2ctgn | #2 |
eye vergence | #2 |
acpts | #2 |
spectrum phenotypes | #2 |
chromosomes inclusion | #2 |
galantamine hbr | #2 |
siblings youth | #2 |
subthreshold diagnoses | #2 |
risk panic disorder | #2 |
scales sex | #2 |
weaknesses youth | #2 |
n2246 | #2 |
investigator ratings | #2 |
developmental subtype | #2 |
strong heritability | #2 |
executive function outcome | #2 |
adhd bpd | #2 |
role adhd | #2 |
effects paternal smoking | #2 |
deficits efds | #2 |
maoa comt | #2 |
adhd growth | #2 |
rates bpd | #2 |
work needed | #2 |
pdd overlap | #2 |
relatives schizophrenic | #2 |
6 17 years | #2 |
aggressive symptoms | #2 |
jackknife procedure | #2 |
7point | #2 |
internal distractibility | #2 |
wky ncrl | #2 |
underlying bipolarity | #2 |
eye vergence responses | #2 |
pilot adult | #2 |
age onset distribution | #2 |
n1934 | #2 |
consecutively referred children | #2 |
association meta analysis | #2 |
odd girls | #2 |
girls adhd | #2 |
tourette spectrum | #2 |
diabetes disorders | #2 |
adra2a polymorphism | #2 |
concurrent attention | #2 |
enigma adhd | #2 |
mirsky | #2 |
iii adhd | #2 |
p161e05 | #2 |
adolescents substance disorder | #2 |
adhd odd | #2 |
function deficits | #2 |
adhd comparison subjects | #2 |
allele schizophrenia | #2 |
cacng2 genes | #2 |
comparative profile analysis | #2 |
adhd relatives | #2 |
bmi adhd symptoms | #2 |
comorbidity adhd | #2 |
n3199 | #2 |
psychotic relatives | #2 |
referred youth | #2 |
youth attention | #2 |
pediatrically | #2 |
ratio081 | #2 |
adhd psychiatric disorders | #2 |
s038 | #2 |
nonpsychotic relatives | #2 |
rs3746544 | #2 |
adhd outcomes | #2 |
adhd objective | #2 |
hypothetical task | #2 |
clinically referred children | #2 |
patterns comorbidity | #2 |
boys maoa | #2 |
target features | #2 |
personal satisfaction | #2 |
testretest reliability screener | #2 |
infancy complications | #2 |
symptoms neuropsychological | #2 |
adhd major | #2 |
disorders findings | #2 |
disorder adults | #2 |
comorbidity attention | #2 |
control subjects adhd | #2 |
variants adhd | #2 |
schizophrenia interactions | #2 |
antisocial disorders relatives | #2 |
molecular genetics schizophrenia | #2 |
stress adhd | #2 |
n2455 | #2 |
correlates adhd | #2 |
n‐acetylcysteine treatment | #2 |
actively reducing | #2 |
ncrl wky | #2 |
617 years | #2 |
alleles attention | #2 |
deficits adults | #2 |
adhd african americans | #2 |
child behavioral inhibition | #2 |
neuropsychological function girls | #2 |
small literature | #2 |
screening diagnosis treatment | #2 |
cbcl profile | #2 |
disease humans receptors | #2 |
cigarette smoking suds | #2 |
asrs health organization | #2 |
consecutively referred | #2 |
adhd lifespan | #2 |
galantamine hbr placebo | #2 |
schizotaxia discussion | #2 |
attention‐deficit hyperactivity | #2 |
adhd acc | #2 |
hrscz | #2 |
ermph children | #2 |
efficacy stimulants | #2 |
child comorbidity | #2 |
young adult years | #2 |
hypothesis adhd | #2 |
10092 | #2 |
bipolar disorder symptomatology | #2 |
comorbid conduct disorder | #2 |
add probands | #2 |
naltrexone adults | #2 |
dsmiv adhd | #2 |
stin2vntr | #2 |
proinflammatory expansion | #2 |
adhd ldx | #2 |
female probands | #2 |
disease humans inhibition | #2 |
selfmedicating | #2 |
efds adults | #2 |
regions studies | #2 |
morbidity dysfunction | #2 |
n11221 | #2 |
rates odd | #2 |
adults adhd | #2 |
comorbidity probands | #2 |
2q143 | #2 |
g72 daao | #2 |
comorbid aggression | #2 |
dsmjbd | #2 |
adhd combined | #2 |
methylphenidate attention | #2 |
studies adderall | #2 |
risk add | #2 |
dimesylate treatment | #2 |
6 17 | #2 |
juvenile bipolar phenotype | #2 |
ldsc heritability | #2 |
adhd genetics | #2 |
wm deficits | #2 |
subjects desr | #2 |
rs1800955 | #2 |
5 loci adhd | #2 |
adhd lower | #2 |
association mtbi | #2 |
adhd genes | #2 |
amses | #2 |
subjects conduct disorder | #2 |
stimulants | #2 |
familial association | #2 |
multigenic inheritance | #2 |
affective probands | #2 |
sex differences adhd | #2 |
subsyndromal manifestations | #2 |
bsfq | #2 |
hyperactivity attention deficit | #2 |
shared genetic background | #2 |
adhd icv | #2 |
hyperactivity diagnostic | #2 |
assessed structured | #2 |
adhdliability | #2 |
items screener | #2 |
risk female cases | #2 |
youth selfreports | #2 |
maternal smoking mothers | #2 |
genome‐wide association scan | #2 |
n328917 | #2 |
addicted | #2 |
juvenile antisocial | #2 |
method subjects | #2 |
6p243 | #2 |
disorder inattentive | #2 |
disorder findings | #2 |
adhd report | #2 |
overlap mania | #2 |
serum neuroleptic activity | #2 |
stimulants adhd | #2 |
familial trait | #2 |
scz data | #2 |
stimulant therapy | #2 |
enigma adventure | #2 |
hantac | #2 |
combinedtype | #2 |
factors attention | #2 |
specific haplotype | #2 |
probands relatives | #2 |
subjects criteria | #2 |
dysfunction offspring | #2 |
heterogeneity schizophrenia | #2 |
anx bipolar disorder | #2 |
trauma adhd | #2 |
association data | #2 |
adult samples | #2 |
evidence adhd | #2 |
status rating scales | #2 |
modest evidence | #2 |
adhd subjects | #2 |
ppv hyperactivity diagnostic | #2 |
genome‐wide association data | #2 |
clinically referred | #2 |
adhd emotional symptoms | #2 |
levels comorbidity | #2 |
systematized delusions | #2 |
adherence stimulants | #2 |
disorder oppositional | #2 |
adhd suds | #2 |
structured diagnostic | #2 |
checklist clinical | #2 |
dsm subtypes | #2 |
polygenic resilience score | #2 |
versus controls | #2 |
adhd autism symptoms | #2 |
default network schizophrenia | #2 |
iii attention | #2 |
hypothalamic abnormalities | #2 |
somatosensory functioning | #2 |
key cognitive phenotypes | #2 |
bpd sud | #2 |
emf impairments | #2 |
millennium consortium | #2 |
disorder adolescent | #2 |
checklist scales | #2 |
subsequent substance | #2 |
desr children | #2 |
factors adhd | #2 |
genetic transmission | #2 |
postcleavage | #2 |
familial adhd | #2 |
expert clinician | #2 |
euphorigenic effects | #2 |
case subjects adhd | #2 |
adhd case subjects | #2 |
disorder background | #2 |
cognition youth | #2 |
disorder impact | #2 |
aklt01 | #2 |
rs1801028 | #2 |
masxr | #2 |
cpt oih | #2 |
prior reports | #2 |
male psychiatric | #2 |
adhd physical conditions | #2 |
manic switches | #2 |
youth rates | #2 |
adverse effects subjects | #2 |
adhd surface area | #2 |
variance adult | #2 |
comorbidity disorders comorbidity | #2 |
blind raters | #2 |
adhd major depression | #2 |
adhd combined subtype | #2 |
bpd adhd | #2 |
scales adolescent | #2 |
wky nhsd | #2 |
adhd control subjects | #2 |
n17666 | #2 |
quetiapine monotherapy treatment | #2 |
chromosomes 6 14 | #2 |
schizophrenia parahippocampal gyrus | #2 |
large controlled | #2 |
d10s1432 | #2 |
derived phenotypes | #2 |
adhd birth | #2 |
deficits executive | #2 |
deficit hyperactivity disorder | #2 |
current adult adhd | #2 |
antisocial disorders | #2 |
adults attention | #2 |
cnvs copy variants | #2 |
adhd families | #2 |
ldsc genetic correlations | #2 |
elusive indicators | #2 |
relatives | #2 |
non500 | #3 |
controls 6 disorders | #3 |
schizophrenia neurocognitive performance | #3 |
wonderlic personnel test | #3 |
genetic receptors serotonin | #3 |
qtl linkage | #3 |
adhd control | #3 |
comt adhd | #3 |
bipolar disease | #3 |
smds scz | #3 |
networks adhd | #3 |
psychopathologic conditions | #3 |
temperamental correlates | #3 |
pdd adhd | #3 |
neuropsychiatric disorders similarities | #3 |
children adhd diagnosis | #3 |
firstdegree relatives | #3 |
simulated workplace laboratory | #3 |
notch4 schizophrenia | #3 |
children vcfsadhd | #3 |
emotional dysregulation adhd | #3 |
comorbidity panic disorder | #3 |
structural imaging findings | #3 |
cognition comorbidity | #3 |
relatives bipolar disorder | #3 |
mania children | #3 |
“negativity | #3 |
amphetamines attention | #3 |
manic symptoms children | #3 |
control probands relatives | #3 |
youths ocd | #3 |
adhd combined type | #3 |
neurological polymorphism | #3 |
asthma adhd | #3 |
gsprs | #3 |
highly heritable disorder | #3 |
schizophrenia allele | #3 |
psychotic behaviour | #3 |
adhd data | #3 |
md females | #3 |
nervous stimulants | #3 |
adhd rare cnvs | #3 |
substance disorders adhd | #3 |
association confounders | #3 |
disproportionate impairment | #3 |
drd5 marker | #3 |
disease humans interviews | #3 |
children mania | #3 |
abstraction verbal memory | #3 |
conduct disorder adhd | #3 |
adhd presence | #3 |
dsmiiir diagnosis | #3 |
common disorders brain | #3 |
7repeat allele | #3 |
experienced pain | #3 |
mtbi studies | #3 |
anxiety disorders parents | #3 |
substances symptoms | #3 |
syndromatic | #3 |
metadoxine extended release | #3 |
oprm1 variants | #3 |
tsuang | #3 |
subjects sud | #3 |
relatives proband groups | #3 |
familial risk factors | #3 |
persistence psychiatric disorders | #3 |
resilience score | #3 |
ocd groups asd | #3 |
nonpsychotic relatives persons | #3 |
dmi addh | #3 |
excess transmission | #3 |
psychiatric comorbidity adhd | #3 |
cigarette smoking children | #3 |
adhd metaanalysis | #3 |
cbcl scales | #3 |
hyperactivity attention | #3 |
caarsss | #3 |
prenatal adversities | #3 |
anxiety disorders authors | #3 |
familial nature | #3 |
27 risk loci | #3 |
inattentive subtype | #3 |
adhd comorbid conditions | #3 |
impulsivity errors | #3 |
lbw adhd | #3 |
impact adhd | #3 |
reln promoter | #3 |
alcohol adhd | #3 |
cgsq | #3 |
educational deficits | #3 |
desr | #3 |
9rcarriers | #3 |
schizophrenia genotype | #3 |
hyperactivity central | #3 |
13q222 | #3 |
adhd ptsd | #3 |
chromosome 10q22 | #3 |
nicotine disorders | #3 |
adolescent adhd | #3 |
european‐american | #3 |
sirolimus 12 months | #3 |
adhd risk | #3 |
morbidity risk | #3 |
remittent | #3 |
impairment adhd | #3 |
methylphenidate studies | #3 |
evidence genetic association | #3 |
response methylphenidate | #3 |
intron13 | #3 |
adhd psychiatric comorbidity | #3 |
adhd polygenic | #3 |
lambdasib | #3 |
dose response effects | #3 |
adhd wm deficits | #3 |
sexdifferentiated effects | #3 |
relatives persons | #3 |
asd ocd groups | #3 |
htr1e | #3 |
ptsd adhd | #3 |
adhd psud | #3 |
topic adolescent | #3 |
teacher reports | #3 |
brain methylation | #3 |
comorbidity diagnosis | #3 |
relationship adhd | #3 |
international adhd | #3 |
z280 | #3 |
studies square | #3 |
girls attention | #3 |
morning school | #3 |
deficient emotional | #3 |
adhd mental disorders | #3 |
weight effects | #3 |
observed age | #3 |
tic disorders adhd | #3 |
genetics initiative | #3 |
interactions schizophrenia | #3 |
cortical thickness cases | #3 |
disorders conclusions | #3 |
rs6565113 | #3 |
candidate gene studies | #3 |
risk panic | #3 |
petronis | #3 |
asrs v11 | #3 |
anxiety behavioral inhibition | #3 |
comorbidities adhd | #3 |
n5827 | #3 |
bipolar psychoses | #3 |
enigma global neuroscience | #3 |
adhd pairwise correlations | #3 |
drug nicotine | #3 |
childhood attention‐deficit | #3 |
probands parental | #3 |
social perception skills | #3 |
comt promoter | #3 |
potential gene | #3 |
nmu prescription stimulants | #3 |
naltrexone methylphenidate | #3 |
adhd mdd | #3 |
risk factors sud | #3 |
similarities genetic etiology | #3 |
enigma wgs wgs | #3 |
dat1 | #3 |
pairwise correlations disorders | #3 |
7 repeat | #3 |
global neuroscience decade | #3 |
schizophrenic outpatients | #3 |
schizoaffective bipolar disorder | #3 |
adhd stimulant medication | #3 |
hyperactivity bipolar | #3 |
snps haplotype | #3 |
adhd mania | #3 |
sud children | #3 |
adhd bipolar disorder | #3 |
longitudinal follow | #3 |
sud youths | #3 |
ldx amphetamine | #3 |
adolescents mania | #3 |
major depression comorbidity | #3 |
parental substance disorders | #3 |
disorder conduct | #3 |
zakzanis | #3 |
clinically referred adults | #3 |
adhd emotional | #3 |
atomoxetine response | #3 |
vcfsadhd | #3 |
disorder comorbid | #3 |
parents panic disorder | #3 |
schizotaxia | #3 |
n1777 | #3 |
enuresis adhd | #3 |
md adhd | #3 |
ermph | #3 |
defined adhd | #3 |
siblings young | #3 |
cpt deficits | #3 |
variance severity | #3 |
npl scores | #3 |
large battery | #3 |
enigma neuroimaging genetics | #3 |
508e7 | #3 |
adult psychiatric outcomes | #3 |
adhd implications | #3 |
n2271 | #3 |
smoking probands | #3 |
checklist cbcl | #3 |
deficits height | #3 |
parents panic | #3 |
bpd rates | #3 |
intra‐individual variability | #3 |
mania disorders | #3 |
sibling trait | #3 |
stimulants treatment | #3 |
faraone reply | #3 |
sud offspring | #3 |
adhd common | #3 |
adhd systematic review | #3 |
adhd mtbi | #3 |
n2323 | #3 |
children adhd | #3 |
schizophrenia schizotaxia | #3 |
vulnerability indicators | #3 |
predisposition schizophrenia | #3 |
manic symptoms youth | #3 |
learning disabilities adhd | #3 |
growth deficits | #3 |
adhdpi | #3 |
model adhd | #3 |
drd4 7 | #3 |
disabilities male | #3 |
67e07 | #3 |
adhd youth | #4 |
adhd control children | #4 |
attention adhd | #4 |
adhd status | #4 |
choice adhd | #4 |
support mechanism | #4 |
comorbid attention | #4 |
presence adhd | #4 |
adderall methylphenidate | #4 |
treatment stimulant medication | #4 |
safren | #4 |
depression parental depression | #4 |
rs3785143 | #4 |
adhd pharmacotherapy | #4 |
rels | #4 |
mhlod | #4 |
tests psychiatric | #4 |
transporter genotypes | #4 |
rate switching | #4 |
openlabel studies | #4 |
adhd participants | #4 |
reported adhd | #4 |
global neuroscience | #4 |
chinese sample | #4 |
secondary psychotic symptoms | #4 |
poor motor performance | #4 |
rates psychiatric | #4 |
rs140700 | #4 |
humans lisdexamfetamine | #4 |
inattentive adhd | #4 |
disorders comorbidity | #4 |
risk factors adhd | #4 |
quantitative phenotype | #4 |
intelligence snps | #4 |
roh risk | #4 |
metadoxine placebo | #4 |
receiver operator characteristic | #4 |
families girls | #4 |
adhd md | #4 |
adhd controls | #4 |
treatment adhd | #4 |
d4s2361 | #4 |
adhd impairments | #4 |
bipolar disorder linkage | #4 |
phenotypes adhd | #4 |
preterm sample | #4 |
factors substance | #4 |
suds adolescents | #4 |
maoa | #4 |
maternal smoking alcohol | #4 |
parental panic | #4 |
aggregation adhd | #4 |
controls basal ganglia | #4 |
vcfs sample | #4 |
inhibition anxiety | #4 |
rs1079727 | #4 |
adhd symptom | #4 |
acting formulations | #4 |
metaanalyzes | #4 |
snpbased | #4 |
adhd neuropsychological performance | #4 |
lgi age | #4 |
distinct disorder | #4 |
cbclaps | #4 |
reward dysfunction | #4 |
comorbid aggression adhd | #4 |
relatives normal controls | #4 |
psychiatrically referred | #4 |
neuropsychoanalytic | #4 |
genetic heterogeneity schizophrenia | #4 |
46222 | #4 |
increased neural responses | #4 |
children comorbid adhd | #4 |
adhd pharmacogenetic studies | #4 |
adhd brain regions | #4 |
odd adhd | #4 |
health female | #4 |
developmental improvement | #4 |
rutter | #4 |
risk variants adhd | #4 |
selenbp1 schizophrenia | #4 |
relatives controls | #4 |
enrichment adhd | #4 |
handedness schizotypy | #4 |
psychiatric gene discoveries | #4 |
findings risk | #4 |
rutters indicators | #4 |
executive function deficits | #4 |
rs3916971 | #4 |
hemmings | #4 |
bpd sud patients | #4 |
nonoral routes administration | #4 |
adhd adulthood | #4 |
independent transmission | #4 |
anxiety disorders mdd | #4 |
adolescent years | #4 |
reported findings | #4 |
bpd sud bpd | #4 |
md individuals | #4 |
stimulantnaïve | #4 |
cbcljbd phenotype | #4 |
risk gene schizophrenia | #4 |
cbcl | #4 |
remittent adhd | #4 |
vcfs adhd | #4 |
psychiatric comorbidity risk | #4 |
pord05 | #4 |
disorders attention | #4 |
disorder objective | #4 |
impaired intellect | #4 |
17q111q12 | #4 |
vulnerability schizophrenia | #4 |
familial vulnerability | #4 |
boys higher prevalence | #4 |
achievement goal orientation | #4 |
image sample | #4 |
schizophrenia genetic factors | #4 |
hypescheme | #4 |
risk factors bpd | #4 |
onset adhd | #4 |
addictive drug | #4 |
coordination problems | #4 |
motor coordination problems | #4 |
adhd children mph | #4 |
angerirritability | #4 |
subthreshold | #4 |
total score week | #4 |
treatment adult adhd | #4 |
adhd association | #4 |
expected height | #4 |
pediatric mania | #4 |
treatment seeking patients | #4 |
subsequent substance disorders | #4 |
adults | #4 |
disorders panic | #4 |
disorders neuropsychological | #4 |
psud | #4 |
primary substance abuse | #4 |
functioning adhd | #4 |
growing literature | #4 |
adolescent outcome | #4 |
notch4 locus | #4 |
anxiety disorders offspring | #4 |
snps intelligence | #4 |
strattera | #4 |
subjects schizotaxia | #4 |
adhd reported | #4 |
quantitative models | #4 |
scores adhd | #4 |
adhd individuals | #4 |
mts growth | #4 |
rs3916968 | #4 |
4year followup | #4 |
time reproduction | #4 |
enigmaadhd | #4 |
adhd etiology | #4 |
comorbid psychiatric | #4 |
neuropsychological performance schizophrenia | #4 |
adhd subgroups | #4 |
psychiatrically referred youth | #4 |
sud bpd sud | #4 |
deficits executive functioning | #4 |
d4s1644 | #4 |
report scale | #4 |
gxr adhd | #4 |
panic disorder pregnancy | #4 |
parents bpd | #4 |
jbd | #4 |
objective studies | #4 |
substance disorders suds | #4 |
offspring sud | #4 |
asd mood disorders | #4 |
pavgrnk000417 | #4 |
psc35 | #4 |
height deficits | #4 |
gender children | #4 |
differences adults | #4 |
comorbidity humans | #4 |
adhd pdd | #4 |
behavior checklist | #4 |
homogeneous subtypes | #4 |
adhd substance abuse | #4 |
child behavior checklist | #4 |
lifetime dimensions | #4 |
sd133 | #4 |
shr ncrl | #4 |
female probands relatives | #4 |
4th international meeting | #4 |
disease genome humans | #4 |
adhd based | #4 |
fmri replication | #4 |
nt5dc1 | #5 |
dsm age | #5 |
referred youths | #5 |
humans interview | #5 |
combined subtype | #5 |
genetic linkage schizophrenia | #5 |
parental sud | #5 |
methylphenidate adults | #5 |
scale adhd | #5 |
kuntsi | #5 |
adhd bupropion | #5 |
disorder anxiety | #5 |
mothers anxiety disorders | #5 |
serum neuroleptic | #5 |
adhd inattentive type | #5 |
parents psychiatric | #5 |
adhdlike symptoms | #5 |
year prospective | #5 |
anxiety disorders anx | #5 |
adhd ld | #5 |
memantine hydrochloride | #5 |
adult probands | #5 |
bipolar disorder pedigrees | #5 |
sud | #5 |
onset criterion | #5 |
rs1799836 | #5 |
nonmedical nmu | #5 |
maternal reports | #5 |
hyperactivity clinical trials | #5 |
psychiatric correlates | #5 |
highly heritable | #5 |
oppositional defiant disorder | #5 |
bipolar disorder bpd | #5 |
desipramine placebo | #5 |
psychosis velocardiofacial syndrome | #5 |
large collaborative study | #5 |
major depression parents | #5 |
intellectually capable adults | #5 |
wcst scores | #5 |
adhd comorbid anxiety | #5 |
elevated rates | #5 |
shared haplotypes | #5 |
youth vcfs | #5 |
kiddieschedule | #5 |
iiv adhd | #5 |
2nd cohort | #5 |
lifetime impact | #5 |
disorders follow | #5 |
psychosis scale | #5 |
criteria schizotaxia | #5 |
prembr | #5 |
severe scores | #5 |
xr adults | #5 |
adolescent alleles | #5 |
pdmd | #5 |
disorder parents | #5 |
behavioral inhibition children | #5 |
clinical obesity | #5 |
risk factors schizophrenia | #5 |
ascertainment source | #5 |
oosterlaan | #5 |
adhd adult | #5 |
children dbds | #5 |
psychiatric disorders study | #5 |
referred children | #5 |
depression panic disorder | #5 |
tass | #5 |
neuropsychological risk | #5 |
adhd youths | #5 |
pathways association | #5 |
palauan | #5 |
disorder sud | #5 |
hyperactivity caregivers | #5 |
checklist child | #5 |
familial distribution | #5 |
child child behavior | #5 |
adolescence adhd | #5 |
height weight | #5 |
social disability | #5 |
report screening | #5 |
referred sample | #5 |
familial subtypes | #5 |
3 probands | #5 |
mood disorders asd | #5 |
desistent | #5 |
symptoms hyperactivity | #5 |
study genetic factors | #5 |
impairment survey | #5 |
auditory vigilance | #5 |
grubb | #5 |
sex adhd | #5 |
inhibited children | #5 |
ncrl rats | #5 |
female individuals | #5 |
puwma | #5 |
pdd subjects | #5 |
resilience project | #5 |
disorder rating | #5 |
zmynd17 | #5 |
adhd treated | #5 |
diagnosis mania | #5 |
adhd cases | #5 |
risk anxiety | #5 |
asrs screener | #5 |
screener | #5 |
schizophrenia palau | #5 |
familial risk adhd | #5 |
impaired parents humans | #5 |
conventional medications | #5 |
interview psychological | #5 |
organization adult | #5 |
adhd nonaffected siblings | #5 |
dopamine risk | #5 |
nonaffected siblings | #5 |
adhd tic disorders | #5 |
hechtman | #5 |
pleiotropic effects disorders | #5 |
disorder genetic | #5 |
initial responsiveness | #5 |
parental adhd | #5 |
sms intervention | #5 |
torture review | #5 |
etiopathologies | #5 |
relatives female probands | #5 |
proband risk | #5 |
function adhd | #5 |
d22s683 | #5 |
adults adult | #5 |
neuropsychiatric comorbidity | #5 |
impairment baseline | #5 |
effects adhd | #5 |
unipolar mdd | #5 |
disorders psychiatric | #5 |
inattentive symptoms | #5 |
3q13 | #5 |
growth dysregulation | #5 |
panic disorder parents | #5 |
cbcl data | #5 |
adult attention | #5 |
mania adhd | #5 |
children ldx | #5 |
ppp3cc schizophrenia | #5 |
boys attention | #5 |
comorbid disorders | #5 |
cardinal symptom | #5 |
aagc | #5 |
adhd response | #5 |
multivariate endophenotypes | #5 |
risk relatives | #5 |
objective marker | #6 |
altered neural connectivity | #6 |
ppp3cb | #6 |
p1e04 | #6 |
year recall | #6 |
pseudocontrols | #6 |
relatives probands | #6 |
neuropsychological functioning | #6 |
children relatives | #6 |
bpd controls | #6 |
association studies schizophrenia | #6 |
xp114p113 | #6 |
stimulant prescription | #6 |
downward extension | #6 |
enigma wgs | #6 |
genome‐wide | #6 |
male odds | #6 |
unfamiliar situations | #6 |
psychoactive substance | #6 |
combined subtypes | #6 |
behavioral inhibition | #6 |
referred children adolescents | #6 |
specific predictor | #6 |
hyperactivity child chromosomes | #6 |
driving simulation | #6 |
prior stimulant treatment | #6 |
clinical features children | #6 |
wm performance patients | #6 |
life adults | #6 |
environmental adversity | #6 |
taan | #6 |
risk attention | #6 |
chromosome 15 locus | #6 |
normal sexual dimorphism | #6 |
liability schizophrenia | #6 |
nmu | #6 |
dopamine transporter gene | #6 |
pediatric mood disorders | #6 |
schizophrenia deficit | #6 |
dsm iii | #6 |
prevalence adult adhd | #6 |
large heterogeneous | #6 |
placebo response response | #6 |
nhe inhibitors | #6 |
depression panic | #6 |
pediatric bpd | #6 |
males adhd | #6 |
total gray matter | #6 |
pediatric bipolar | #6 |
females adhd | #6 |
adhd increased risk | #6 |
hyperactivity disease models | #6 |
oceanic palau | #6 |
literature efficacy | #6 |
genetic linkage genome | #6 |
teenage parenthood | #6 |
risk sud | #6 |
fspd | #6 |
mixed amphetamine | #6 |
adhd mood disorders | #6 |
scales psychometrics | #6 |
adhd tic | #6 |
nonparanoid schizophrenia | #6 |
clinical scales | #6 |
cognitive impairments adhd | #6 |
4634 | #6 |
schizophrenia premorbid | #6 |
loci autism | #6 |
cpg sites methylation | #6 |
bpd comorbid | #6 |
followup studies | #6 |
genetic child | #6 |
adults disorder | #6 |
disorders adolescent | #6 |
facial memory | #6 |
cognition adults | #6 |
dnajc9 | #6 |
hierarchical factor model | #6 |
adhd mental retardation | #6 |
vulnerability indicator | #6 |
adhdia | #6 |
differences cortical thickness | #6 |
parental major depression | #6 |
cbcljbd | #6 |
adhd variability | #6 |
t515 | #6 |
adhd life | #6 |
niacin schizophrenia | #6 |
druggable genome | #6 |
premorbid cognitive ability | #6 |
adhd children adults | #6 |
tmcq | #6 |
adhd firstdegree relatives | #6 |
neuroleptic activity | #6 |
paternal age schizophrenia | #6 |
bpdsud | #6 |
familial loadings | #6 |
adhd women | #6 |
psychiatric disorders prss | #6 |
individual alleles | #6 |
referred adults | #6 |
maniclike symptoms | #6 |
irmph | #6 |
value09 | #6 |
psychopathology children | #6 |
combined condition | #6 |
benefitrisk ratio | #6 |
symptoms disorder | #6 |
schizophrenia g72 | #6 |
gxr efficacy | #6 |
child delayed | #6 |
psychiatric | #6 |
parents major | #6 |
pavgrnk | #6 |
adhd compared | #6 |
140 children | #6 |
seidman | #6 |
anxiety disorder relatives | #6 |
concurrent validation | #6 |
groups adults | #6 |
criteria adhd | #6 |
oppositional defiant | #6 |
symptoms adhd | #6 |
ascertained | #6 |
schizophrenic probands | #6 |
t518 | #6 |
disorder combined | #6 |
disorders relatives | #6 |
adhd genetic factors | #6 |
interpreting estimates | #6 |
stimulant treatment children | #6 |
schizophrenia spectrum schizophrenia | #6 |
spn812 | #7 |
n1031 | #7 |
adhd asrs | #7 |
qlesqsf | #7 |
outpatient child | #7 |
pmee | #7 |
adhd improvement | #7 |
nalysis | #7 |
development adhd | #7 |
teachers boys | #7 |
wonderlic | #7 |
long repeats | #7 |
haplotype schizophrenia | #7 |
statistical measure | #7 |
adhd symptoms association | #7 |
child impaired | #7 |
studies dopamine | #7 |
saica | #7 |
neuroimage study | #7 |
attention task | #7 |
methylphenidate therapy | #7 |
markov chain analysis | #7 |
boys adhd | #7 |
relatives schizophrenic patients | #7 |
pdag mdd | #7 |
ldx treatment | #7 |
adhdct | #7 |
coming years | #7 |
children learning disorders | #7 |
palauans | #7 |
hraff | #7 |
locus haplotypes | #7 |
snap25 adhd | #7 |
parents prevalence | #7 |
systematic chart review | #7 |
disorders probands | #7 |
skin flush response | #7 |
hyperactivity brain | #7 |
mdd pdag | #7 |
seeking substance | #7 |
mph adhd adults | #7 |
disorder substance | #7 |
adhd symptoms | #7 |
genome‐wide association | #7 |
velo‐cardio‐facial | #7 |
parents psychiatric disorders | #7 |
exon15 | #7 |
relatives risk | #7 |
nmu prescription | #7 |
asd asd youth | #7 |
measures adhd | #7 |
adhd substance disorders | #7 |
kgas | #7 |
adhd criteria | #7 |
sensorimotor timing | #7 |
children bpd | #7 |
dependence rates | #7 |
pediatric major depression | #7 |
pdqr | #7 |
exome chip analyses | #7 |
neurocognitive performances | #7 |
adhd persistence | #7 |
flush response | #7 |
swedish registry data | #7 |
candidate gene schizophrenia | #7 |
persistence anxiety disorders | #7 |
adhd boys girls | #7 |
adhd emotional dysregulation | #7 |
idir | #7 |
bipolar unipolar disorders | #7 |
children tourettes syndrome | #7 |
association cdh13 | #7 |
myosin5b | #7 |
conduct disorder girls | #7 |
highrisk siblings | #7 |
mph adhd | #7 |
nrp104 | #7 |
childhood disorder | #7 |
6 psychiatric disorders | #7 |
confusability | #7 |
asd youth | #7 |
implicating | #7 |
adhd sud sud | #7 |
prevention schizophrenia | #7 |
adhd authors | #7 |
adhd overweight obesity | #7 |
chromosome workshop | #7 |
drd5 | #7 |
dimensional measures | #7 |
parent reports | #7 |
ancestry attention | #7 |
members schizophrenia | #7 |
tomoxetine | #7 |
methylomics | #7 |
controls probands | #7 |
adhdrs | #7 |
combined type adhd | #7 |
authors goal | #7 |
polygenic scores adhd | #7 |
odd | #7 |
rs3916966 | #8 |
avoidant disorder | #8 |
adhd boys | #8 |
promising directions | #8 |
male multifactorial inheritance | #8 |
ordered subsets | #8 |
disorders baseline | #8 |
aversion adhd | #8 |
studies provide | #8 |
participants adhd | #8 |
disorders families | #8 |
symptoms behaviors | #8 |
diagnosis major depression | #8 |
link adhd | #8 |
treatment lead | #8 |
schizophrenia members | #8 |
adhdcd | #8 |
chromosome schizophrenia | #8 |
adhd unaffected | #8 |
substantial evidence | #8 |
nonpsychotic | #8 |
biological relatives | #8 |
therapeutic dilemmas | #8 |
abbreviated questionnaire | #8 |
adhd manic symptoms | #8 |
probands risk | #8 |
biederman | #8 |
treatment sirolimus | #8 |
disease humans polymorphism | #8 |
control adhd | #8 |
attention | #8 |
adhdhi | #8 |
n1314 | #8 |
pvalues005 | #8 |
bpd disorders | #8 |
human aggression | #8 |
diagnosed adhd | #8 |
sample youth | #8 |
nonverbal social | #8 |
adhd associations | #8 |
adhd rtv | #8 |
indicators schizophrenia | #8 |
mph adults | #8 |
volumetric reductions | #8 |
mwq | #8 |
pempirical | #8 |
affairs cooperative | #8 |
euphoria | #8 |
familial aggregation adhd | #8 |
cadhd | #8 |
gender effects | #8 |
analysis association | #8 |
behavioral inhibition risk | #8 |
offspring trios | #8 |
notch4 | #8 |
impaired motor performance | #8 |
adhd remission | #8 |
agreement measures | #8 |
rs3916965 | #8 |
behavior attention | #8 |
crossover comparison | #8 |
stimulanttreated | #8 |
familybased association study | #8 |
multigenerational pedigree | #8 |
subjects children | #8 |
adhd stimulant | #8 |
adhd adolescence | #8 |
metaanalysis schizophrenia | #8 |
differential utility | #8 |
onset bpd | #8 |
adhd dat1 | #8 |
symptoms impairment | #8 |
autistic traits children | #8 |
childhood mania | #8 |
negative symptoms scale | #8 |
dimesylate ldx | #8 |
polygenic associations | #8 |
controls relatives | #8 |
adhd symptom scores | #8 |
unaffected siblings adhd | #8 |
adhd inattentive | #8 |
pliszka | #8 |
hemideletion | #8 |
behavioral inhibition anxiety | #8 |
attention deficit adhd | #8 |
prescription stimulant | #8 |
child diagnostic | #8 |
schizophrenia polymorphisms | #8 |
presence autistic traits | #8 |
psychiatric genomics | #8 |
10q223 | #8 |
impulsivity adhd | #8 |
disorder probands | #8 |
shared familial effects | #8 |
comparison girls | #9 |
haplotype snps | #9 |
adhd enuresis | #9 |
extendedrelease methylphenidate | #9 |
rs685012 | #9 |
orosmph irmph | #9 |
dao gene | #9 |
rasd2 | #9 |
disruptive behavior disorders | #9 |
adhd healthy | #9 |
disorders sex interaction | #9 |
mdd youth | #9 |
schizophrenia resilience | #9 |
serotonin gene polymorphisms | #9 |
proband groups | #9 |
hhrr | #9 |
alzheimer disease schizophrenia | #9 |
comorbidity female | #9 |
ldps | #9 |
39 datasets | #9 |
festschrift | #9 |
hyperactivity automobile | #9 |
moderate sensitivity | #9 |
pregnancy depression | #9 |
adhd article | #9 |
n41 | #9 |
symptoms mania | #9 |
male nuclear | #9 |
adhdi | #9 |
nonreplications | #9 |
children assessed | #9 |
lag sequential analysis | #9 |
netherlands twin registry | #9 |
serotonin genes | #9 |
hyperactivity humans | #9 |
taiwanese families | #9 |
subtypes adhd | #9 |
sud bipolar disorder | #9 |
aisrs | #9 |
stimulant medication | #9 |
snp7 | #9 |
nuremberg code | #9 |
nonparanoids | #9 |
25e07 | #9 |
neuropsychologic function | #9 |
adhd loci | #9 |
childhood psychosis | #9 |
ecpbhs | #9 |
schizotaxic | #9 |
genes risk factors | #9 |
etiologically | #9 |
adderall | #9 |
inattentive | #9 |
endophenotypic | #9 |
blindly | #9 |
sustained attention schizophrenia | #9 |
addh | #9 |
ads individuals | #9 |
substantial risk | #9 |
rpdr | #9 |
diagnostic efficiency | #9 |
g×s interaction disorders | #9 |
hum genet | #9 |
adult report | #9 |
deficit disruptive | #9 |
gwas psychiatric disorders | #9 |
depression offspring | #9 |
adult symptoms | #9 |
drd4 | #10 |
comorbid bpd | #10 |
association dat1 | #10 |
gwas adhd | #10 |
panic depression | #10 |
genetics network | #10 |
association death | #10 |
asd tourette syndrome | #10 |
nephews | #10 |
shared neurobiology | #10 |
risk md | #10 |
evidence genetic | #10 |
parent‐of‐origin effects | #10 |
childhood adhd symptoms | #10 |
amphetamine salts | #10 |
deficits adhd | #10 |
genes disorders | #10 |
psychiatric genetic studies | #10 |
irmph orosmph | #10 |
rorb | #10 |
caadid | #10 |
adult years | #10 |
comorbid odd | #10 |
genetic vulnerability schizophrenia | #10 |
sleep problems adhd | #10 |
kruglyak | #10 |
ascertainment methods | #10 |
cbclap | #10 |
preteen | #10 |
slod | #10 |
case identification | #10 |
aged attention | #10 |
adhd childhood | #10 |
4th | #10 |
severity adhd | #10 |
reassessed | #10 |
groups boys | #10 |
new specialty | #10 |
nonpharmacologic treatments | #10 |
image project | #10 |
diminished risk | #10 |
noninhibited | #10 |
untreated adhd | #10 |
linkage analyses | #10 |
systematic qualitative review | #10 |
adulthood association | #10 |
probands bpd | #10 |
comorbidity | #10 |
normal sexual | #10 |
rates abuse | #10 |
d4 receptor gene | #10 |
comorbidity depressive | #10 |
anxiety disorders children | #10 |
sexual dimorphisms | #10 |
adhd unaffected siblings | #10 |
psychiatric clinic | #10 |
adhd substance disorder | #10 |
conduct disorder | #10 |
dms1 | #10 |
adhd difficulties | #10 |
adhd sud | #10 |
preschool depressive | #10 |
disorder age | #10 |
pthreshold | #10 |
small effects | #10 |
stimulants child | #10 |
young adult outcome | #10 |
bipolar disorder probands | #10 |
stimulants humans | #10 |
adhd quality | #10 |
juvenile mania | #11 |
children bipolar | #11 |
differences parents | #11 |
adhd time | #11 |
inattentive type | #11 |
psychiatric disorders youth | #11 |
symptom subtype | #11 |
hydrochloride attention | #11 |
comorbidity patterns | #11 |
cutraits | #11 |
offspring bipolar parents | #11 |
inhibition adhd | #11 |
familybased association test | #11 |
markers adhd | #11 |
paternal smoking | #11 |
cardinal symptoms | #11 |
remission adhd | #11 |
achievement adolescent | #11 |
shared familial | #11 |
female relatives | #11 |
adolescents adhd | #11 |
differences adhd | #11 |
gene adhd | #11 |
vcfs | #11 |
ldx placebo | #11 |
deficits schizophrenia patients | #11 |
effects genes | #11 |
panic disorder comorbidity | #11 |
defiant disorder | #11 |
rs1137070 | #11 |
adhd female humans | #11 |
agoraphobia anxiety | #11 |
hyperactivity child cross | #11 |
dimesylate | #11 |
release methylphenidate | #11 |
children addh | #11 |
youth bpd | #11 |
neuropsychological test scores | #11 |
shr model | #11 |
study perspective | #11 |
multiple domains | #11 |
nonadhd controls | #11 |
rora rorb | #11 |
pediatric bipolar disorder | #11 |
attention deficit disorder | #11 |
major depression adhd | #11 |
disorders mothers | #11 |
disorder pedigrees | #11 |
adhd intellectual disability | #11 |
adhd substance | #11 |
lisdexamfetamine ldx | #11 |
differentiated genetic | #11 |
adhd psychopathology | #11 |
disorders | #11 |
informativeness | #11 |
4372 | #11 |
real progress | #11 |
sample adults | #11 |
maternal antenatal anxiety | #11 |
adult relatives | #11 |
ppp3cc | #11 |
fbatpc | #11 |
nosologists | #11 |
diagnosis adults | #11 |
disease humans schizophrenia | #11 |
prodromal psychosis | #11 |
adhd onset | #11 |
growth delays | #11 |
serotonin genetic receptor | #11 |
dopamine d5 receptors | #11 |
n136 | #11 |
preschool depressive disorder | #11 |
polymorphism 5 | #11 |
studies mtbi | #11 |
etiology pathophysiology | #11 |
impaired parents child | #12 |
sec23ip | #12 |
onelevel | #12 |
response atomoxetine | #12 |
twins humans models | #12 |
common psychiatric | #12 |
cbcl children | #12 |
disorder subjects | #12 |
nonoral | #12 |
deficits attention | #12 |
adhd offspring | #12 |
sample consisted | #12 |
unaffected sibs | #12 |
epilepsy mothers | #12 |
comorbid disorder | #12 |
impulsivity children | #12 |
adhd core symptoms | #12 |
symptom rating | #12 |
impaired parents | #12 |
sud adhd | #12 |
genes methylation | #12 |
perceived motor competence | #12 |
girls relationship | #12 |
dat1 polymorphism | #12 |
adhd age | #12 |
metan | #12 |
striatal sensitivity | #12 |
covid19 restrictions children | #12 |
nhe9 | #12 |
youths bpd | #12 |
convergent functional | #12 |
lossavoidance | #12 |
unaffected siblings individuals | #12 |
disorder adult | #12 |
assessment adhd | #12 |
salts extended | #12 |
adhd symptoms adults | #12 |
psychotic mood disorders | #12 |
rs947267 | #12 |
cnvs risk | #12 |
studies relatives | #12 |
40–48 | #12 |
systematized | #12 |
treatment paliperidone | #12 |
psychiatric clinics | #12 |
effects time | #12 |
treatment attention | #12 |
digital treatment | #12 |
adult outcome | #12 |
sexually dimorphic effects | #12 |
common disorders | #12 |
juvenile bipolar | #12 |
early psychosis study | #12 |
multiplex schizophrenia | #12 |
rs778293 | #12 |
psychotic behavior | #12 |
thalamic activation | #12 |
obesity risk alleles | #12 |
adhd dopamine | #12 |
ksadse | #12 |
functional impairments | #12 |
sud patients adhd | #12 |
n1397 | #12 |
probands siblings | #12 |
defiant | #12 |
psychiatric genetics | #12 |
obesity adhd | #12 |
stimulant medication children | #12 |
pleiotropic mechanisms | #12 |
neurocognitive measures | #12 |
comorbidity diagnostic | #12 |
hawi | #12 |
test wcst | #12 |
kappa coefficients | #12 |
adolescent adult age | #12 |
variable age | #12 |
scales treatment | #12 |
amfetamine | #12 |
psychometric measure | #13 |
taiwanese sample | #13 |
diagnostic concepts | #13 |
methods subjects | #13 |
late onset | #13 |
colorado springs | #13 |
morbidity risks | #13 |
disorders child | #13 |
robust effects | #13 |
response inhibition adolescents | #13 |
studies bipolar | #13 |
weight bmi | #13 |
psychotic mood | #13 |
rates comorbidity | #13 |
cognitive impulsivity | #13 |
longallele | #13 |
velocardiofacial syndrome vcfs | #13 |
bpd offspring | #13 |
diagnostic threshold | #13 |
symptoms attention | #13 |
male samples | #13 |
adhd cognitive | #13 |
risk mood | #13 |
necrotic death | #13 |
114 years | #13 |
transdermal methylphenidate | #13 |
adhd alterations | #13 |
disorder childhood | #13 |
chi12 | #13 |
genomewide significance | #13 |
adhd alcohol | #13 |
permutation testing | #13 |
scale studies | #13 |
specific hypotheses | #13 |
familial risk schizophrenia | #13 |
adverseevents | #13 |
adderall mph | #13 |
girls | #13 |
pair 6 chromosomes | #13 |
convergent functional genomics | #13 |
nonoral routes | #13 |
label studies | #13 |
psychiatric risk | #13 |
adhdodd | #13 |
risk parents | #13 |
overanxious | #13 |
pkcm | #13 |
ravg | #13 |
disorders sud | #13 |
disorder youth | #13 |
humans methylphenidate | #13 |
iiv | #13 |
environment adolescent | #13 |
adhd diagnosis | #13 |
persistence remission | #13 |
psychometrics reproducibility | #13 |
studies adults | #14 |
suds | #14 |
lisdexamfetamine dimesylate ldx | #14 |
older adults adhd | #14 |
genetic studies schizophrenia | #14 |
factors schizophrenia | #14 |
genes schizophrenia | #14 |
prss mdd | #14 |
comorbid condition | #14 |
geschwind | #14 |
ocd scz | #14 |
children stimulants | #14 |
disorder child | #14 |
emotional impulsivity | #14 |
adhd symptoms adulthood | #14 |
cautiously | #14 |
familial disorder | #14 |
diagnosis mdd | #14 |
economic psychology | #14 |
siblings probands | #14 |
subcortical brain volume | #14 |
children criteria | #14 |
cnvs park2 | #14 |
stimulant abuse | #14 |
bipolar probands | #14 |
relatives male probands | #14 |
n643 | #14 |
lphn3 adhd | #14 |
symptoms psychiatric disorders | #14 |
mph adderall | #14 |
early precursors | #14 |
social school | #14 |
differential heritability | #14 |
siblings cases | #14 |
hillside | #14 |
adhd phenotype | #14 |
disorder odd | #14 |
children bipolar disorder | #14 |
teachers reports | #14 |
sud patients | #14 |
common disorder | #14 |
quetiapine bipolar disorder | #14 |
unaffected siblings controls | #14 |
wraadds | #14 |
nimh genetics | #14 |
associations adhd | #14 |
selfcontained | #14 |
attention executive | #14 |
mixed amphetamine salts | #14 |
adhd brain | #14 |
disorders comorbid | #14 |
worldwide prevalence | #14 |
aadhd | #14 |
adhd performance | #15 |
sackett | #15 |
card sorting | #15 |
adhd functional connectivity | #15 |
substance disorder patients | #15 |
association schizophrenia | #15 |
adults substance disorders | #15 |
pregnancy risk factor | #15 |
study design features | #15 |
seconddegree relatives | #15 |
velocardiofacial | #15 |
risk substance | #15 |
tests psychomotor | #15 |
ocd comorbid adhd | #15 |
interaction genotype | #15 |
4669 | #15 |
poor perception | #15 |
disord | #15 |
disorder evidence | #15 |
adhd disorders | #15 |
gxr children | #15 |
d10s1423 | #15 |
zranb2 | #15 |
adhd study | #15 |
treatment xr | #15 |
agents attention | #15 |
daily living administration | #15 |
metabolic syndrome obesity | #15 |
adhd treatment | #15 |
behavior disorders | #15 |
male relatives | #15 |
genderdifferences | #15 |
symptoms adulthood | #15 |
persons schizophrenia | #15 |
methylation gene expression | #15 |
snps methylation | #15 |
nhsd | #15 |
diagnostic interviews | #15 |
chi2 | #15 |
cbclpbd | #15 |
49 children | #15 |
prodromal symptoms psychosis | #15 |
male mood | #15 |
psychiatric interviews | #15 |
asd mdd | #15 |
wfirsp | #15 |
mphmlr | #15 |
rs2652511 | #15 |
bipolar schizoaffective disorder | #15 |
symptom count | #15 |
healthy comparison subjects | #15 |
paediatric bipolar disorder | #15 |
executive function theory | #15 |
adhd diagnostic | #15 |
schizophrenia families | #15 |
special classes | #16 |
youths adhd | #16 |
adhd symptom severity | #16 |
risk psychotic disorders | #16 |
regional cortical thickness | #16 |
n424 | #16 |
adhd diagnoses | #16 |
adhd obesity | #16 |
ntac | #16 |
dbds | #16 |
pervasive developmental disorder | #16 |
onset anticipation | #16 |
scz risk | #16 |
brainbody | #16 |
delayed action | #16 |
control participants participants | #16 |
informant assessment | #16 |
familial relationship | #16 |
linkage findings | #16 |
“difficulty | #16 |
longitudinal assessments | #16 |
growth children | #16 |
rdoc framework | #16 |
cprsr | #16 |
geneenvironment interaction | #16 |
drug disorder | #16 |
parents anxiety disorders | #16 |
multiple test | #16 |
factual factor analysis | #16 |
adhd anxiety symptoms | #16 |
hyperkinetic disorders | #16 |
dexedrine | #16 |
study adhd | #17 |
multiple anxiety disorders | #17 |
schizophrenia psychosis | #17 |
pediatric samples | #17 |
samples children | #17 |
adulthood adhd | #17 |
pediatric disorder | #17 |
random forest regression | #17 |
childhood predictors | #17 |
psychology schizotypal | #17 |
disability adhd | #17 |
prevalence adhd | #17 |
assessment positive symptoms | #17 |
driving behaviors | #17 |
studies psychiatric | #17 |
response inhibition network | #17 |
ldx children | #17 |
substance disorders sud | #17 |
ocd age | #17 |
association markers | #17 |
combined type | #17 |
diagnostic statistical | #17 |
association scan | #17 |
method participants | #17 |
larger sample | #17 |
mania | #17 |
considerable overlap | #17 |
depression md | #17 |
parents adhd | #17 |
condfdr | #17 |
a161t | #17 |
resultsfirst | #17 |
persistent adhd | #17 |
rbfox1 | #17 |
neuropsychiatric evaluation | #17 |
nonparametric linkage | #17 |
accn2 | #17 |
hyperactivity attitude | #17 |
factors siblings | #17 |
asd ocd | #17 |
relation adhd | #17 |
medication type | #17 |
bipolar disorder subjects | #17 |
young offspring | #17 |
5071 | #17 |
prospective follow | #17 |
operationalized | #18 |
illness twins | #18 |
poor tolerability | #18 |
potential contributor | #18 |
prolonged therapy | #18 |
linkage regions | #18 |
single nucleotide severity | #18 |
low dose naltrexone | #18 |
kcnj4 | #18 |
bipolar choice trial | #18 |
depression genetic risk | #18 |
dcdq | #18 |
unaffected siblings | #18 |
adhd sud patients | #18 |
adhd cannabis | #18 |
relatives control subjects | #18 |
4286 | #18 |
marijuana age | #18 |
bipolar major | #18 |
symptom overlap | #18 |
minisatellite repeats | #18 |
psuds | #18 |
behavior scale | #18 |
transporter gene | #18 |
hrr 95 | #18 |
meet criteria | #18 |
fullsiblings | #18 |
risk disorders | #18 |
anxiety mdd | #18 |
neuropsychologic | #18 |
unemotionality | #18 |
schizophrenia dtnbp1 | #18 |
preschool diagnostic | #18 |
childhood traumas | #18 |
adhd groups | #18 |
children vcfs | #18 |
stimulant | #18 |
adhd severity | #18 |
lisdexamfetamine dimesylate | #18 |
primary substance | #18 |
conduct disorder children | #18 |
schizophrenia patients relatives | #18 |
action preparations | #19 |
verbal memory task | #19 |
disorders adults | #19 |
familial transmission | #19 |
nature nurture | #19 |
rs3918342 | #19 |
medication trials | #19 |
adhd young adults | #19 |
hyperconnectivity | #19 |
comorbidity rates | #19 |
scz ocd | #19 |
improvement symptoms | #19 |
substance adhd | #19 |
candidate loci | #19 |
adhd neurodevelopmental | #19 |
psychosocial features | #19 |
addicted patients | #19 |
adolescent age onset | #19 |
mcgue | #19 |
lod1 | #19 |
disconfirmations | #19 |
assessing outcome | #19 |
adolescent age | #19 |
euphoric effects | #19 |
casecontrol sample | #19 |
symptoms adolescent | #19 |
mental health human | #19 |
adolescent | #20 |
slc6a2 | #20 |
illness female humans | #20 |
human ortholog | #20 |
humanhap550v3 | #20 |
disorders polymorphism | #20 |
deficits children | #20 |
response curve | #20 |
neuroleptic dose | #20 |
rbfox1 gene | #20 |
neuropsychologically | #20 |
transmission ratio distortion | #20 |
pedigree selection | #20 |
prenatal exposure nicotine | #20 |
notch4 gene | #20 |
controlled pilot study | #20 |
parent origin | #20 |
mflynn | #20 |
manual mental | #20 |
dicap | #20 |
nonpsychotic siblings | #20 |
ratings adhd | #20 |
gsma | #20 |
depression adhd | #20 |
linkage scans | #20 |
outcome attention | #20 |
kiddie | #20 |
parents risk | #20 |
inhibition children | #20 |
neuropsychological function | #20 |
biological families | #20 |
sibpair | #20 |
schizophrenia attention | #20 |
genehunterplus | #21 |
male probands | #21 |
rs778294 | #21 |
motor problems | #21 |
prescription stimulants | #21 |
risk offspring | #21 |
childhood conduct disorder | #21 |
treatment growth | #21 |
bipolar pedigrees | #21 |
children pdd | #21 |
agler | #21 |
rat shr | #21 |
prospective longitudinal | #21 |
methods age | #21 |
cacng2 | #21 |
linkage chromosomes | #21 |
gender comparisons | #21 |
humans linkage | #21 |
sodium hydrogen exchanger | #21 |
prevalent cases | #21 |
children comorbid | #21 |
life enjoyment | #21 |
prenatal exposure alcohol | #21 |
comorbid adhd | #21 |
palau | #21 |
schizotypals | #21 |
11year followup | #21 |
psychiatric symptoms patients | #21 |
chronic tics | #21 |
monoamine oxidase maoa | #21 |
schizophrenia taiwan | #21 |
schizophrenia united | #21 |
schizophrenia disease humans | #21 |
stimulants children | #22 |
youth bipolar | #22 |
partial replication | #22 |
pre‐school | #22 |
diagnostic interview | #22 |
genetic phenotype | #22 |
adhd stimulants | #22 |
disruptive | #22 |
children attention | #22 |
familiality | #22 |
disorders major | #22 |
polygenic overlap | #22 |
adhd susceptibility | #22 |
neurocognitive performance schizophrenia | #22 |
syndrome vcfs | #22 |
study methodology | #22 |
adhd impulsivity | #22 |
neuropsychological profiles | #22 |
preliminary reliability | #22 |
association prs | #22 |
amygdala structure | #22 |
adhd anxiety | #22 |
ldx | #22 |
schizophrenia pgc | #22 |
youth mdd | #22 |
bpd subjects | #22 |
amphetamine methylphenidate | #22 |
adderall xr | #22 |
niacin skin | #22 |
6 disorders | #22 |
controls | #22 |
rg022 | #22 |
depression treatment patients | #22 |
10p | #22 |
adhd rating scale | #22 |
overtransmission | #22 |
wechsler scales | #23 |
executive functions efs | #23 |
notch4 receptors | #23 |
scq asd | #23 |
siblings | #23 |
wide linkage | #23 |
comprehensively | #23 |
asd scq | #23 |
syp | #23 |
handful | #23 |
snapiv | #23 |
n449 | #23 |
male individuals | #23 |
propylamines | #23 |
kotkin | #23 |
phenotype definition | #23 |
adhd symptoms childhood | #23 |
intrinsic curvature | #23 |
interview dsm | #23 |
twins genetic predisposition | #23 |
neuroleptic withdrawal | #23 |
oppositional | #23 |
serotonin receptor gene | #23 |
interacting molecules | #23 |
diagnostician | #23 |
anxious mothers | #23 |
heterogeneity genetic | #23 |
adolescents bpd | #23 |
disequilibrium male | #23 |
metadoxine | #23 |
genetic investigation | #23 |
risk studies | #23 |
rs464049 | #23 |
mdd anxiety disorders | #23 |
conduct problems adhd | #24 |
snorting | #24 |
children meeting | #24 |
ocd asd | #24 |
guanfacine extended release | #24 |
amrs | #24 |
0535 | #24 |
dsmiiir criteria | #24 |
child female humans | #24 |
nieces | #24 |
aggression anxiety | #24 |
chromosomes 6 | #24 |
quantitative phenotypes | #24 |
adra2a | #24 |
refilled | #24 |
female humans illness | #24 |
stroop task performance | #24 |
adhd comorbidities | #24 |
statistical manual | #24 |
15q13 | #24 |
symptoms psychosis | #24 |
lithium bipolar disorder | #24 |
mental control | #24 |
genome‐wide linkage scans | #24 |
actigraphy studies | #24 |
intelligence schizophrenia | #24 |
expected growth | #24 |
stress exposure | #24 |
nonstimulant | #24 |
sassr | #24 |
deficits | #24 |
age regions | #24 |
adhd characteristics | #24 |
receptor d4 | #24 |
neural activation patterns | #24 |
major affective disorders | #25 |
psychiatric nosology | #25 |
d22s283 | #25 |
task patients | #25 |
vietnam twin registry | #25 |
understanding adhd | #25 |
copy variants schizophrenia | #25 |
–environment interactions | #25 |
exposure adhd | #25 |
nudt3 | #25 |
bipolar choice | #25 |
splicing regulator | #25 |
dyscalculia | #25 |
clinical interviews | #25 |
baseline assessment | #25 |
anticipation schizophrenia | #25 |
biased transmission | #25 |
liker | #25 |
efficacy atomoxetine | #25 |
slc6a3 gene | #25 |
decreased volume | #25 |
conners parent | #25 |
dapple | #25 |
symptom subtypes | #25 |
neurocognitive predictors | #25 |
young relatives | #25 |
screening scale | #25 |
association snps | #25 |
or194 | #25 |
maternal criticism | #25 |
psychiatric disorders children | #25 |
behavioral disinhibition | #25 |
school failure | #25 |
psychometrically | #25 |
wkht | #25 |
unique profile | #25 |
nonmedical prescription stimulants | #26 |
gender risk | #26 |
twins humans | #26 |
adults symptoms | #26 |
maob gene | #26 |
adhd mothers | #26 |
affair | #26 |
htr1d | #26 |
psychometric measures | #26 |
voxel based morphometry | #26 |
screening diagnosis | #26 |
association allele | #26 |
social impairment | #26 |
alcohol drug abuse | #26 |
neurodevelopmental genes | #26 |
behavioral disorder | #26 |
selfmonitor | #26 |
bipolar phenotype | #26 |
prenatal health | #26 |
adrenergic uptake | #26 |
efpc | #26 |
label study | #26 |
core symptoms adhd | #26 |
n81 | #26 |
rs3730358 | #26 |
structured interviews | #26 |
major depression md | #26 |
wm microstructure | #26 |
agreement raters | #26 |
add | #26 |
inrich | #26 |
controls adhd | #26 |
orosmethylphenidate | #26 |
offspring risk | #27 |
asherson | #27 |
rate remission | #27 |
mdd asd | #27 |
potential confounds | #27 |
intelligence male | #27 |
genetic susceptibility schizophrenia | #27 |
schizophrenia genetic | #27 |
ptsd adults | #27 |
aff | #27 |
consecutively | #27 |
weaker effects | #27 |
bipolar disorder comorbidity | #27 |
cnvs adhd | #27 |
treatment atomoxetine | #27 |
disorders executive | #27 |
international meeting | #27 |
hyperactivity disorder adhd | #27 |
childreniv | #27 |
based association | #27 |
osterrieth | #27 |
association signals | #27 |
t102c polymorphism | #27 |
d22s278 | #27 |
greater severity | #27 |
adhd autism | #28 |
symptoms inattention | #28 |
symptom reports | #28 |
parent teacher | #28 |
adhd differences | #28 |
rest task | #28 |
sustained attention deficits | #28 |
slc6a3 | #28 |
persons bipolar disorder | #28 |
disorder compared | #28 |
clinical correlates | #28 |
dopamine transporter binding | #28 |
maternal adhd | #28 |
subjects bpd | #28 |
adults study | #28 |
genomewide studies | #28 |
vigilance performance | #28 |
assessment negative symptoms | #28 |
image study | #28 |
snp18 | #28 |
new genetics | #28 |
families schizophrenia | #28 |
emotional dysregulation | #28 |
preliminary findings | #28 |
dopamine receptor d4 | #28 |
metaalgorithm | #28 |
6179 | #28 |
genetic etiology | #28 |
guze | #28 |
schizophrenia onset | #28 |
male methylphenidate | #28 |
ocd disorders | #28 |
child clinical | #28 |
polysomnography actigraphy | #28 |
cortical gyrification | #28 |
raters | #28 |
male polymorphism | #29 |
disorders offspring | #29 |
medication usage | #29 |
shared genetic basis | #29 |
misuse diversion | #29 |
etiological heterogeneity | #29 |
childhood diagnosis | #29 |
childhood antecedents | #29 |
disorder bipolar | #29 |
bipolar disorder youth | #29 |
parents bipolar disorder | #29 |
hyperactivity impulsivity | #29 |
adhd patients controls | #29 |
inattention hyperactivity impulsivity | #29 |
offspring parents | #29 |
psychosocial dysfunction | #29 |
dsmiiir | #29 |
attention‐deficit | #29 |
kcnn3 | #29 |
medication misuse | #29 |
studies genes | #29 |
comorbidity ptsd | #29 |
african‐american | #29 |
infants weight | #29 |
comorbid | #30 |
specific psychopathology | #30 |
problems attention | #30 |
nimh | #30 |
treatment adolescents | #30 |
genetic perspective | #30 |
caarsinv | #30 |
diagnosticians | #30 |
relatives age | #30 |
adhd child | #30 |
nonaffected | #30 |
parental predictors | #30 |
structural brain features | #30 |
juvenile bipolar disorder | #30 |
association paternal age | #30 |
bmi growth | #30 |
hyperactive symptoms | #30 |
robust statistical methods | #30 |
individual studies | #30 |
growth childhood | #30 |
nicotine pregnancy | #30 |
antisocial behavior asb | #30 |
potential endophenotypes | #31 |
nonadhd | #31 |
discriminates | #31 |
neuroimage | #31 |
95 adhd | #31 |
depression genetic | #31 |
methylphenidate | #31 |
extant literature | #31 |
bpd risk | #31 |
sex effects | #31 |
n305 | #31 |
charles river | #31 |
lodscore | #31 |
twin concordance | #31 |
neuropsychologic deficits | #31 |
kif16b | #31 |
prs adhd | #31 |
impulsivity inattention | #31 |
genotype haplotypes | #31 |
reanalyzed | #31 |
smoking substance | #31 |
rgs4 schizophrenia | #31 |
variable tandem | #31 |
randomized crossover study | #32 |
attentiondeficit | #32 |
70–80 | #32 |
anterior insular | #32 |
10p13 | #32 |
anxiety disorders | #32 |
studies schizophrenia | #32 |
kremen | #32 |
gender | #32 |
adhd adolescents | #32 |
wiscr | #32 |
psychiatric genetic | #32 |
psychiatric disorders | #32 |
schizophrenia affective psychosis | #32 |
studies adolescent | #32 |
child psychiatric | #32 |
psdq | #32 |
rs206936 | #32 |
aggression attention | #32 |
repeat length | #32 |
parents child | #32 |
slc6a4 | #32 |
bipolar disorder bpi | #32 |
impulsecontrol | #32 |
subfields hippocampus | #32 |
psychosis youth | #32 |
asd symptoms children | #32 |
adhd patients | #33 |
children risk | #33 |
mood anxiety | #33 |
aspd bpd | #33 |
wfirs | #33 |
adhd evidence | #33 |
neuropsychiatric sle | #33 |
youth bipolar disorder | #33 |
current adhd | #33 |
val allele | #33 |
subcortical brain | #33 |
twins factor analysis | #33 |
quetiapine monotherapy | #33 |
briefa | #33 |
rhobtb3 | #33 |
maternal smoking pregnancy | #33 |
pharmacotherapy trials | #33 |
animal model adhd | #33 |
disorder symptom | #33 |
psychiatric sample | #33 |
rs1130214 | #33 |
autism symptoms | #33 |
neural reward processing | #33 |
psychiatric status | #33 |
prior findings | #33 |
frontopolar | #33 |
single snps | #33 |
original study | #33 |
neuropsychological deficits | #33 |
10repeat allele | #33 |
comorbidity cross | #33 |
ld adhd | #33 |
qsf | #33 |
association genes | #33 |
harvard | #34 |
md risk | #34 |
snp4 | #34 |
dsm5 dsmiv | #34 |
grm5 | #34 |
pharmacotherapy adhd | #34 |
social anxiety children | #34 |
treatment sud | #34 |
candidate gene polymorphisms | #34 |
disorders mood | #34 |
emerging consensus | #34 |
linkage studies | #34 |
treatment memantine | #34 |
disorder traits | #34 |
gxr | #34 |
disorders diagnostic | #34 |
risk psychiatric disorders | #34 |
psychological tests | #34 |
inattention | #34 |
young adults adhd | #34 |
cognition interaction | #34 |
structural brain asymmetries | #34 |
adhd sleep problems | #35 |
#35 | |
schizophrenia relatives | #35 |
bipolar spectrum disorders | #35 |
catechol‐o‐methyltransferase | #35 |
sample description | #35 |
familial risk | #35 |
recall patients | #35 |
choice impulsivity | #35 |
plink | #35 |
n64 | #35 |
lifetime rates | #35 |
adhd rating | #35 |
humans intelligence | #35 |
participants bpd | #35 |
schizophrenia schizotypy | #35 |
complex figure | #35 |
htr1b | #35 |
risk females | #35 |
bipolar disorder offspring | #35 |
schizophrenia gene | #35 |
lithium quetiapine | #35 |
n265 | #35 |
hyperactive disorder | #35 |
structure psychopathology | #36 |
neurotransmissions | #36 |
neurocognitive markers | #36 |
groups adhd | #36 |
term neuropsychological | #36 |
suny | #36 |
infant gender | #36 |
schizophrenia genes | #36 |
annett | #36 |
n185 | #36 |
comorbidity children | #36 |
stimulant medications | #36 |
adhd drug | #36 |
intracranial volume icv | #36 |
gypc | #36 |
adult antisocial | #36 |
orosmph | #36 |
disorder bpd | #36 |
nocebo response | #36 |
d6s274 | #36 |
siblings controls | #36 |
95 siblings | #36 |
young adult females | #36 |
overanxious disorder | #36 |
retrospective recall | #36 |
adhd control groups | #36 |
tests schizophrenia | #37 |
predictive utility | #37 |
n278 | #37 |
rs5 | #37 |
adhd asd | #37 |
offspring association | #37 |
parents adhd children | #37 |
slc22a16 | #37 |
dat1 gene | #37 |
disorder severity | #37 |
child behavioral | #37 |
studies comorbidity | #37 |
delayedaction preparations | #37 |
lisdexamfetamine | #37 |
mapping genomic loci | #37 |
combined sample | #37 |
genetics | #37 |
odd dimensions | #37 |
symptom criteria | #37 |
functioning adults | #37 |
adhd problems | #38 |
16 genes | #38 |
boys | #38 |
school age children | #38 |
methylphenidate treatment | #38 |
genome‐wide search | #38 |
pik4ca | #38 |
unfamiliar | #38 |
polymorphism gene | #38 |
rs2391191 | #38 |
d15s1360 | #38 |
height children | #38 |
familial risk depression | #38 |
pediatric adhd | #38 |
genetic risk schizophrenia | #38 |
kiddie schedule | #38 |
family‐based | #38 |
dsm criteria | #38 |
wisconsin card | #39 |
manic symptoms | #39 |
washu | #39 |
mood stabilization | #39 |
dsm5 criteria | #39 |
increased risk adhd | #39 |
ocd adhd | #39 |
nonparanoid | #39 |
female cases | #39 |
mdd ocd | #39 |
behavioral traits | #39 |
antisocial traits | #39 |
git1 | #39 |
iii personality | #39 |
test association | #39 |
markers genetic | #39 |
mlod | #39 |
adhd behavior | #39 |
onset children | #39 |
structural brain abnormalities | #39 |
asthma systematic review | #39 |
suggestive | #39 |
pharmacologic treatment | #39 |
cardiovascular adverse effects | #40 |
genetics schizophrenia | #40 |
rs2283265 | #40 |
chromosome 10p | #40 |
brainspan | #40 |
anx | #40 |
genetic studies | #40 |
gxe | #40 |
rare copy variants | #40 |
bipolars | #40 |
heinrichs | #40 |
familial effects | #40 |
onset | #40 |
genome scan | #40 |
dsmiv criteria | #40 |
reln gene | #40 |
diagnosis bipolar disorder | #40 |
psychosocial adversity | #41 |
methodological advances | #41 |
sibpairs | #41 |
pediatric subjects | #41 |
methylphenidate response | #41 |
male parents | #41 |
parent‐of‐origin | #41 |
effects growth | #41 |
neuropsychiatr | #41 |
bdnf adhd | #41 |
chromosomes 6q | #41 |
schizophrenia severity illness | #41 |
normal comparison subjects | #41 |
fhrs | #41 |
sirolimus patients | #41 |
tic disorders | #42 |
male panic | #42 |
individual items | #42 |
schizophrenia disorders | #42 |
schizophrenia | #42 |
serotonergic pathway | #42 |
n262 | #42 |
diagnostic comorbidity | #42 |
disorder social | #42 |
sorting test | #42 |
dtnbp1 schizophrenia | #42 |
fiveyear followup | #42 |
gwas meta | #42 |
adhd deficits | #42 |
child female | #42 |
p094 | #43 |
adhd prs | #43 |
neuropsychological tasks | #43 |
digs | #43 |
practitioner review | #43 |
adhd depression | #43 |
neuropsychological differences | #43 |
n176 | #43 |
candidate endophenotype | #43 |
snp1 | #43 |
n232 | #43 |
brain scans | #43 |
children enuresis | #43 |
simplex families | #43 |
massachusetts general | #43 |
mri study | #43 |
youngadult | #43 |
p023 | #43 |
disorder prevalence | #43 |
n242 | #43 |
n140 | #44 |
multidimensionality | #44 |
asd adults | #44 |
secondborns | #44 |
treatment adult | #44 |
adolescents attention | #44 |
immediaterelease | #44 |
mental disorders diseases | #44 |
nosologic | #44 |
odds ratio association | #44 |
prior studies | #44 |
sidp | #44 |
dopamine d5 | #44 |
uncaring | #45 |
behavior rating | #45 |
pooled size | #45 |
wnl | #45 |
controls subjects | #45 |
baseline adhd | #45 |
tcerg1l | #45 |
altered brain activation | #45 |
snpbased heritability | #45 |
inflation rate | #45 |
suggestive associations | #45 |
cep85l | #45 |
schizophrenia genome | #45 |
risk reduction strategies | #45 |
illness stress | #45 |
genetic underpinnings | #45 |
substance disorder | #45 |
genetic loading | #45 |
institute mental | #45 |
offspring adhd | #45 |
risk schizophrenia | #45 |
adhd parents | #45 |
pharmacogenetic studies | #45 |
prevalence psychiatric | #45 |
volume reductions | #45 |
familial coaggregation | #46 |
converging evidence | #46 |
previous findings | #46 |
gender influences | #46 |
adhd effects | #46 |
natural reward | #46 |
nat genet | #46 |
12 months treatment | #46 |
10year followup | #46 |
stronger connectivity | #46 |
lyons | #46 |
machine learning study | #46 |
neuropsychological performance | #46 |
referral bias | #46 |
response mph | #46 |
sex bias | #46 |
n164 | #46 |
cbt intervention | #46 |
loci chromosomes | #47 |
ocd mdd | #47 |
genetic study | #47 |
compromised | #47 |
desipramine dmi | #47 |
disorders studies | #47 |
schizophrenia alleles | #47 |
trauma risk | #47 |
meehl | #47 |
association bipolar disorder | #47 |
abstract objective | #47 |
shared polygenic risk | #47 |
pooled odds ratio | #47 |
or125 | #47 |
baiap2 | #47 |
psychiatric status rating | #47 |
childhood disorders | #47 |
parents depression | #47 |
comt | #47 |
velocardiofacial syndrome | #47 |
oppositional symptoms | #47 |
n280 | #47 |
scientific foundation | #48 |
n27 | #48 |
rtv | #48 |
effects gender | #48 |
1711 | #48 |
nullhypothesis | #48 |
mpp3 | #48 |
association test | #48 |
adhd dyslexia | #48 |
adhd prevalence | #48 |
n103 | #48 |
disorder case | #48 |
revised | #48 |
shared heritability | #48 |
negative schizotypy | #49 |
volume differences | #49 |
weak evidence | #49 |
disorder cognitive | #49 |
familial loading | #49 |
drug holidays | #49 |
schizophrenia cognition | #49 |
snap‐25 | #49 |
anxa7 | #49 |
nurture | #49 |
mental disorders children | #49 |
inbred wky rats | #49 |
hyperactivity autism | #49 |
rs2494732 | #49 |
serotonin plasma | #49 |
vdm | #50 |
proteins polymorphism | #50 |
n168 | #50 |
dsmiv dsm5 | #50 |
caseness | #50 |
rocf | #50 |
studies biomarkers | #50 |
pair 6 | #50 |
parent teacher ratings | #50 |
geneenvironment interactions | #50 |
impulsivity symptoms | #50 |
extended pedigrees | #50 |
life outcomes | #50 |
maoauvntr | #50 |
early onset schizophrenia | #50 |
intergenerational effects | #50 |
wais | #50 |
wiat | #50 |
genomic relationships | #50 |
common psychiatric disorders | #51 |
adults ocd | #51 |
substantial role | #51 |
bpd | #51 |
epilepsy adhd | #51 |
gender association | #51 |
male personality | #51 |
psychology adult | #51 |
compelling | #51 |
peer affiliation | #51 |
disorders children | #51 |
adhd knowledge | #51 |
1542 | #51 |
manovas | #51 |
adra1a | #52 |
gray matter alterations | #52 |
oros methylphenidate | #52 |
bipolar disorder children | #52 |
metaanalysis association | #52 |
asdadhd | #52 |
schizophrenia sex | #52 |
a218c | #52 |
major depression | #52 |
combined adhd | #52 |
youth asd | #52 |
intracranial volume | #52 |
schizophrenia controls | #52 |
chronic schizophrenia patients | #52 |
selenbp1 | #52 |
growth height | #52 |
ppm1h | #53 |
parahippocampal gyrus | #53 |
n138 | #53 |
snps candidate genes | #53 |
scales schizophrenia | #53 |
mania depression | #53 |
smoking schizophrenia | #53 |
risk analysis | #53 |
risktaking behavior | #53 |
dopamine plasma | #53 |
placebo children | #53 |
tourettes disorder | #53 |
extended‐release | #53 |
adoption study | #53 |
psychopathology | #53 |
schizophrenia adolescent | #53 |
adhdc | #53 |
chromosome 6p | #54 |
jackknife | #54 |
psychlit | #54 |
onset bipolar | #54 |
risk study | #54 |
dnms | #54 |
pregnancy time | #54 |
bpd children | #54 |
alcohol drug | #54 |
genetic reproducibility | #54 |
schizophrenia psychotic disorders | #54 |
ablim1 | #54 |
unphased | #54 |
longitudinal case | #55 |
flat affect | #55 |
disorders risk | #55 |
children diagnosis | #55 |
sample children | #55 |
childhood trauma exposure | #55 |
gene interaction | #55 |
1252 | #55 |
disorders prevalence | #55 |
emotional lability | #55 |
endophenotype | #55 |
tova | #55 |
mid adolescence | #55 |
neuropsychological studies | #55 |
viloxazine | #55 |
child behavior | #55 |
hyperactive | #56 |
pair chromosomes | #56 |
subfield | #56 |
tics children | #56 |
alcohol substance | #56 |
degree relatives | #56 |
disorder agoraphobia | #56 |
extendedrelease | #56 |
entry points | #56 |
cotwin | #56 |
schizophrenia offspring | #56 |
children siblings | #56 |
n43 | #56 |
methylphenidate hydrochloride | #57 |
model attention | #57 |
brain structure function | #57 |
atomoxetine hydrochloride | #57 |
interregional profiles differences | #57 |
oddsratio | #57 |
shared genetic etiology | #57 |
apol | #57 |
barkley | #57 |
zdhhc8 | #57 |
etdt | #57 |
rating inventory | #57 |
controls children | #58 |
childhood young adulthood | #58 |
100 children | #58 |
dbq | #58 |
association comt | #58 |
vntr polymorphisms | #58 |
repeat alleles | #58 |
controlled study | #58 |
single snp | #58 |
analysis schizophrenia | #58 |
tests attention | #58 |
children | #58 |
function schizophrenia | #58 |
heritable receptors | #58 |
comorbid psychiatric disorders | #58 |
adhd atomoxetine | #58 |
conners | #58 |
compelling evidence | #58 |
risk siblings | #59 |
risk psychiatric | #59 |
schizophrenia smoking | #59 |
mdd children | #59 |
rtn4r | #59 |
mdd adhd | #59 |
neuroleptic | #59 |
comt schizophrenia | #59 |
lphn3 | #60 |
duval | #60 |
inattention hyperactivity | #60 |
reported associations | #60 |
abuse dependence | #60 |
disruptive behavior disorder | #60 |
functional remission | #60 |
executive functioning | #60 |
3 domains | #60 |
disorders including | #60 |
generalize | #60 |
dysregulation profile | #61 |
homogeneous subgroups | #61 |
disorders asd | #61 |
study adherence | #61 |
oih | #61 |
comparison subjects | #61 |
unipolars | #61 |
cronbachs alpha | #61 |
disruptive behavior | #61 |
uncles | #61 |
uninhibited | #61 |
study adults | #61 |
wide scan | #61 |
13q32 | #61 |
relatives schizophrenia | #62 |
mph treatment | #62 |
schizophrenia human | #62 |
4 year | #62 |
bipolar youth | #62 |
substantial heritability | #62 |
inhibition memory | #62 |
maternal psychopathology | #62 |
1537 | #62 |
factors anxiety | #62 |
polygenic risk schizophrenia | #62 |
symptoms | #62 |
tdts | #62 |
neurocognitive | #63 |
structured interview | #63 |
behavioral dysregulation | #63 |
n179 | #63 |
accounted | #63 |
treatments adhd | #63 |
schizophrenia schizophrenic | #63 |
risk severity | #63 |
stability time | #63 |
ksads | #63 |
disorders bipolar | #63 |
treatment desipramine | #64 |
endosomal | #64 |
rating scales | #64 |
phacking | #64 |
children mph | #64 |
qlesq | #64 |
diagnostic utility | #64 |
40 countries | #64 |
males association | #64 |
risk trauma | #64 |
methylation cpg sites | #64 |
prefrontal dysfunction | #64 |
linkage | #64 |
europeanamerican | #64 |
methylphenidate adhd | #64 |
adhd 95 | #64 |
child | #64 |
methylphenidate mph | #64 |
childhood onset | #64 |
zcchc4 | #65 |
disorders genetic | #65 |
prior work | #65 |
male siblings | #65 |
etiology schizophrenia | #65 |
oxidase gene | #65 |
temperamental | #65 |
comorbid diagnosis | #65 |
emo | #65 |
neuropsychological impairments | #65 |
occurrence adhd | #65 |
net gene | #65 |
marry | #65 |
function female | #65 |
emotional regulation | #65 |
schizophrenic | #65 |
adhd epilepsy | #65 |
small sample size | #65 |
controls siblings | #65 |
behavioral genetic | #66 |
afternoons | #66 |
ci105 | #66 |
study studies | #66 |
simple phobia | #66 |
global ratings | #66 |
vswm | #66 |
extended release | #66 |
tourettes syndrome | #66 |
attention hyperactivity | #66 |
children mental retardation | #66 |
disorder chromosome | #66 |
adhd dcd | #66 |
neuropsychological profile | #66 |
tic disorder | #66 |
cbcldp | #66 |
risk bipolar | #67 |
n217 | #67 |
questionnaires treatment | #67 |
treatment quetiapine | #67 |
grade retention | #67 |
label trial | #67 |
patients bipolar disorders | #67 |
substance disorder sud | #67 |
variance attention | #67 |
entire sample | #67 |
nonrighthandedness | #67 |
subjects | #67 |
findings association | #67 |
parents teachers | #67 |
chronic tic disorder | #67 |
mental diseases | #67 |
conceptual issues | #68 |
brain gene | #68 |
snparray | #68 |
qms | #68 |
hypofrontality | #68 |
delay aversion | #68 |
offspring | #68 |
naturalistic | #68 |
stress response genes | #69 |
panic disorder | #69 |
physical anhedonia | #69 |
illicit substances | #69 |
polymorphism schizophrenia | #69 |
clarifying | #69 |
chronological age | #69 |
people adhd | #69 |
regulatory enzymes | #69 |
symptom checklist | #69 |
low adherence | #69 |
impulsivity hyperactivity | #69 |
humans schizophrenia | #69 |
ctgn | #69 |
scale assessment | #69 |
nonrandom mating | #70 |
neuropsychological consequences | #70 |
linkage scan | #70 |
new diagnoses | #70 |
smoking children | #70 |
subsequent diagnosis | #70 |
interactions genes | #70 |
latrophilin | #70 |
a2bp1 | #70 |
core adhd symptoms | #70 |
oros mph | #70 |
npl | #70 |
objective examine | #71 |
treated children | #71 |
vergence | #71 |
genetic | #71 |
adhd behaviors | #71 |
mspi polymorphism | #71 |
neuroimaging genetics | #71 |
adhd anxiety disorders | #71 |
genes role | #71 |
boys age | #72 |
ocd subjects | #72 |
learning disorders | #72 |
methodological issues | #72 |
digital health intervention | #72 |
digital intervention | #72 |
molecular genetic | #72 |
school functioning | #72 |
genetic receptors | #72 |
3372 | #73 |
adhd medications | #73 |
poison control centers | #73 |
etiological | #73 |
disorders childhood | #73 |
logodds | #73 |
patients rest | #73 |
cellular models | #73 |
adhd subtype | #73 |
kagan | #73 |
relapse depression | #73 |
anxiety adhd | #73 |
youth | #73 |
cortical abnormalities | #73 |
adult | #73 |
schizophrenia genetics | #73 |
candidate endophenotypes | #73 |
transmission disequilibrium | #74 |
age schizophrenia | #74 |
allele association | #74 |
preferential transmission | #74 |
desipramine | #74 |
reaction time variability | #74 |
pfkfb2 | #74 |
based diagnosis | #74 |
antisocial | #75 |
slc1a1 | #75 |
drd4 gene | #75 |
referred | #75 |
onset anxiety | #75 |
weight body mass | #75 |
adhd traits | #75 |
linkage schizophrenia | #75 |
risk sample | #75 |
efficacy outcome | #75 |
neale | #75 |
akl | #75 |
impairment children | #75 |
hyperactivity adhd | #75 |
mind wandering | #75 |
child china | #75 |
chronic tic | #76 |
disorders brain | #76 |
positive schizotypy | #76 |
depression pregnancy | #76 |
schizophrenia young | #76 |
adhd total | #76 |
centers disease control | #76 |
yates | #76 |
nondeficit | #76 |
child humans | #76 |
child depressive | #76 |
performance schizophrenia | #77 |
childhood adhd | #77 |
cortex schizophrenia | #77 |
wcst performance | #77 |
psychological male | #77 |
lod score | #77 |
performance adhd | #77 |
atomoxetine children | #77 |
disorders female | #78 |
local gyrification | #78 |
rare copy | #78 |
bpi | #78 |
adhd impairment | #78 |
pharmacologic treatments | #78 |
predixcan | #78 |
bipolar disorder adhd | #78 |
women antidepressants | #78 |
cardinal | #79 |
age adhd | #79 |
studies relationship | #79 |
schizophrenic patients | #79 |
patients adhd | #79 |
n46 | #79 |
student athletes | #79 |
anxiety separation | #79 |
genetic linkage studies | #79 |
obesity metabolic syndrome | #79 |
nosological | #79 |
disorder panic | #79 |
additive effects | #79 |
retrospective assessment | #79 |
pregnancy mothers | #79 |
linkage chromosome | #80 |
total brain | #80 |
adhd rats | #80 |
adhd drugs | #80 |
maternal smoking | #80 |
clinical interview | #80 |
siblings schizophrenia | #80 |
pathophysiology adhd | #81 |
disliking | #81 |
oral routes | #81 |
children parents | #81 |
eyhs | #81 |
subcortical brain volumes | #81 |
bipolar disorder | #81 |
treatment adults | #81 |
major diagnostic | #81 |
hacking | #81 |
interregional profiles | #81 |
endophenotypes | #81 |
body mass diabetes | #81 |
differences age | #81 |
adults asd | #82 |
association maternal smoking | #82 |
symptoms diagnosis | #82 |
gene schizophrenia | #82 |
genes pathways | #82 |
cumulative evidence | #82 |
behavior assessment | #82 |
impaired quality life | #82 |
frontopolar cortex | #82 |
square distribution | #82 |
auditory verbal | #82 |
comorbidity disorders | #82 |
comorbidity survey | #82 |
tests risk | #83 |
unreliability | #83 |
management adhd | #83 |
illness | #83 |
substance disorders | #83 |
oros | #83 |
disorders anxiety | #83 |
multifactorial inheritance | #83 |
neurocognitive functioning | #83 |
adult form | #83 |
paterson | #83 |
women adhd | #84 |
adhd adhd symptoms | #84 |
21 months | #84 |
15q133 | #84 |
complex disorder | #84 |
wide significance | #85 |
adhdrsiv | #85 |
buprenorphine maintenance | #85 |
adhd assessment | #85 |
atomoxetine | #85 |
linkage loci | #85 |
european samples | #85 |
monitoring response | #85 |
humans risk | #85 |
adhd subtypes | #85 |
9r | #85 |
brain asymmetry | #85 |
hyperkinetic disorder | #85 |
recycling endosome | #85 |
genomics consortium | #85 |
pord | #86 |
siblings children | #86 |
findings implications | #86 |
humans inhibition | #86 |
paranoid | #86 |
parents | #86 |
affective psychosis | #86 |
child conduct | #86 |
bipolar spectrum disorder | #87 |
n203 | #87 |
3utr | #87 |
risk alleles | #87 |
synaptosomal protein | #87 |
bipolar | #87 |
ptsd trauma | #87 |
comparison children | #87 |
putamen volume | #87 |
comorbid psychopathology | #88 |
hyperkinetic | #88 |
drug effects | #88 |
common risk | #88 |
bonferroni correction | #88 |
druggable | #88 |
prenatal nicotine exposure | #89 |
metaanalytic review | #89 |
22 studies | #89 |
auditory attention | #89 |
2455 | #89 |
nucleotide schizophrenia | #89 |
comprehensive identification | #89 |
chrna2 | #89 |
empirically | #89 |
euphoric | #89 |
machine learning analysis | #89 |
caars | #89 |
1month | #90 |
association metaanalysis | #90 |
snps haplotypes | #90 |
watt | #90 |
linkage genome | #90 |
antidepressants pregnancy | #90 |
attention deficit hyperactivity | #90 |
verbal ability | #90 |
male neuropsychological | #90 |
pervasive | #90 |
242 | #90 |
naturalistic study | #91 |
identified studies | #91 |
adhd treatments | #91 |
parental socioeconomic status | #91 |
callousness | #91 |
adhd males | #91 |
complicates | #91 |
adhd efficacy | #91 |
cortical brain | #91 |
assertion | #91 |
wcst | #91 |
studies association | #92 |
documenting | #92 |
adults schizophrenia | #92 |
treatment mania | #92 |
studies sex | #92 |
h2snp | #92 |
raise | #92 |
candidate gene | #92 |
lifetime cannabis | #93 |
rate adult | #93 |
narrowly | #93 |
ymrs | #93 |
referral consultation | #93 |
standardized differences | #93 |
controls participants | #93 |
adhd measures | #94 |
gottman | #94 |
sustained attention | #94 |
hyperactivity autistic | #94 |
social development | #94 |
performance variability | #94 |
hfasd | #94 |
brain case | #94 |
growing body | #94 |
gprc5b | #94 |
aldh1l1 | #94 |
cdh13 | #94 |
underachievement | #94 |
cadps2 | #95 |
minisatellite | #95 |
asd study | #95 |
studies differences | #95 |
total brain volume | #95 |
mdd bip | #95 |
executive | #95 |
adolescents bipolar | #95 |
infa | #95 |
nxph1 | #96 |
chromosome 9q34 | #96 |
uvntr | #96 |
phenotype polymorphism | #96 |
scq | #96 |
nominally | #96 |
behavior rating inventory | #96 |
genome‐wide association study | #97 |
low cardiorespiratory fitness | #97 |
adolescent onset | #97 |
7q36 | #97 |
children tics | #97 |
studies asthma | #97 |
hcadherin | #97 |
driving behavior | #98 |
identically | #98 |
wdpcp | #98 |
syn2 | #98 |
hyperactivity brazil | #98 |
bipolar disorder risk | #98 |
concerta | #98 |
induced hyperalgesia | #98 |
massachusetts general hospital | #98 |
linkage study | #98 |
single nucleotide receptor | #98 |
nonfamilial | #98 |
oppositionality | #98 |
psychoactive | #99 |
neurodevelopmental processes | #99 |
metaanalysis trials | #99 |
disorder diagnosis | #99 |
abuse potential | #99 |
disease genetics | #99 |
nonspecificity | #99 |
adhd role | #99 |
methodssubjects | #99 |
chd6 | #99 |
medication effects | #99 |
xp114 | #99 |
substrains | #99 |
motor timing | #99 |
reticence | #100 |
pelham | #100 |
terror | #100 |
adhd methylphenidate | #100 |
12year | #100 |
obesity abdominal obesity | #100 |
hippocampal subfield volumes | #100 |
clinical effects | #100 |
addictive drugs | #101 |
diagnostic boundaries | #101 |
harlan | #101 |
genomewide | #101 |
upsit | #101 |
genetic risk scores | #101 |
empirical test | #101 |
cosegregation | #101 |
advanced paternal age | #101 |
roh | #101 |
schizophrenia psychotic | #101 |
neurocognitive impairments | #101 |
slc6a4 gene | #101 |
depression pregnant women | #101 |
torture | #101 |
tsls | #101 |
disorder psychiatric | #102 |
functional pathways | #102 |
klf13 | #102 |
sob | #102 |
inhibition psychological | #102 |
individuals aud | #102 |
treatment seeking | #102 |
parents offspring | #102 |
male neuropsychological tests | #102 |
ocd children | #103 |
pgc | #103 |
genome wide association | #103 |
symptom profile | #103 |
genetic pedigree polymorphism | #103 |
patients 12 months | #103 |
schizophrenia mood disorders | #103 |
touchstone | #103 |
clinical picture | #103 |
controlled studies | #104 |
genetic mechanism | #104 |
tourette disorder | #104 |
1934 | #104 |
schizophrenia metaanalysis | #104 |
motor competence | #104 |
individual sites | #104 |
genomic region | #104 |
academic problems | #105 |
current article | #105 |
school dropout | #105 |
adhd review | #105 |
dsmiv diagnosis | #105 |
neuropsychological dysfunction | #105 |
schizophrenia probands | #105 |
drug dyskinesia | #105 |
children methylphenidate | #106 |
cogs | #106 |
humans lod | #106 |
children odd | #106 |
disorder female | #107 |
functional correlates | #107 |
oral methylphenidate | #107 |
λs | #107 |
matter volumes | #107 |
sequential analysis | #107 |
growth outcomes | #107 |
daao | #107 |
chronic tic disorders | #107 |
lenticular | #107 |
mothers adhd | #107 |
consecutive sample | #107 |
adolescents bipolar disorder | #107 |
ldn | #107 |
aged psychiatric | #108 |
afni | #108 |
918 | #108 |
proband | #108 |
pervasive developmental | #108 |
site differences | #108 |
origin effects | #108 |
symptoms childhood | #108 |
n197 | #108 |
antimanic agents | #108 |
nesarc | #108 |
maternal warmth | #108 |
pediatric psychopharmacology | #108 |
association cigarette smoking | #108 |
psychosis proneness | #109 |
irrespective | #109 |
depression bipolar | #109 |
worthy | #109 |
gabra6 | #109 |
neuroleptic medication | #109 |
risk bipolar disorder | #109 |
adhd medication | #109 |
longitudinal trajectories | #109 |
total scores | #109 |
adult adhd symptoms | #110 |
enlistment | #110 |
linkage association | #110 |
rat models | #110 |
markers genome | #110 |
adhd parent | #110 |
5httlpr genotype | #111 |
dao | #111 |
affective symptoms | #111 |
n107 | #111 |
affective psychoses | #111 |
selective reporting | #111 |
symptom ratings | #111 |
dimorphisms | #111 |
unmedicated | #112 |
brain gene expression | #112 |
childhood risk factors | #112 |
pediatric obsessive | #112 |
substantial proportion | #112 |
independent studies | #112 |
bipolar parents | #112 |
dopamine d4 receptors | #112 |
factors social | #112 |
impact exposure | #112 |
xr | #113 |
neuropsychological functions | #113 |
cronbach | #113 |
male prevalence | #113 |
functional neuroanatomy | #114 |
omim | #114 |
analysis statistical | #114 |
comorbid anxiety | #114 |
nuclear families | #115 |
liability | #115 |
–r | #115 |
n34 | #115 |
schizophrenia severity | #115 |
endorsed | #115 |
genet | #115 |
neuropsychological | #116 |
schizophrenic psychology | #116 |
formulating | #116 |
wm abnormalities | #116 |
diseases twins | #116 |
unipolar | #117 |
current symptoms | #117 |
trait impulsivity | #117 |
polygenic association | #117 |
quality life outcomes | #117 |
neurocognitive endophenotypes | #117 |
z29 | #117 |
coordinated analysis | #117 |
prenatal smoking | #117 |
spm2 | #118 |
academic functioning | #118 |
definitively | #118 |
grandiosity | #118 |
prevention science | #118 |
major female | #118 |
grandfathers | #118 |
genetic receptor serotonin | #118 |
satisfaction questionnaire | #118 |
large study | #118 |
dopaminergic genes | #119 |
naa ratio | #119 |
efd | #119 |
method data | #119 |
midadolescence | #119 |
schizophrenia linkage | #119 |
misunderstandings | #120 |
differences children | #120 |
t01 | #120 |
n108 | #121 |
subfield volumes | #121 |
remittance | #121 |
disorder autism | #121 |
new avenues | #121 |
neurocognitive deficits | #121 |
aunts | #121 |
cgibp | #121 |
neuropsychiatric disorders | #122 |
structural brain alterations | #122 |
refute | #122 |
disregard | #122 |
msit | #122 |
male risk | #122 |
pabs | #122 |
v11 | #122 |
levels adhd | #122 |
schizoaffective | #122 |
urvs | #122 |
anxious | #122 |
psychopathology symptoms | #122 |
brain alterations | #122 |
adhd comorbidity | #122 |
disorder depressive | #122 |
adhd ocd | #123 |
chr psychosis | #123 |
adcy2 | #123 |
clinical status | #123 |
wechsler | #123 |
age initiation | #123 |
longitudinal sample | #124 |
laboratory observations | #124 |
g×s interaction | #124 |
p097 | #124 |
treatment subjects | #124 |
trios | #124 |
wechsler intelligence scale | #124 |
maximum lod score | #124 |
9q34 | #124 |
drug placebo | #124 |
attention regulation | #124 |
twothirds | #124 |
caregiver strain | #125 |
patients chronic schizophrenia | #125 |
disorder risk | #125 |
anxiety problems | #125 |
segregation analysis | #125 |
machine learning prediction | #125 |
psychosis individuals | #125 |
biological parents | #126 |
developmental aspects | #126 |
familial influences | #126 |
positive negative symptoms | #126 |
memory adhd | #126 |
parent version | #126 |
complex genetics | #126 |
drug disorders | #126 |
odd conduct disorder | #126 |
taiwanese population | #127 |
genes | #127 |
attention child | #127 |
adult alleles | #127 |
stevenson | #127 |
psychiatric diagnoses | #127 |
disinhibited | #127 |
drd2 | #127 |
neuropsychological measures | #128 |
aged 6 | #128 |
n102 | #129 |
implicate | #129 |
intactness | #129 |
personality assessment | #129 |
familial | #129 |
behavioral outcome | #129 |
opiate antagonists | #129 |
1990a | #130 |
families | #130 |
adhd inattention | #130 |
retrospective data analysis | #130 |
adolescents ocd | #131 |
kinesthesia | #131 |
bip mdd | #131 |
mood anxiety disorders | #131 |
differed | #131 |
pair 15 chromosomes | #131 |
register study | #131 |
moderating effects | #131 |
snps | #131 |
incapacitation | #131 |
strong evidence | #131 |
animals attention | #131 |
learning disabilities | #132 |
large european cohort | #132 |
p074 | #132 |
hkd | #132 |
sodas | #132 |
child cognition | #132 |
late adolescents | #132 |
male prospective | #132 |
linkage humans | #132 |
childhood anxiety disorders | #132 |
n79 | #132 |
entire brain | #132 |
heroin dependence | #133 |
mph | #133 |
onset bipolar disorder | #133 |
disorders social | #134 |
children adults | #134 |
preliminary examination | #134 |
vntr | #134 |
social deficits | #135 |
association analyses | #135 |
male massachusetts | #135 |
olfactory identification | #136 |
firstborns | #136 |
tspan8 | #136 |
relied | #136 |
social environments | #136 |
adolescents young | #136 |
sorcs3 | #136 |
risk factors smoking | #136 |
adolescent bipolar | #137 |
association asthma | #137 |
studies examined | #137 |
gaming | #137 |
longitudinal evidence | #137 |
schizophrenia affective disorders | #137 |
memantine treatment | #137 |
expressed emotion | #137 |
psychological male memory | #137 |
biomarkers diagnosis | #138 |
mtor activation | #138 |
asds | #138 |
6q | #138 |
control individuals | #138 |
evidence association | #138 |
n129 | #139 |
schizophrenia studies | #139 |
meet | #139 |
mgh | #139 |
symptoms disorders | #139 |
neuropsychiatric | #139 |
fhr | #139 |
schizotypal traits | #140 |
parental anxiety | #140 |
intriguing | #140 |
n115 | #140 |
haplotype block | #141 |
prss | #141 |
genetic vulnerability | #141 |
emotional symptoms | #141 |
disorder comorbidity | #141 |
disorders personality | #142 |
5ht1b receptors | #142 |
neurotrophic | #142 |
22q112 deletion syndrome | #142 |
disorders psychotic | #142 |
covid19 restrictions | #142 |
hydrogen exchangers | #143 |
conduct | #143 |
molecular genetics | #143 |
risk factors obesity | #143 |
fetal movement | #143 |
peripheral biomarkers | #143 |
agents tricyclic | #144 |
diagnosed attention | #144 |
statistical female humans | #144 |
child psychopathology | #144 |
blind study | #144 |
diagnostic procedure | #144 |
rfg | #144 |
elston | #144 |
humans linear | #144 |
g72 | #144 |
n105 | #145 |
individual symptoms | #145 |
major psychoses | #145 |
drug alcohol | #145 |
common genetic variants | #145 |
pcb exposure | #145 |
affs | #145 |
p00018 | #145 |
genome‐wide association studies | #145 |
studies depressive | #145 |
genetic heterogeneity | #145 |
early initiation | #145 |
twin studies | #146 |
warranted | #146 |
prenatal nicotine | #146 |
oppositional behavior | #146 |
genders | #146 |
atypicality | #146 |
intelligence quotient | #146 |
adult psychopathology | #146 |
intraindividual variability | #147 |
comprising | #147 |
abbreviated | #147 |
lras | #147 |
histrionic | #147 |
p0016 | #147 |
sabp | #148 |
basc | #148 |
single locus | #148 |
cognitive variables | #148 |
adolescent young | #148 |
adhd symptoms children | #149 |
cdrsr | #149 |
parental substance | #149 |
schizotypy | #149 |
risk mdd | #149 |
brain correlates | #149 |
adhd relationship | #150 |
categorical | #150 |
sud treatment | #150 |
impulsive | #150 |
highlighting | #150 |
chrnb2 | #150 |
nonmedical | #150 |
consisted | #151 |
higher burden | #151 |
synaptic biology | #151 |
placebo subjects | #152 |
parent report | #152 |
implicates | #152 |
diagnostic systems | #152 |
copy variants cnvs | #152 |
xq21 | #152 |
httlpr | #152 |
linkage disequilibrium mapping | #152 |
schizophrenia diagnosis | #152 |
undegraded | #152 |
metaanalytic | #152 |
large sample | #152 |
functional impairment | #152 |
autistic traits | #152 |
increases risk | #152 |
atxn1 | #152 |
schizophrenia bipolar disorder | #153 |
caucasian children | #153 |
schizophrenia deficits | #153 |
genomewide linkage | #153 |
5 httlpr | #153 |
demoralization | #153 |
editions | #153 |
alcohol conditions | #153 |
humans learning | #153 |
marginally | #153 |
schizophrenia magnetic resonance | #154 |
dsm | #154 |
exposure maternal | #154 |
wisc | #154 |
disorder phenotype | #154 |
emphasizing | #154 |
atomoxetine placebo | #154 |
ncsr | #155 |
year follow | #155 |
snpheritability | #155 |
humans polymorphism | #155 |
genomewide scan | #155 |
clarification | #155 |
genetic risk | #156 |
n84 | #156 |
prospective controlled study | #156 |
interpersonal functioning | #156 |
600000 | #156 |
tests male | #156 |
dopamine d4 | #157 |
enigma consortium | #157 |
panic disorder agoraphobia | #157 |
new knowledge | #157 |
adolescents | #158 |
myo5b | #158 |
cognitive tempo | #158 |
drd4 genotype | #158 |
htr2c | #158 |
sledai | #158 |
greatest | #158 |
primary setting | #158 |
ppp2r2b | #158 |
clinical diagnostic | #158 |
genetic linkage | #158 |
oprm1 | #158 |
patients substance | #159 |
selfratings | #159 |
teachers parents | #159 |
quetiapine treatment | #159 |
adult human brain | #159 |
dav | #159 |
nonpersistent | #159 |
age onset | #160 |
humans impulsive | #160 |
separation anxiety disorder | #160 |
smds | #160 |
medial temporal | #160 |
schizophrenia bipolar | #161 |
hyperactivity disorders | #161 |
tic symptoms | #161 |
population samples | #161 |
genetic component | #161 |
adult adhd patients | #161 |
behavioral difficulties | #161 |
rats wky | #162 |
disorder depression | #162 |
disorder clinical | #162 |
ksadspl | #162 |
140 | #162 |
cooccurring disorders | #162 |
empirical tests | #162 |
neurobiology | #163 |
dn cells | #163 |
sample | #163 |
dsmiv | #163 |
neuropsychological tests | #163 |
paternal age | #163 |
5htt | #163 |
complex phenotype | #164 |
illness schizophrenia | #164 |
familial liability | #164 |
diagnostic status | #164 |
impairments | #164 |
anxiety attention | #164 |
years children | #165 |
risk subsequent | #165 |
boys girls | #165 |
washington university | #165 |
neurocognitive performance | #165 |
symptom reduction | #166 |
earlyonset schizophrenia | #166 |
antidepressant therapy | #166 |
alcohol disorders aud | #166 |
linkage genetic | #166 |
cotwins | #166 |
genetic influence | #166 |
shared environment | #166 |
receptor gene | #166 |
domain criteria | #166 |
12–14 | #166 |
moderates | #167 |
ipsych | #167 |
association obesity | #167 |
polygenic architecture | #168 |
wisciii | #168 |
children 6 years | #168 |
leonard | #168 |
neurocognitive functions | #168 |
duration illness | #169 |
genetic association analysis | #169 |
matter microstructure | #169 |
international congress | #169 |
multifactorial | #169 |
perseverations | #169 |
n111 | #169 |
traumas | #170 |
disorders young | #170 |
risk gene | #170 |
lgi | #170 |
arrb2 | #170 |
anxiety child | #170 |
pharmacodynamic properties | #170 |
single nucleotide schizophrenia | #170 |
cfg | #170 |
conditional probability | #170 |
functional laterality humans | #171 |
genesets | #171 |
n91 | #171 |
child psychiatry | #171 |
inattention impulsivity | #172 |
treatment studies | #172 |
immune disorders | #172 |
enuresis | #173 |
disorders study | #173 |
interpersonal sensitivity | #173 |
gabbr1 | #174 |
male mental | #174 |
subsyndromal | #175 |
tics | #175 |
large samples | #175 |
development schizophrenia | #176 |
confounds | #176 |
mph placebo | #176 |
kraepelin | #177 |
patients opioid | #177 |
independent datasets | #177 |
confounded | #177 |
disorders sex | #177 |
ascertainment | #177 |
suicide death | #177 |
hyperactive children | #177 |
cortical surface | #178 |
n78 | #178 |
strong genetic component | #178 |
parent rated | #178 |
underpinnings | #179 |
pregnancy children | #179 |
atomoxetine atx | #179 |
strongest evidence | #179 |
behaviorally | #179 |
genetic confounding | #179 |
gene interactions | #179 |
cvlt | #180 |
nagelkerke | #180 |
connectivity networks | #180 |
copy variants | #180 |
combinatory | #181 |
perceptual disorders | #181 |
mothers pregnancy | #181 |
unemotional traits | #181 |
htr4 | #182 |
control participants | #182 |
structured | #182 |
scz bip | #182 |
phenocopies | #182 |
271 | #182 |
mechanistic target | #183 |
psychometric testing | #183 |
genotype humans | #183 |
studies gwas | #183 |
rating | #183 |
reading difficulties | #184 |
based morphometry | #184 |
effects atomoxetine | #184 |
wei | #184 |
pdd | #185 |
genome human | #185 |
long acting | #185 |
n‐acetylcysteine | #185 |
phenocopy | #185 |
reward sensitivity | #185 |
allison | #185 |
biomarker studies | #186 |
218 | #186 |
predominately | #186 |
hyperactivity symptoms | #186 |
statistical female | #186 |
risperidone placebo | #187 |
stratifying | #187 |
schizophrenia evidence | #187 |
schizophrenia major depression | #187 |
blood biomarkers | #188 |
depression treatment | #188 |
enigma | #188 |
autocorrelation | #188 |
3 untranslated region | #188 |
parahippocampus | #188 |
undertreatment | #189 |
differential association | #189 |
genetic correlations | #189 |
bna | #189 |
linkage evidence | #190 |
scwt | #190 |
functioning children | #190 |
medication adhd | #190 |
childhood | #190 |
fsiq | #191 |
implicated | #191 |
mood disorder | #191 |
greater activation | #191 |
mph children | #191 |
psychiatric phenotypes | #191 |
schedule female | #191 |
social dysfunction | #191 |
clarify | #191 |
dopamine genes | #191 |
iasp | #192 |
association response | #192 |
612 years | #192 |
inconsistent findings | #194 |
freedman | #194 |
joseph | #194 |
polymorphisms snps | #195 |
sza | #195 |
placebo p001 | #195 |
cognitive endophenotypes | #195 |
clinical global | #195 |
perinatal complications | #197 |
wm performance | #197 |
neural substrates | #197 |
dependence symptoms | #197 |
arhgef9 | #197 |
overactivity | #197 |
mdd scz | #198 |
developmentally | #198 |
lifetime diagnosis | #198 |
snps schizophrenia | #198 |
g×s | #198 |
ptk2b | #198 |
raises | #199 |
childhood symptoms | #199 |
specific genes | #199 |
male phenotype | #199 |
bsd | #199 |
male | #199 |
asic1a | #199 |
disruptive disorders | #200 |
childhood attention | #200 |
neuropsychological battery | #200 |
mri data | #200 |
small samples | #200 |
asd adhd | #200 |
parents schizophrenia | #201 |
catecholomethyltransferase | #201 |
functional genomics | #201 |
disorder humans | #201 |
pain tolerance | #202 |
cognitive flexibility | #202 |
pdq | #203 |
childhood adulthood | #203 |
genetic liability | #203 |
control association | #203 |
neuropsychological correlates | #203 |
unaffected | #203 |
stopsignal task | #203 |
concurrent validity | #204 |
respond | #204 |
adolescent psychiatry | #204 |
attentional control | #204 |
schizophreniform | #204 |
microsatellite marker | #204 |
extend | #204 |
uptodate | #206 |
selfdirectedness | #206 |
nonshared | #206 |
genes risk | #206 |
method drug | #207 |
sluggish cognitive tempo | #207 |
susceptibility schizophrenia | #208 |
prkg1 | #208 |
parental alcohol | #208 |
prolactin levels | #208 |
variable expression | #209 |
clinical benefits | #209 |
baseline follow | #209 |
n96 | #210 |
acds | #210 |
maudsley | #210 |
5year followup | #210 |
60mg | #210 |
correspondence | #210 |
park2 | #210 |
vntr polymorphism | #211 |
greater risk | #211 |
predisposition disease | #211 |
grm7 | #212 |
adult patients adhd | #212 |
stroop task | #212 |
apoe4 allele | #212 |
ps005 | #212 |
dimensional models | #212 |
hkdc1 | #212 |
sampling strategy | #213 |
replication studies | #213 |
trauma ptsd | #213 |
negative outcomes | #213 |
sought | #213 |
disorders models | #214 |
cvltii | #214 |
rare cnvs | #214 |
continuous performance test | #214 |
humans neuropsychological | #214 |
schizophrenia chinese | #214 |
suggestive evidence | #214 |
lifetime version | #215 |
bilag | #215 |
male mental disorders | #215 |
adult cognition | #215 |
vivo correlation | #216 |
functional mri study | #216 |
chromosome 15 | #217 |
antisocial personality | #217 |
male schizophrenia | #217 |
glr | #217 |
panic | #218 |
parental | #218 |
gene based | #218 |
trim31 | #218 |
hippocampal subfield | #218 |
study selection | #219 |
polygenic | #219 |
misunderstood | #219 |
snpa | #220 |
drug double | #220 |
normal controls | #220 |
symptoms adults | #221 |
parental psychopathology | #221 |
irritable mood | #221 |
studies cognition | #221 |
telephone interview | #221 |
triangularis | #221 |
score male | #222 |
methyltransferase comt | #222 |
patient engagement | #222 |
diagnoses | #222 |
childhoodonset | #222 |
n76 | #222 |
learning disability | #223 |
revisited | #223 |
study findings | #223 |
axis disorders | #224 |
effective treatments | #224 |
sensing ion | #224 |
abnormalities schizophrenia | #224 |
adhd sleep | #224 |
gria2 | #224 |
coordination disorder | #225 |
default network | #225 |
bipolar spectrum | #225 |
inattentiveness | #226 |
subfields | #226 |
children placebo | #226 |
hk3 | #226 |
criteria diagnosis | #227 |
individual variability | #227 |
unemotional | #227 |
scales psychotic | #227 |
subcortical regions | #227 |
dependent variables | #227 |
disorder study | #227 |
comorbid anxiety disorders | #228 |
age subjects | #228 |
control based | #228 |
atomoxetine treatment | #228 |
male twins | #228 |
overlapped | #229 |
birth complications | #229 |
structural abnormalities | #229 |
equally | #229 |
psychiatric outcomes | #230 |
international multicenter | #231 |
commission errors | #231 |
4years | #231 |
heritable | #231 |
risk indicators | #231 |
hyperactivity behavior | #232 |
differences prevalence | #232 |
serotonin transporter gene | #232 |
candidate genes | #234 |
worse performance | #234 |
study sample | #234 |
discriminating | #235 |
probabilistic forecasts | #235 |
disorder medication | #235 |
shr wky rats | #236 |
route administration | #238 |
placebo response | #238 |
agoraphobia | #238 |
fifty years | #238 |
reliably | #238 |
allelic heterogeneity | #239 |
healthy siblings | #240 |
acid oxidase | #240 |
pdag | #240 |
patients siblings | #240 |
nosology | #240 |
scientific data | #240 |
adolescent offspring | #241 |
doubleblind | #241 |
disorder asd | #241 |
adequately | #241 |
symptoms quality | #241 |
neurodevelopmental model | #242 |
joint analysis | #242 |
psychiatric comorbidities | #242 |
reward processing | #242 |
impulsive choice | #242 |
sodium hydrogen | #242 |
patients relatives | #243 |
valid | #243 |
female | #243 |
aggressive behaviors | #243 |
onset obsessive | #243 |
n74 | #244 |
giftedness | #244 |
paliperidone | #245 |
population differences | #245 |
disorder ptsd | #245 |
interregional | #245 |
adversity | #245 |
5ht2a receptor | #245 |
community controls | #246 |
cadm2 | #246 |
expression genetic | #246 |
dsmivtr | #246 |
motor performance | #247 |
812 | #247 |
cigarette smoking | #248 |
epigenetic studies | #248 |
chinese families | #248 |
studies associations | #248 |
developmental disorder | #249 |
childs | #251 |
behavioral characteristics | #251 |
hypoactivation | #252 |
german patients | #252 |
iqs | #253 |
female subjects | #253 |
genomewide association | #253 |
tourette | #253 |
intellect | #253 |
kappas | #254 |
studies metaanalysis | #254 |
benzodiazepine | #254 |
cpt performance | #254 |
schizophrenia adult | #254 |
study schizophrenia | #254 |
conduct problems | #255 |
biochemical studies | #256 |
cacna1c gene | #256 |
shared genetic | #256 |
larsson | #256 |
carlson | #257 |
children adhd symptoms | #257 |
year study | #259 |
endorsement | #259 |
parental depression | #259 |
n61 | #260 |
piq | #260 |
dexamphetamine | #261 |
anxiety depressive disorders | #261 |
pharmacotherapy | #261 |
diagnosis | #261 |
22q11ds | #263 |
obsessive compulsive disorder | #263 |
sex factors | #263 |
fluid intelligence | #263 |
selfreports | #263 |
genomewide linkage scan | #263 |
adverse health | #264 |
confirm | #264 |
disorder personality | #264 |
distinct subtypes | #264 |
conceptualized | #264 |
attention problems | #264 |
long term outcomes | #265 |
5090 | #266 |
schizophrenia cases | #266 |
new models | #266 |
diagnostic validity | #266 |
ptsd risk | #266 |
scz mdd | #267 |
phenotype schizophrenia | #267 |
diagnosis schizophrenia | #268 |
strong support | #268 |
neuropsychological impairment | #268 |
genetic approaches | #268 |
diagnostic process | #269 |
test scores | #269 |
years baseline | #269 |
phlda1 | #270 |
withdrawn | #270 |
age effects | #270 |
segregate | #270 |
largest | #270 |
sibling pairs | #271 |
social adversity | #271 |
adult psychiatric | #271 |
symptoms assessed | #271 |
genetic overlap | #271 |
circadian genes | #271 |
structural brain | #272 |
diagnostic issues | #272 |
schizophrenia siblings | #273 |
age | #273 |
alcohol smoking | #273 |
szs | #273 |
statistics topic | #273 |
search terms | #273 |
4year | #273 |
rora | #273 |
444 | #273 |
sleep behavior | #274 |
22 years | #274 |
reading disability | #275 |
underlie | #275 |
surgency | #275 |
maf1 | #275 |
missingness | #276 |
familial schizophrenia | #276 |
2q | #276 |
t102c | #276 |
mania symptoms | #277 |
growing evidence | #277 |
adolescent risk | #277 |
nicotinic schizophrenia | #277 |
adhd healthy controls | #277 |
synaptosomal | #278 |
manual | #278 |
clinical setting | #278 |
nr3c1 | #278 |
early psychosis | #278 |
ocd | #279 |
silico approach | #279 |
nicotine dependence | #279 |
intelligence scale | #279 |
rating scale | #280 |
remitted | #280 |
acting | #280 |
child parent | #280 |
polygenic risk | #280 |
n47 | #280 |
brain volumes | #280 |
cognition female | #280 |
abuser | #280 |
individuals | #281 |
psychotic bipolar | #281 |
disorders adult | #281 |
premature death | #281 |
phenotyped | #281 |
collaborative analysis | #282 |
onset ocd | #282 |
reading problems | #282 |
response inhibition | #282 |
5ht1b | #282 |
antisocial behaviors | #283 |
continue | #283 |
velo | #283 |
titrated | #283 |
aspd | #284 |
neuroanatomical | #285 |
3untranslated region | #285 |
normal variation | #285 |
gria3 | #285 |
neoffi | #285 |
quantitative traits | #285 |
quantitative analyses | #286 |
siblings patients | #286 |
scale children | #286 |
swanson | #286 |
explication | #286 |
clues | #286 |
effects age | #287 |
schizophrenia abnormalities | #288 |
deficit schizophrenia | #288 |
postmortem brain | #289 |
bmisds | #289 |
22q112 | #290 |
pediatric ocd | #290 |
disease haplotypes | #290 |
psychiatric traits | #290 |
low serum levels | #291 |
subcortical volumes | #291 |
publication bias | #291 |
substrain | #292 |
groups children | #293 |
modest | #293 |
salary | #294 |
subjective responses | #294 |
hypertensive rat | #294 |
cognition disorders | #294 |
post‐traumatic stress disorder | #295 |
interference control | #295 |
european populations | #295 |
dtnbp1 | #295 |
adverse impact | #295 |
psychosis schizophrenia | #295 |
risk factors children | #295 |
continuous performance | #296 |
ldsc | #296 |
executive functions | #296 |
anxiety disorder | #297 |
early onset | #297 |
asd traits | #297 |
obesity overweight | #297 |
discriminated | #298 |
reanalysis | #298 |
diagnostic approach | #298 |
predisposition | #299 |
negative symptom | #299 |
cortical thickness | #300 |
effects stress | #300 |
qvalues | #300 |
psychiatric hospitalization | #301 |
roc analysis | #301 |
cognitive measures | #301 |
emotional problems | #302 |
prefrontal function | #302 |
states adolescent | #302 |
intrasubject variability | #302 |
published literature | #302 |
psychometrics | #303 |
permuted | #303 |
height body | #303 |
795 | #304 |
psychiatric conditions | #304 |
case subjects | #305 |
interviewers | #305 |
ats | #305 |
manifest | #305 |
aggressive behavior | #305 |
dsm5 | #305 |
affective disorders | #305 |
early morning | #306 |
dopamine transporter | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
perseveration | #309 |
myh9 | #309 |
spencer | #309 |
documented | #309 |
omission errors | #309 |
membrane transport | #309 |
gene environment | #309 |
memory wm | #310 |
genetic schizophrenia | #310 |
motor domain | #310 |
efficacy treatment | #310 |
life social support | #310 |
adolescent aggression | #310 |
rdoc | #311 |
stroop test | #312 |
mainstays | #312 |
gender age | #312 |
childhood adolescence | #312 |
npsr1 | #313 |
mapping female | #313 |
genetic analyses | #314 |
underscore | #314 |
risk estimation | #315 |
bedtimes | #315 |
asb | #317 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
demonstrable | #318 |
schizophrenia review | #318 |
individual genes | #319 |
n55 | #319 |
5ht2c | #319 |
adolescent adrenergic | #320 |
addictive disorders | #321 |
intelligence tests | #321 |
gene | #321 |
shared genetic influences | #321 |
127 | #322 |
risperidone treatment | #322 |
humans longitudinal | #322 |
bipolar type | #322 |
robins | #322 |
time variability | #323 |
abusers | #323 |
nolan | #324 |
guanfacine | #324 |
conceptual models | #324 |
manic | #325 |
sex characteristics | #326 |
neonatal abstinence syndrome | #326 |
yielded | #326 |
spurious | #327 |
xq26 | #327 |
status female | #327 |
impaired | #327 |
comprised | #328 |
etiologic | #328 |
8q | #329 |
disorders pervasive | #329 |
overrepresented | #330 |
sexdifferences | #330 |
metaanalyses | #330 |
htr2a | #331 |
drug response | #331 |
scores patients | #331 |
women schizophrenia | #332 |
familial factors | #333 |
txndc5 | #333 |
naltrexone | #333 |
expression brain | #333 |
cognitive dysfunctions | #334 |
multiple comparisons | #334 |
obesity diabetes | #334 |
mood disorders | #335 |
24weeks | #335 |
forthcoming | #335 |
adler | #335 |
rey | #336 |
humans mental | #336 |
persist | #336 |
methylphenidate placebo | #336 |
inferior parietal lobule | #336 |
neuropsychological test | #337 |
777 | #337 |
tph2 | #337 |
mobp | #337 |
asd individuals | #337 |
disentangle | #338 |
evening | #339 |
replications | #339 |
psychopathological | #339 |
patients attention | #339 |
disorder ocd | #340 |
pnmt | #340 |
exclusion criteria | #340 |
consistently | #340 |
evidence linkage | #340 |
intelligence | #341 |
placebo effects | #341 |
encompassing | #341 |
treatment bipolar | #341 |
visual memory | #342 |
neuroimaging studies | #342 |
phobic | #342 |
bipolarity | #342 |
multicenter analysis | #342 |
maoa genotype | #342 |
schizoaffective disorder | #344 |
tbv | #344 |
mood problems | #344 |
integrated analysis | #344 |
comorbid diagnoses | #344 |
frontal pole | #344 |
casecontrol studies | #345 |
catechol methyltransferase | #345 |
systematically | #345 |
gifts | #346 |
864 | #346 |
study genotype | #347 |
mdd bpd | #347 |
confused | #347 |
tic severity | #348 |
converging | #348 |
psychotic | #348 |
schizotypal personality disorder | #349 |
collaborative study | #349 |
temporal processing | #349 |
adolescent anxiety | #350 |
aetiological | #350 |
methylphenidate atomoxetine | #350 |
suspiciousness | #351 |
disequilibrium | #352 |
distractibility | #352 |
adults children | #352 |
receptor genes | #352 |
impairing | #353 |
disease genome | #353 |
gabra1 | #354 |
maob | #354 |
disorders middle | #354 |
genetic environmental | #354 |
brain atlas | #354 |
child attention | #354 |
reln | #354 |
substantial | #354 |
executive attention | #354 |
rgs4 | #355 |
male adolescent | #355 |
prodh | #355 |
dsmiii | #355 |
schizophrenia data | #356 |
phobic disorders | #356 |
heterogeneous disorder | #356 |
chrna7 | #357 |
measures attention | #357 |
children anxiety disorders | #357 |
gottesman | #358 |
persists | #359 |
deviant | #359 |
maternal cigarette smoking | #359 |
psychiatric symptoms | #359 |
disorder patients | #359 |
symptom scores | #360 |
linkage analysis | #360 |
chromosomal regions | #361 |
n54 | #361 |
neuroleptic treatment | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
paralimbic | #365 |
tid | #365 |
confirmation | #366 |
elevated risk | #366 |
core symptoms | #366 |
memory load | #367 |
771 | #367 |
pediatric populations | #367 |
bpd mdd | #368 |
comparison groups | #368 |
study entry | #368 |
risk psychopathology | #368 |
differential involvement | #369 |
702 | #369 |
young adulthood | #369 |
hyperactivityimpulsivity | #369 |
differential susceptibility | #370 |
nervousness | #370 |
representativeness | #370 |
damphetamine | #371 |
current concepts | #371 |
schizophrenia risk | #371 |
endorse | #372 |
replicate | #372 |
prevention strategies | #372 |
comt gene | #372 |
5httlpr | #373 |
genomewide association studies | #373 |
executive function | #373 |
snp heritability | #374 |
small sample | #374 |
driving performance | #374 |
dozens | #375 |
scz | #375 |
wide analysis | #375 |
916 | #375 |
medication children | #376 |
teenage | #376 |
emphases | #376 |
memory short | #377 |
children medication | #377 |
data studies | #377 |
child adolescent | #377 |
sas | #377 |
genetic architecture | #377 |
children adolescents | #378 |
impression | #378 |
schizotypal personality | #378 |
marriages | #379 |
control adults | #379 |
converged | #380 |
opd | #380 |
pearson | #380 |
youths | #380 |
ht1b | #380 |
receptors dopamine | #381 |
disorder diagnostic | #381 |
invaluable | #381 |
general cognitive ability | #381 |
methylphenidate children | #381 |
relevant articles | #381 |
culmination | #381 |
overlap | #381 |
adolescent patients | #382 |
chisquare | #382 |
antimanic | #383 |
psychopathologies | #383 |
carefully | #383 |
psychopharmacological treatment | #383 |
summary statistics | #384 |
researched | #384 |
gad2 | #385 |
7r | #385 |
18p | #386 |
multigenerational | #386 |
treatment children | #386 |
neural activation | #387 |
chinese subjects | #387 |
evenings | #388 |
npas2 | #388 |
versa | #388 |
contrasted | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
studies children | #390 |
perinatal morbidity | #390 |
lefthandedness | #390 |
handedness | #390 |
brain circuits | #390 |
disorder symptoms | #390 |
genetic predisposition | #391 |
interaction genetic | #391 |
lambert | #392 |
schizophrenia susceptibility | #392 |
comorbid substance | #392 |
p54 | #393 |
substance users | #394 |
genes expression | #394 |
function humans | #395 |
hippocampal subfields | #395 |
dopamine norepinephrine | #395 |
adolescents adults | #396 |
psychometric | #397 |
disorders schizophrenia | #397 |
schizophrenia disorder | #397 |
mental health children | #397 |
fbat | #397 |
3methoxy4hydroxyphenylglycol | #397 |
clinical risk psychosis | #398 |
earlier onset | #398 |
wandering | #398 |
spm8 | #398 |
neuropsychological testing | #400 |
control sample | #401 |
academic outcomes | #402 |
core symptom | #402 |
suffocation | #402 |
inattention symptoms | #402 |
implications findings | #403 |
relations male | #403 |
inconsistencies | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
neuropsychiatric conditions | #406 |
vntrs | #406 |
parahippocampal | #406 |
diagnosis children | #406 |
n52 | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
behavior genetics | #409 |
0038 | #409 |
communitybased | #409 |
distinct subsets | #410 |
substance | #410 |
children studies | #411 |
reading comprehension | #411 |
impulsive behavior | #411 |
twin study | #411 |
dextroamphetamine | #411 |
tourette syndrome | #412 |
childhood anxiety | #412 |
consistent evidence | #412 |
psychotic disorders | #412 |
neanderthal | #412 |
apoe4 | #412 |
interview | #412 |
systematic literature search | #413 |
anticipation | #413 |
moderated | #413 |
performance tests | #414 |
151 | #414 |
reviewing | #414 |
polymorphism snp | #415 |
volition | #415 |
genetic receptor | #416 |
elucidating | #416 |
schizotypal | #416 |
effects brain | #417 |
functional effects | #417 |
adolescent psychiatric | #418 |
adult intelligence | #418 |
conferred | #418 |
deletion syndrome | #419 |
questionnaires adolescent | #419 |
srsa | #419 |
genetic association | #419 |
daily doses | #420 |
kdm4a | #420 |
dopamine d4 receptor | #420 |
antidepressive agents | #420 |
modestly | #421 |
adult subjects | #421 |
sexes | #421 |
drug dependence | #422 |
cdis | #422 |
operating characteristic | #422 |
iccs | #422 |
reliability validity | #423 |
tricyclic | #423 |
medicated | #423 |
characteristic curve | #424 |
gcta | #424 |
subtests | #425 |
discovery sample | #425 |
transport proteins | #425 |
cardiff | #426 |
parent ratings | #426 |
attain | #427 |
hum | #427 |
diversion | #428 |
brain volume | #428 |
spectrum disorders | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
personality development | #431 |
disentangling | #431 |
operating characteristics | #432 |
teacher | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
frequency genotype | #436 |
perceptual organization | #436 |
cprs | #436 |
1433 | #436 |
12q | #436 |
relatives patients | #437 |
grin2a | #437 |
disorder brain | #437 |
lower scores | #437 |
impulsiveness | #438 |
srs2 | #438 |
correlation coefficients | #438 |
visual learning | #438 |
adolescent psychopathology | #438 |
toddlerhood | #438 |
digit span | #439 |
genetic genetic predisposition | #439 |
22q112ds | #439 |
nominal | #439 |
risk psychosis | #439 |
major risk factor | #440 |
snps association | #440 |
method female | #440 |
aged neuropsychological | #440 |
meaningful | #441 |
gmo | #441 |
white matter microstructure | #441 |
post hoc analysis | #441 |
trex | #441 |
corroborated | #441 |
allelic association | #441 |
logistic regression model | #442 |
planum temporale | #442 |
adult analysis | #442 |
virtual histology | #442 |
female functional | #442 |
disorders autism | #442 |
n80 | #443 |
conferring | #444 |
emphasize | #444 |
differential female | #444 |
10 year | #444 |
disorders surveys | #444 |
pcdh10 | #445 |
nucleotide receptors | #446 |
534 | #446 |
ntrk3 | #446 |
862 | #446 |
statistic | #446 |
holland | #447 |
originally | #448 |
behavior child | #448 |
genome wide | #448 |
motor coordination | #448 |
expressiveness | #449 |
earlier age | #449 |
wistar kyoto | #450 |
early response | #450 |
risk variants | #450 |
sex | #451 |
exceptions | #451 |
brain abnormalities | #452 |
prevalence correlates | #452 |
subsequent risk | #452 |
clinical expression | #452 |
chat | #456 |
children adolescent | #456 |
79 | #457 |
zscores | #457 |
psychiatry | #457 |
preliminary study | #458 |
masse | #458 |
independently | #458 |
structural magnetic | #458 |
22q112 deletion | #460 |
polygenic risk score | #460 |
psychotic disorders schizophrenia | #460 |
522 | #460 |
genetic correlation | #460 |
lander | #460 |
smoking pregnancy | #461 |
hyperkinesis | #461 |
jw | #462 |
d4 | #463 |
pregnancy complications | #465 |
neuroanatomy | #465 |
life treatment | #465 |
affection | #465 |
decrements | #465 |
runs | #466 |
gene sets | #466 |
control rates | #466 |
inbred wky | #467 |
mini | #467 |
anxiety depressive | #467 |
bpad | #468 |
subjects patients | #469 |
disorders treatment | #470 |
cacna1c | #470 |
patient adherence | #470 |
genetic effects | #470 |
receiver operating | #471 |
remission relapse | #471 |
risk allele | #472 |
psychology adolescent | #472 |
chrna4 | #473 |
response remission | #473 |
environmental risk factors | #474 |
plp1 | #474 |
norepinephrine transporter | #474 |
cautious | #476 |
opioid addiction | #476 |
developmental coordination | #476 |
multiple measures | #477 |
obesity children | #477 |
broader | #478 |
multiplex families | #479 |
dysthymia | #479 |
5th | #479 |
humans | #480 |
symptom | #480 |
genetic risk variants | #480 |
adds | #480 |
semistructured | #481 |
cortex child | #481 |
diagnostic categories | #481 |
data extraction | #482 |
genotyped | #482 |
maternal anxiety | #482 |
etiology | #483 |
arithmetic | #483 |
nfil3 | #484 |
treatment methylphenidate | #484 |
sml | #484 |
verbal learning | #484 |
conception | #484 |
adulthood | #485 |
agents bipolar | #485 |
756 | #485 |
outcome variables | #486 |
epidemiologically | #486 |
baseline age | #486 |
adult anxiety | #487 |
symptom dimensions | #487 |
123 | #487 |
evaluates | #487 |
spontaneity | #488 |
female adolescents | #489 |
unpublished | #489 |
longterm effects | #489 |
genetic disorders | #489 |
schizophrenia autism | #490 |
neuropsychiatric disorder | #490 |
administration schedule | #490 |
shared environmental | #490 |
common variant | #492 |
schizophrenia age | #492 |
smoking prevention | #492 |
pnds | #493 |
overlapping | #493 |
frequency genetic | #495 |
late adolescence | #495 |
antisocial personality disorder | #495 |
anxiety | #497 |
restlessness | #497 |
schizophrenia patients | #497 |
psychobiology | #497 |
pair human | #497 |
separation anxiety | #497 |
bonferroni | #498 |
longitudinal studies | #498 |
genetic mechanisms | #499 |
candidate | #499 |
addressed | #499 |
placebos | #499 |
daoa | #499 |
identifying | #500 |
case reports | #500 |
comt val158met polymorphism | #500 |
rat strains | #501 |
d4 receptors | #501 |
nocebo | #501 |
additional evidence | #503 |
865 | #503 |
verbal memory | #503 |
circadian clock genes | #505 |
child executive | #505 |
n26 | #506 |
fallacy | #506 |
subscale | #506 |
continued | #507 |
cooperativeness | #507 |
reflecting | #508 |
tobacco disorder | #508 |
delay discounting | #509 |
developing schizophrenia | #509 |
agg | #510 |
shared | #511 |
dichotomous | #511 |
educational status | #511 |
p80 | #512 |
identifiable | #512 |
obsessive compulsive | #512 |
95 death | #512 |
lod | #513 |
risk haplotype | #513 |
coaggregation | #514 |
disproportionate | #514 |
phis | #515 |
disorders depression | #515 |
morning | #515 |
assessments | #515 |
total sample | #516 |
normal control | #516 |
cognitive traits | #517 |
n39 | #517 |
contributing | #517 |
15q | #518 |
missing link | #519 |
pbat | #520 |
fn1 | #520 |
environmental influences | #520 |
gyrus cinguli | #521 |
dichotic | #521 |
specificity ppv | #521 |
polymorphism single | #522 |
disorder obsessive | #522 |
social class | #522 |
selfreport | #522 |
dibenzothiazepines | #523 |
attention memory | #523 |
adult bipolar | #524 |
phg | #524 |
assortative | #524 |
dmi | #524 |
dedication | #524 |
clinical diagnoses | #525 |
covariates | #525 |
disorder treatment | #525 |
sciencedirect | #525 |
pacific island | #525 |
affiliations | #526 |
functioning | #527 |
criminality | #527 |
persistence | #527 |
symptomatic remission | #528 |
depression anxiety disorders | #528 |
adverse life events | #528 |
design study | #528 |
adolescent children | #528 |
ruled | #529 |
compulsive disorder | #529 |
parental reports | #529 |
community samples | #529 |
flnc | #529 |
abrupt | #529 |
tagsnps | #530 |
control children | #530 |
increased burden | #531 |
strongest | #531 |
medications | #531 |
existing studies | #532 |
autism schizophrenia | #532 |
n40 | #532 |
subjects age | #533 |
clinical sample | #533 |
temperament character | #534 |
analyses conducted | #534 |
selective review | #535 |
asd | #535 |
intercorrelations | #535 |
parsing | #537 |
global impression | #537 |
autistic symptoms | #538 |
child adhd | #538 |
models genetic | #538 |
d4 receptor | #539 |
personality factors | #541 |
milder | #541 |
lobe humans | #542 |
disease genotype | #543 |
taiwanese | #543 |
single nucleotide | #543 |
complexities | #544 |
independent samples | #544 |
severe symptoms | #544 |
ld | #545 |
population sample | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
computer program | #548 |
functional variant | #548 |
healthy control subjects | #548 |
nonclinical sample | #549 |
behavior male | #549 |
dichotomized | #549 |
clash | #549 |
risk children | #549 |
oral route | #549 |
patients schizophrenia | #549 |
schizophrenia study | #549 |
genetic pathways | #550 |
765 | #550 |
fam | #550 |
motor inhibition | #551 |
case control | #551 |
ideally | #551 |
define | #551 |
major diagnosis | #552 |
performance test | #552 |
n29 | #553 |
verbal | #553 |
preadolescent | #554 |
prs schizophrenia | #555 |
release oral | #555 |
viewed | #555 |
suggests | #555 |
spectrum disorder | #556 |
phenotypic features | #556 |
nogo task | #557 |
child anxiety | #557 |
neuropsychiatric diseases | #557 |
equivocal | #558 |
neurodevelopmental | #558 |
africanamerican | #558 |
justify | #559 |
gray matter volumes | #560 |
response variability | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
adolescents risk | #565 |
risk smoking | #565 |
patients sud | #566 |
risky behaviors | #566 |
4th edition | #566 |
twins female | #566 |
intermediate phenotypes | #566 |
neurocognitive impairment | #567 |
3050 | #567 |
haplotype | #567 |
unaffected relatives | #568 |
replication study | #569 |
diverging | #570 |
onsets | #570 |
environment interaction | #570 |
10−8 | #570 |
birthday | #571 |
risk genes | #571 |
keywords | #571 |
dose reduction | #573 |
obesity body mass | #574 |
white matter abnormalities | #574 |
irritability | #574 |
questionnaires adult | #575 |
inbred shr | #575 |
asd diagnosis | #576 |
spaced | #576 |
gyri | #576 |
medical genetics | #577 |
schizophrenia sample | #577 |
individually | #577 |
parent | #577 |
chromosomes human | #577 |
impulsivity | #578 |
finetuning | #578 |
82 | #578 |
subsample | #579 |
symptoms children | #579 |
development anxiety | #580 |
5httlpr polymorphism | #580 |
cold pressor test | #580 |
preschool age | #580 |
haplotype analysis | #581 |
psychiatric association | #582 |
rdc | #582 |
drd1 | #582 |
apol1 | #582 |
delinquent behavior | #583 |
3rd | #583 |
new approaches | #584 |
hk1 | #584 |
fine mapping | #585 |
separately | #585 |
data children | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
defaultmode network | #588 |
compared controls | #588 |
examine | #588 |
nback task | #588 |
138 | #589 |
haplotypes humans | #590 |
patients comorbid | #591 |
estonian | #591 |
40mg | #591 |
behavior adult | #591 |
criticism | #593 |
concordant | #594 |
2005 | #594 |
brain child | #595 |
overrepresentation | #596 |
cognition schizophrenia | #596 |
nonpharmacologic | #597 |
generalizable | #597 |
snap25 | #597 |
discounted | #597 |
899 | #598 |
new directions | #598 |
affymetrix | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
clinical settings | #604 |
diagnosing | #604 |
diagnostic specificity | #604 |
disorganized | #606 |
performance children | #606 |
clinician | #606 |
cognitive outcomes | #606 |
social environment | #607 |
personality traits | #607 |
4 6 | #608 |
small fraction | #608 |
sizeable | #608 |
antisocial behavior | #609 |
executive dysfunctions | #609 |
true | #609 |
gold standard | #609 |
polygenic risk scores | #610 |
functional outcomes | #610 |
informant | #611 |
pleiotropic | #612 |
complex disorders | #612 |
chromosome 6 | #613 |
schizophrenia brain | #614 |
educational achievement | #614 |
grandmothers | #614 |
snp markers | #615 |
curve analysis | #615 |
disease etiology | #615 |
behavior disorder | #615 |
genetic epidemiology | #616 |
prevalence severity | #616 |
memory deficits | #616 |
genome scans | #617 |
tscores | #617 |
genetic associations | #618 |
val158met | #618 |
african children | #618 |
differ | #618 |
digeorge | #619 |
correcting | #619 |
vigilance | #620 |
genetic markers | #620 |
antisocial behaviour | #621 |
md | #621 |
confer | #622 |
adverse health outcomes | #623 |
juvenile delinquency | #624 |
receptor serotonin | #624 |
executive dysfunction | #625 |
executive control | #625 |
misconceptions | #625 |
mood stabilizers | #626 |
attentional deficits | #627 |
seeks | #627 |
hrr | #627 |
child gender | #629 |
treatment disorder | #629 |
fibromyalgia | #629 |
schizophrenia findings | #630 |
deficits schizophrenia | #631 |
reject | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
icv | #638 |
generalisability | #638 |
obsessivecompulsive disorder | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
adult outcomes | #641 |
advertisement | #641 |
ranks | #641 |
illness duration | #642 |
inconsistent | #643 |
gateway | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
treatment effects | #652 |
gene association | #652 |
avoidant | #652 |
physical conditions | #653 |
128 | #653 |
hyperactivity inattention | #653 |
stroop | #654 |
federation | #654 |
intergenerational transmission | #655 |
random allocation rats | #656 |
reward anticipation | #656 |
bipolar disorder schizophrenia | #656 |
studies evidence | #657 |
impairment | #658 |
groups compared | #658 |
boldness | #658 |
psychosocial treatment | #658 |
hypomanic | #659 |
volumes | #659 |
association exposure | #660 |
poorer performance | #661 |
core feature | #661 |
referrals | #662 |
structural alterations | #662 |
peer relations | #662 |
digeorge syndrome | #665 |
permission | #665 |
lowlevel | #665 |
subcortical | #666 |
dacc | #666 |
psychiatric illnesses | #667 |
mood | #668 |
swedish population | #669 |
prominent | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
disorders memory | #678 |
unselected | #678 |
sleep difficulties | #679 |
129 | #679 |
middle childhood | #680 |
mental disorders humans | #680 |
psychopathological symptoms | #680 |
gene frequency | #681 |
neurotic | #681 |
semantic fluency | #682 |
trait | #682 |
soviet union | #682 |
quetiapine | #682 |
severe phenotype | #683 |
scales | #685 |
east asian | #685 |
remitting | #685 |
p0019 | #687 |
children groups | #688 |
chromosomal region | #688 |
17q | #688 |
postmortem brains | #689 |
fibromyalgia patients | #689 |
younger children | #689 |
average age | #694 |
disorder schizophrenia | #694 |
tcas | #694 |
testretest reliability | #695 |
participants | #696 |
parcellation | #696 |
cortical surface area | #696 |
5years | #697 |
pharmacokinetic profile | #697 |
4–5 | #697 |
relevant studies | #699 |
drug abuse | #699 |
122 | #699 |
effects methylphenidate | #700 |
nonrandom | #701 |
adult mental | #701 |
illness surveys | #701 |
quota | #701 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
gwa studies | #704 |
follow studies | #705 |
preschool years | #706 |
pathogenesis schizophrenia | #706 |
adaptive functioning | #706 |
autism spectrum | #708 |
p009 | #709 |
school settings | #709 |
children diagnosed | #710 |
informative | #713 |
chronic schizophrenia | #713 |
dysphoric | #714 |
eric | #714 |
prs | #714 |
misuse | #714 |
maternal report | #714 |
stress disorder | #715 |
disorders substance | #715 |
728 | #715 |
ethanol consumption | #715 |
3 weeks | #716 |
641 | #716 |
contradictory | #717 |
groundwork | #719 |
abstraction | #719 |
meta‐analysis | #720 |
clinical population | #721 |
multiple genes | #721 |
recurrence risk | #722 |
household income | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
lateonset | #726 |
common snps | #726 |
gender dysphoria | #726 |
male adolescents | #726 |
attention deficits | #727 |
schizophrenics | #727 |
statistical | #728 |
dizygotic | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
voxel based | #733 |
git | #733 |
correlates | #733 |
finding | #734 |
phenotypic heterogeneity | #734 |
wky | #735 |
health intervention | #737 |
life cycle | #737 |
gyrification | #737 |
substancerelated disorders | #738 |
opioid dependence | #738 |
inflation | #739 |
polygenic score | #739 |
validating | #740 |
rapid cycling | #741 |
refill | #742 |
caudate | #742 |
boston | #742 |
time task | #743 |
comparators | #744 |
amphetamines | #744 |
soviet | #745 |
bupropion | #745 |
topic twins | #745 |
compulsive | #746 |
neuropsychological status | #746 |
manifested | #747 |
child interaction | #748 |
duplications | #748 |
adrb1 | #749 |
934 | #750 |
examining | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
347 | #754 |
molecular genetic analysis | #754 |
post hoc | #755 |
comt val158met | #755 |
mental disorders | #756 |
neuroleptics | #756 |
recalled | #756 |
bipolar depression | #756 |
schizophrenia scz | #757 |
nhe | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
workday | #764 |
matter abnormalities | #764 |
likelihoods | #765 |
humans logistic | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
emerged | #772 |
comt polymorphism | #772 |
performance patients | #774 |
parent reported | #776 |
birth rates | #776 |
human pair | #777 |
depressive | #777 |
behavioral phenotypes | #777 |
phenotypes | #778 |
deletion polymorphism | #779 |
euthymic | #779 |
risky behavior | #780 |
schizophrenia relationship | #780 |
weaknesses | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
questioning | #783 |
combined analysis | #783 |
fourth edition | #783 |
emerging roles | #784 |
mega | #784 |
teaes | #785 |
reformulation | #785 |
faced | #786 |
963 | #787 |
pbd | #787 |
adolescence | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
cgi | #791 |
spelling | #791 |
behavioral | #791 |
subtypes | #792 |
clinical criteria | #793 |
individuals schizophrenia | #793 |
association polymorphisms | #794 |
symptom burden | #794 |
motivations | #794 |
caveats | #796 |
delinquent | #796 |
separate | #797 |
additional studies | #800 |
363 | #800 |
genomic regions | #802 |
dopamine d1 receptors | #803 |
prenatal exposure | #803 |
stimulant drugs | #804 |
randomized clinical trials | #804 |
dysfunction | #805 |
superior frontal | #805 |
clinically | #805 |
dorsolateral | #806 |
male memory | #806 |
novelty seeking | #806 |
latent classes | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
dopamine function | #810 |
ucla | #810 |
adjusting | #811 |
dopamine serotonin | #811 |
phonemic | #811 |
preschool female humans | #811 |
blind | #813 |
coadministration | #815 |
mhpg | #816 |
declarative | #816 |
tryptophan hydroxylase | #817 |
quantitative measures | #817 |
lasting | #817 |
cfb | #817 |
breakthroughs | #817 |
epigenetic factors | #818 |
memory attention | #818 |
single gene | #818 |
substance dependence | #818 |
cortical development | #820 |
meeting | #820 |
patients psychotic disorders | #821 |
counties | #821 |
rated | #821 |
hme | #822 |
switches | #822 |
parental report | #824 |
transcriptomic analysis | #824 |
prefrontal regions | #824 |
common genetic | #825 |
rare coding variants | #825 |
humans models | #827 |
adolescents asd | #827 |
s100a6 | #828 |
treatment interventions | #829 |
timeframe | #830 |
multipoint | #830 |
lifetime prevalence | #831 |
multiple testing | #831 |
prevalent | #831 |
association tests | #832 |
conduct disorders | #832 |
liabilities | #833 |
college students | #834 |
sleep disorder | #837 |
gray | #837 |
n60 | #837 |
inbred shr rats | #838 |
matter humans | #838 |
aversion | #838 |
obstetric complications | #839 |
symptom profiles | #839 |
prescription | #839 |
neurocognition | #841 |
parenthood | #842 |
participants completed | #843 |
sporadic cases | #843 |
consensus statement | #844 |
biological basis | #844 |
facial emotion recognition | #845 |
n35 | #846 |
dnm | #847 |
exception | #847 |
dgcr8 | #848 |
dysregulated | #848 |
gwas summary | #848 |
factor model | #851 |
prefrontal | #855 |
putative | #857 |
nonsignificant | #857 |
putamen | #858 |
schizophrenia healthy | #858 |
heightened risk | #858 |
estimated prevalence | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
glossary | #866 |
seventy | #866 |
global assessment | #866 |
crosssectional studies | #867 |
nnt | #869 |
mental | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
shr rats | #874 |
perseverative errors | #874 |
pediatric | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
hypotheses | #876 |
manova | #876 |
genetic counseling | #876 |
positive symptoms | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
obsessive | #893 |
n95 | #893 |
n17 | #893 |
decade | #894 |
bonn | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
anterior cingulate | #903 |
biological psychiatry | #903 |
aptitude | #904 |
bipolar illness | #904 |
reinforcer | #904 |
sibling | #904 |
weight body | #904 |
genetic contribution | #904 |
visit | #905 |
826 | #906 |
psychosocial functioning | #906 |
late childhood | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
symptom control | #911 |
ggc | #911 |
amygdala reactivity | #912 |
pedigrees | #912 |
psychosocial | #912 |
visuospatial memory | #913 |
complications pregnancy | #913 |
versions | #914 |
underlying pathophysiology | #914 |
association age | #916 |
disorder specific | #917 |
school performance | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
pharmacogenetic | #924 |
screening tool | #924 |
dysthymic | #925 |
vulnerability | #925 |
wide | #926 |
dividing | #927 |
developmental trajectories | #927 |
affective disorder | #928 |
cpg sites | #930 |
participating | #930 |
nucleotide | #930 |
194 | #933 |
heroin addiction | #933 |
permutation | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
study designs | #938 |
diagnostic | #938 |
female genotype | #938 |
irrs | #940 |
robustly | #940 |
severe form | #941 |
critics | #941 |
tdt | #943 |
gwas | #946 |
brain regions | #946 |
22q | #948 |
sles | #948 |
risk developing | #949 |
fetal exposure | #950 |
albeit | #950 |
subtest | #952 |
amphetamine | #954 |
relapsers | #954 |
personality disorder | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
female frontal | #963 |
clinical assessment | #963 |
children epilepsy | #963 |
cgis | #965 |
tandem repeat | #965 |
dopamine uptake | #965 |
scores | #965 |
scarce | #966 |
body height | #966 |
heritability estimates | #967 |
cuneus | #968 |
splicing factor | #968 |
freesurfer | #969 |
examined | #970 |
pharmacological treatment | #970 |
schizophrenia association | #970 |
mtbi | #970 |
medication treatment | #971 |
aggression | #972 |
risky sexual behavior | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
vmat2 | #978 |
psychosis risk | #978 |
resolve | #978 |
neurodevelopmental disorder | #980 |
2–4 | #980 |
pertaining | #982 |
educational | #982 |
459 | #982 |
seriousness | #985 |
logistic regression models | #986 |
symptoms age | #986 |
alleles | #986 |
patients sle | #987 |
difficulties | #988 |
ranked | #990 |
tci | #990 |
small proportion | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
detoxification | #999 |
keystone | #999 |
diathesis | #999 |
adolescent analysis | #1000 |
child child | #1001 |
interviews | #1003 |
stata | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
allele | #1007 |
0016 | #1007 |
preschool cohort | #1007 |
long‐term outcome | #1007 |
daughter | #1007 |
confounding factors | #1007 |
structural mri | #1008 |
norms | #1008 |
risk alcohol | #1009 |
posttraumatic stress disorder | #1009 |
multiplex | #1009 |
qualifications | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
metabotropic | #1020 |
maturational | #1020 |
conclusive | #1021 |
relates | #1024 |
risk prediction | #1024 |
insufficient | #1026 |
pharmacotherapies | #1027 |
004 | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
wwwclinicaltrialsgov | #1031 |
frontostriatal | #1031 |
analytic | #1031 |
patients panic disorder | #1032 |
symptoms child | #1032 |
predicted | #1034 |
73 | #1034 |
– compulsive | #1034 |
preface | #1034 |
rodent models | #1035 |
negative symptoms | #1035 |
brain disorders | #1035 |
total score | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
general intelligence | #1041 |
serotonin | #1041 |
twin | #1043 |
mental health treatment | #1044 |
gaf | #1044 |
relate | #1045 |
heightened | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
psychiatric morbidity | #1056 |
vice | #1056 |
major humans | #1058 |
nogo | #1058 |
obscure | #1060 |
youth report | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
illicit | #1063 |
199 | #1063 |
genes involved | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
heritability | #1068 |
pooled | #1068 |
awakenings | #1068 |
childhood trauma | #1068 |
paranoia | #1068 |
negative impact | #1069 |
memantine | #1069 |
emotional | #1069 |
human genetics | #1070 |
memory impairments | #1070 |
word reading | #1070 |
reading ability | #1071 |
risk scores | #1071 |
genetic model | #1071 |
controlled clinical | #1071 |
social problems | #1071 |
single nucleotide receptors | #1071 |
4q | #1072 |
character inventory | #1072 |
associations | #1073 |
validity | #1073 |
obesity risk | #1074 |
3′utr | #1075 |
studying | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
transdiagnostic | #1080 |
exposure delayed | #1080 |
schizophrenia social | #1082 |
adult antipsychotic | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
autoreceptors | #1086 |
psds | #1086 |
onset psychosis | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
distinctive | #1090 |
subtype | #1090 |
development disorders | #1092 |
polygenic scores | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
scientific literature | #1096 |
semistructured interview | #1096 |
irritable | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
daughters | #1103 |
external validity | #1103 |
future work | #1103 |
cnvs | #1104 |
odds | #1106 |
psychosis | #1107 |
diagnostic groups | #1107 |
10 weeks | #1107 |
bip | #1108 |
emotional behavioral | #1108 |
prioritized | #1110 |
psychoses | #1110 |
experimental test | #1110 |
share | #1111 |
10−5 | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
coexisting | #1125 |
mts | #1125 |
projects | #1127 |
quantifies | #1128 |
similarities | #1128 |
dysthymic disorder | #1128 |
enriched | #1128 |
investigator | #1129 |
adult alcoholism | #1130 |
weighting | #1130 |
n28 | #1134 |
attention performance | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
blood pressure response | #1138 |
laterality humans | #1138 |
susceptibility loci | #1139 |
social phobia | #1142 |
clinical samples | #1142 |
signal task | #1144 |
prodromal | #1145 |
cognitive domains | #1145 |
early adolescent | #1145 |
demographic factors | #1146 |
measurement invariance | #1147 |
emotionality | #1147 |
normal volunteers | #1147 |
refine | #1149 |
discriminability | #1150 |
children association | #1150 |
humans intellectual | #1150 |
discounting | #1150 |
quick | #1152 |
continents | #1152 |
developmental model | #1152 |
generalizability | #1153 |
normals | #1153 |
refinements | #1153 |
clinical profiles | #1154 |
alspac | #1154 |
sensory gating | #1154 |
ht2c | #1160 |
uncorrected | #1160 |
differential humans | #1160 |
phenotype | #1161 |
” “ | #1163 |
review findings | #1163 |
phobia | #1164 |
studies data | #1164 |
neurocognitive function | #1165 |
affective | #1166 |
deteriorated | #1166 |
clinical groups | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
bpd patients | #1176 |
gwas data | #1176 |
cohen | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
male subjects | #1178 |
clinical validation | #1178 |
study gwas | #1179 |
reward | #1182 |
cinguli humans | #1182 |
childhood exposure | #1182 |
persisting | #1182 |
nonverbal | #1183 |
paradox | #1184 |
triads | #1184 |
addressing | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
addictions | #1198 |
compulsivity | #1198 |
onequarter | #1198 |
placebo | #1199 |
wm | #1199 |
asian continental | #1200 |
230 | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
systematic search | #1204 |
sib | #1204 |
millennium | #1207 |
nationwide cohort study | #1209 |
externalizing symptoms | #1209 |
problems children | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
lbw | #1220 |
underlying | #1220 |
antecedent | #1221 |
prospects | #1222 |
child cognitive | #1222 |
study role | #1224 |
profile | #1226 |
approximated | #1227 |
partly | #1227 |
0011 | #1229 |
refining | #1232 |
subgroup | #1232 |
molecular alterations | #1232 |
poster | #1233 |
health organization | #1234 |
pregnancy prenatal | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
tandem repeats | #1242 |
brain structure | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
risk asthma | #1247 |
enjoyment | #1247 |
kf | #1247 |
avenues | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
roc | #1251 |
delineate | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
serotonin transporter | #1256 |
summarize | #1256 |
risk ratio | #1256 |
nervous | #1257 |
goal | #1257 |
dysfunctions | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
386 | #1277 |
entire | #1277 |
developmental pathways | #1277 |
n24 | #1278 |
study evidence | #1281 |
04 | #1281 |
paternal | #1282 |
priori | #1282 |
neuroimaging | #1283 |
behavior adolescent | #1283 |
hopes | #1283 |
increased rates | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
087 | #1286 |
general cognitive | #1286 |
somatic complaints | #1288 |
orbitofrontal | #1288 |
male nerve | #1288 |
warmth | #1289 |
aspect | #1289 |
1hmrs | #1291 |
dual psychiatry | #1291 |
posttraumatic | #1291 |
unmyelinated | #1291 |
clomipramine | #1292 |
animal conditioning | #1292 |
quantitative trait | #1292 |
misclassification | #1292 |
negative emotion | #1295 |
136 | #1297 |
pvalue | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
1520 | #1305 |
935 | #1305 |
cortical volume | #1306 |
prediction accuracy | #1309 |
sgas | #1309 |
vin | #1310 |
extant | #1310 |
risperidone | #1311 |
arrests | #1312 |
factor analyses | #1313 |
motor speed | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
class analysis | #1317 |
minds | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
parents adolescents | #1323 |
short | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
influencing | #1330 |
confusion | #1330 |
defining | #1331 |
polysubstance | #1334 |
measures | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
obsessive–compulsive disorder | #1338 |
fronto | #1338 |
clinical phenotypes | #1342 |
longterm outcome | #1342 |
542 | #1344 |
registry data | #1344 |
llysine | #1345 |
explaining | #1345 |
interpretation statistical | #1349 |
early adulthood | #1353 |
compared children | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
loci genetic | #1356 |
diagnostic tool | #1356 |
flush | #1357 |
variabilities | #1357 |
simon | #1357 |
seekers | #1358 |
antidepressive | #1359 |
gene discovery | #1359 |
broad spectrum | #1361 |
middle frontal gyrus | #1362 |
mammalian target | #1362 |
intergenerational | #1365 |
abcd | #1367 |
unexplored | #1369 |
uptake inhibitors | #1369 |
school teachers | #1369 |
neuronal development | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
new onset | #1386 |
highlighted | #1386 |
thought disorder | #1386 |
dimensional approach | #1389 |
familial aggregation | #1391 |
treatment depression | #1391 |
prodrome | #1391 |
6 years | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
manuscripts | #1395 |
thalamic | #1395 |
rats shr | #1395 |
satisfying | #1395 |
racial | #1398 |
emotional stimuli | #1399 |
timely | #1399 |
suggesting | #1400 |
lability | #1400 |
17 | #1402 |
sufficient | #1403 |
blinded | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
issue | #1414 |
shyness | #1414 |
independent | #1415 |
prepubertal children | #1416 |
impressions | #1416 |
332 | #1417 |
carry | #1419 |
logical | #1419 |
humans memory | #1421 |
parents children | #1422 |
discoveries | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
taps | #1431 |
163 | #1431 |
cognitive profiles | #1432 |
interaction effects | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
443 | #1448 |
psychotic illness | #1448 |
chp | #1449 |
prevalence obesity | #1450 |
hydroxylase | #1450 |
ratings | #1451 |
square | #1453 |
height | #1453 |
ewas | #1453 |
78 | #1453 |
population stratification | #1454 |
hypermethylation | #1454 |
switching | #1455 |
dorsal striatum | #1457 |
collaborations | #1457 |
replicability | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
stronger | #1463 |
biological pathways | #1463 |
treatment duration | #1464 |
discordant | #1467 |
principal | #1467 |
partial remission | #1468 |
untranslated | #1468 |
valuable | #1468 |
hippocampi | #1469 |
groups differences | #1469 |
contrast effects | #1472 |
statistically | #1474 |
openlabel | #1474 |
cognition patients | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
allele carriers | #1497 |
mri studies | #1497 |
smaller | #1497 |
lifespan | #1499 |
small sample sizes | #1499 |
twins monozygotic | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
male mothers | #1505 |
multisite | #1505 |
ddc | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
objectivity | #1511 |
existing literature | #1511 |
emotions female | #1513 |
reports | #1513 |
attained | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
screening instrument | #1517 |
eicosapentaenoic acid | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
topic | #1523 |
cna | #1523 |
114 | #1523 |
inconsistency | #1526 |
bipolar patients | #1526 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
nacetylaspartate | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
nucleotide risk | #1541 |
default | #1541 |
poses | #1542 |
adult life | #1542 |
dopamine receptor | #1542 |
stress disorders | #1543 |
gwass | #1544 |
yale | #1545 |
treatment schizophrenia | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
influenced | #1554 |
problem behaviors | #1554 |
857 | #1556 |
automobile | #1556 |
early exposure | #1559 |
failed | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
subscales | #1565 |
475 | #1565 |
insular | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
swedish | #1573 |
191 | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
meta | #1579 |
life quality | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
single nucleotide polymorphism | #1582 |
findings studies | #1582 |
located | #1582 |
cutoffs | #1583 |
models male | #1583 |
network dmn | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
firstepisode schizophrenia | #1588 |
major depressive | #1588 |
rs4680 | #1588 |
pain patients | #1589 |
genetic data | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
moderators | #1599 |
tpv | #1599 |
psychotropic medications | #1601 |
statistics nonparametric | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
1979 | #1610 |
proneness | #1610 |
monoamine oxidase | #1611 |
alcoholism | #1613 |
emotional faces | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
large body | #1622 |
risk mental | #1622 |
distinguishing | #1622 |
childhood asthma | #1624 |
hbr | #1624 |
paucity | #1626 |
snp | #1626 |
ht2a receptor | #1627 |
spatial organization | #1627 |
louis | #1628 |
dysphoria | #1628 |
verbal behavior | #1629 |
genomics humans | #1629 |
study children | #1630 |
kyoto | #1630 |
memory task | #1631 |
emrs | #1631 |
ambiguous | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
rack1 | #1643 |
tendency | #1643 |
social communication | #1643 |
alpha7 | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
controlled | #1653 |
rea | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
comorbid depression | #1663 |
presentations | #1663 |
asm | #1664 |
510 | #1665 |
mood symptoms | #1666 |
dlpfc | #1666 |
chronic patients | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
statements | #1675 |
alcohol spectrum | #1675 |
53 | #1677 |
calling | #1678 |
introns | #1678 |
registers | #1678 |
social anxiety | #1679 |
homogeneous | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
46 | #1684 |
prescribed | #1684 |
mildly | #1684 |
memory deficit | #1685 |
ancestries | #1685 |
autistic disorder | #1689 |
github | #1689 |
mdd | #1689 |
agenda | #1692 |
psychotropic drugs | #1692 |
impulse control | #1693 |
motor skills | #1698 |
recruited | #1698 |
diagnose | #1699 |
91 | #1702 |
item | #1704 |
memory consolidation | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
rater | #1712 |
neuroscience | #1712 |
health records | #1712 |
personality characteristics | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
inhibitory control | #1731 |
107 | #1731 |
cbs | #1732 |
hindered | #1733 |
highlight | #1735 |
machine | #1735 |
identical | #1736 |
stand | #1736 |
predictors | #1739 |
aimed | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
forum | #1746 |
curated | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
social | #1761 |
genetic models | #1761 |
ventral striatum | #1761 |
bipolar affective | #1763 |
drowsiness | #1763 |
includes | #1765 |
chance | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
dizygotic twins | #1773 |
treatment implications | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
267 | #1776 |
patients adult | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
commonalities | #1786 |
higher doses | #1786 |
major | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
male motor | #1791 |
frustration | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
positive association | #1797 |
causal variants | #1797 |
disabilities | #1797 |
autism spectrum disorders | #1800 |
members | #1801 |
aged models | #1801 |
reporters | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
146 | #1813 |
aetiology | #1813 |
european descent | #1813 |
internationality | #1815 |
frequently | #1815 |
purchases | #1816 |
brain imaging | #1816 |
hippocampal volume | #1819 |
cohens | #1819 |
lds | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
binocular | #1833 |
foundation | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
neural activity | #1841 |
patterns | #1841 |
trauma exposure | #1842 |
assessment tools | #1842 |
initiative | #1845 |
twins | #1845 |
distinctions | #1845 |
literacy | #1846 |
psychological | #1847 |
pertinent | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
individual | #1851 |
fearful | #1851 |
vocabulary | #1851 |
nonparametric | #1852 |
brainderived neurotrophic factor | #1853 |
young | #1853 |
differentiating | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
prevalence | #1859 |
tph | #1859 |
behavioral measures | #1860 |
incentives | #1860 |
cnb | #1861 |
affiliation | #1861 |
8p | #1862 |
obstacle | #1864 |
vocalization | #1865 |
multilevel | #1865 |
poison | #1865 |
switch | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
histograms | #1879 |
roc curve | #1879 |
shrs | #1880 |
animal model | #1880 |
delusions | #1881 |
longer duration | #1882 |
afb | #1882 |
common genetic variation | #1883 |
genome | #1885 |
differs | #1888 |
false | #1888 |
metaanalysis studies | #1890 |
substance abuse | #1890 |
spanning | #1894 |
heterogeneous | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
specific symptoms | #1907 |
increasingly | #1907 |
emotion | #1908 |
majority | #1909 |
epidemiologic | #1909 |
ads | #1910 |
disorders mental | #1911 |
support vector machine | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
association maternal | #1923 |
satisfied | #1923 |
liking | #1923 |
aggregate | #1926 |
child cross | #1926 |
overview | #1927 |
advertising | #1928 |
sleep problems | #1928 |
251 | #1928 |
empirical studies | #1929 |
ssri | #1930 |
asd children | #1934 |
95 cis | #1934 |
simulation study | #1937 |
borderline personality disorder | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
traumatic brain injury | #1950 |
representing | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
depression | #1972 |
correctly | #1972 |
clinical implications | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
repeats | #1977 |
child depression | #1977 |
conflicting | #1978 |
listing | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
chinese population | #1984 |
common mental disorders | #1984 |
pax5 | #1986 |
phase 3 trial | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
formulations | #2005 |
asian continental ancestry | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
muscle function | #2014 |
akt1 | #2014 |
absence | #2014 |
sms | #2015 |
noradrenergic | #2015 |
possibility | #2016 |
cognitive deficits | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
sleep disturbances | #2030 |
phenomenology | #2030 |
brain responses | #2031 |
memory verbal | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
erythematosus systemic | #2041 |
asperger | #2041 |
nicotinic acetylcholine | #2045 |
cognitive processing | #2046 |
227 | #2046 |
informants | #2048 |
erythematosus | #2049 |
cognition | #2050 |
functional | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
insula | #2061 |
common diseases | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
overweight obesity | #2066 |
demography | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
functional mri | #2069 |
massachusetts | #2069 |
0008 | #2071 |
parental education | #2072 |
phenotypic | #2072 |
psychotic symptoms | #2077 |
international consensus | #2078 |
degree | #2078 |
descent | #2079 |
wake disorders | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
latent class | #2090 |
43 | #2090 |
factors child | #2093 |
49 | #2095 |
wky shr | #2096 |
aud | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
child relations | #2112 |
nicotinic | #2112 |
specific genetic | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
poorer | #2119 |
postpartum period | #2119 |
monoamine | #2119 |
relative age | #2119 |
84 | #2121 |
career | #2122 |
pgs | #2122 |
51 | #2122 |
sixth | #2124 |
identifies | #2126 |
pbls | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
episode schizophrenia | #2137 |
dbh | #2137 |
psychosocial factors | #2140 |
interpretability | #2141 |
adversities | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
intraclass | #2147 |
receptors adrenergic | #2147 |
105 | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
232 | #2150 |
represents | #2150 |
glutamatergic | #2150 |
finemapping | #2150 |
repositioning | #2151 |
assessing | #2151 |
mao | #2153 |
rrr | #2153 |
psychiatric patients | #2155 |
abdominal obesity | #2164 |
differentiated | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
genetic association studies | #2168 |
differential diagnostic | #2168 |
differing | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
mb | #2171 |
prevalences | #2171 |
adversely | #2171 |
severity | #2172 |
tardive dyskinesia | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
thought | #2188 |
computerassisted imaging | #2188 |
processing speed | #2189 |
differential expression | #2189 |
regular | #2192 |
generalized anxiety disorder | #2192 |
scale | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
lifecycle | #2197 |
conceptual | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
confounding | #2201 |
ages | #2201 |
double | #2205 |
brain mapping | #2206 |
developing brain | #2206 |
abstract background | #2207 |
ottawa | #2209 |
remained | #2209 |
169 | #2209 |
homozygosity | #2210 |
surveys questionnaires | #2210 |
accidents | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
completed | #2220 |
complex diseases | #2220 |
hippocampal formation | #2220 |
biologically | #2220 |
autism | #2221 |
val66met | #2222 |
cognitive task | #2225 |
visuospatial | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
novo mutations | #2263 |
cognitive deficit | #2263 |
earlier | #2264 |
cigarette | #2264 |
criterion | #2265 |
pathways | #2266 |
rewards | #2266 |
bds | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
cognitive development | #2275 |
axis | #2275 |
remain | #2275 |
gray matter volume | #2275 |
tend | #2276 |
imaging male | #2277 |
mtl | #2277 |
random allocation | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
moderation | #2283 |
lithium | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
physical health | #2294 |
regions | #2294 |
diverse populations | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
clinic | #2304 |
biology | #2304 |
239 | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
difficult | #2310 |
lupus | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
questionnaires | #2332 |
organ size | #2332 |
subset | #2333 |
mind | #2334 |
archives | #2335 |
covariate | #2335 |
disorganization | #2335 |
early risk | #2336 |
depression female | #2340 |
lesser extent | #2342 |
utility | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
providing | #2353 |
time perception | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
concurrently | #2368 |
limited evidence | #2368 |
smallest | #2369 |
symptoms schizophrenia | #2369 |
efforts | #2376 |
social cognitive | #2377 |
antipsychotic agents | #2379 |
catecholamine | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
gray matter | #2401 |
essence | #2401 |
frontal | #2403 |
pubmed | #2406 |
addictive | #2407 |
sirolimus | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
alternative | #2418 |
statistical significance | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
salience | #2426 |
disease genetic | #2426 |
143 | #2428 |
term outcome | #2429 |
bdnf | #2429 |
confounders | #2431 |
fmri data | #2431 |
protein interactions | #2433 |
241 | #2433 |
clinical trial | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
timepoints | #2448 |
dimorphism | #2448 |
items | #2449 |
multiple studies | #2450 |
mvr | #2452 |
deconvolution | #2452 |
prefrontal cortical | #2456 |
overweight children | #2456 |
systemic lupus erythematosus | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
logistic | #2461 |
traumatic stress | #2461 |
concordance | #2461 |
autosomes | #2462 |
sex distribution | #2464 |
crossover study | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unclear | #2473 |
unique | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
180 | #2496 |
hoc analysis | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
original | #2504 |
establish | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
thresholds | #2515 |
quotient | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
alterations | #2532 |
october | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
psychotic features | #2553 |
risky | #2553 |
depressive disorders | #2554 |
quantitative | #2555 |
exploratory study | #2555 |
neural responses | #2555 |
bipolar affective disorder | #2557 |
memory tasks | #2557 |
risk loci | #2560 |
chronological | #2560 |
income | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
numerous | #2573 |
30 years | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
elucidate | #2585 |
correction | #2585 |
problems | #2586 |
pvalues | #2586 |
brothers | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
disrupted | #2595 |
exist | #2595 |
229 | #2596 |
internalizing externalizing | #2598 |
brain response | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
advances | #2611 |
increased activation | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
multiple levels | #2624 |
evidence role | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
imaging studies | #2633 |
bdnf gene | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
global functioning | #2642 |
fetal alcohol | #2642 |
preschool female | #2644 |
genetic variants | #2644 |
behavior | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
periodicals | #2665 |
puzzle | #2665 |
n14 | #2666 |
089 | #2669 |
health disorders | #2669 |
genetic evidence | #2670 |
chromosome | #2670 |
88 | #2670 |
polysomnography | #2671 |
pcps | #2675 |
spectrum | #2675 |
partially | #2676 |
inconclusive | #2676 |
mediating | #2676 |
physiotherapy | #2678 |
memory tests | #2678 |
adolescent development | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
conditional | #2689 |
triad | #2689 |
age range | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
immaturity | #2698 |
evidenced | #2698 |
extended | #2700 |
chr | #2701 |
neurite | #2702 |
interrogation | #2702 |
attenuate | #2702 |
flares | #2703 |
delinquency | #2707 |
ext | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
occurring | #2714 |
aggressive | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
curve | #2731 |
teens | #2731 |
awakening | #2732 |
doubt | #2733 |
systematic literature review | #2733 |
thicker | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
patients bipolar disorder | #2760 |
naa | #2760 |
collaboration | #2760 |
gt | #2761 |
manifestations | #2762 |
4 years | #2765 |
unadjusted | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
preventive measures | #2777 |
25 | #2777 |
mechanisms underlying | #2783 |
clinical heterogeneity | #2783 |
children symptoms | #2784 |
bivariate | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
dna copy | #2791 |
411 | #2791 |
dyslexia | #2792 |
overt | #2794 |
neurotrophic factor | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
clinical experience | #2808 |
recognition visual | #2808 |
397 | #2809 |
monetary | #2809 |
misdiagnosis | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
indexes | #2823 |
circuitry | #2823 |
telephone | #2824 |
1300 | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
early recognition | #2839 |
discriminant validity | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
depression scale | #2863 |
continental ancestry | #2863 |
parenting parents | #2865 |
addresses | #2866 |
screened | #2866 |
mothers children | #2867 |
internal external | #2867 |
cognition humans | #2868 |
discordance | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
measure | #2884 |
appeared | #2884 |
citations | #2885 |
age differences | #2885 |
shifting | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
amph | #2916 |
cognitive control | #2916 |
biological mechanisms | #2919 |
institutes | #2919 |
variability | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
disorders sleep | #2942 |
causal relationship | #2942 |
distinct | #2946 |
disorders patients | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
overlaps | #2971 |
markers | #2971 |
models neurological | #2976 |
stratification | #2981 |
725 | #2983 |
qtl | #2983 |
weight height | #2988 |
investigators | #2989 |
imaging mri | #2991 |
attempts | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
centres | #3006 |
196 | #3006 |
377 | #3007 |
19th century | #3010 |
genetic variation | #3011 |
remission | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
difficulties questionnaire | #3039 |
symptoms patients | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
280 | #3061 |
pilot | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
brain health | #3107 |
076 | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
amygdala hippocampus | #3123 |
articles | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
383 | #3127 |
ptsd symptoms | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
european countries | #3146 |
nation | #3146 |
exploratory | #3150 |
99 | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
explanations | #3165 |
spd | #3165 |
functional consequences | #3166 |
biological processes | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
status humans | #3171 |
caution | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
imaging study | #3187 |
adolescents young adults | #3187 |
methyltransferase | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
attempt | #3202 |
initial treatment | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
gene polymorphisms | #3216 |
pathophysiological | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
scanner | #3229 |
discontinuity | #3229 |
situation | #3229 |
65 | #3235 |
depression study | #3236 |
htt | #3237 |
mediation analysis | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
caudate nucleus | #3265 |
publicly | #3265 |
17p | #3266 |
humans magnetic | #3266 |
interactive effects | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
longitudinal cohort | #3282 |
increased likelihood | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
synaptic function | #3306 |
clinical severity | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
clock gene | #3336 |
ambiguity | #3336 |
metropolitan | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
frontal regions | #3371 |
glycolysis | #3371 |
battery | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
impaired performance | #3386 |
typically developing | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
cnp | #3393 |
accounting | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
traumatic brain | #3405 |
depression symptoms | #3405 |
desirability | #3406 |
oxidase | #3411 |
pool | #3413 |
performing | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
experiencing | #3439 |
definition | #3439 |
exert | #3441 |
fluency | #3446 |
children mothers | #3448 |
showing | #3448 |
lca | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
cognitive behavioral | #3466 |
genomewide association study | #3466 |
hallucinations | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
methylation | #3477 |
remaining | #3477 |
behavioral response | #3478 |
irr | #3480 |
postmortem | #3482 |
transmission | #3482 |
slower | #3488 |
exposure pregnancy | #3489 |
convergent | #3489 |
lesser | #3489 |
epidemiological study | #3492 |
applying | #3492 |
alpha2 | #3497 |
083 | #3497 |
short stature | #3497 |
social behaviors | #3497 |
aged polymorphism | #3497 |
matched healthy | #3502 |
p002 | #3506 |
brain function | #3506 |
identifier | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
specificity | #3519 |
104 | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
constitutes | #3527 |
pediatricians | #3527 |
basis | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
preferentially | #3536 |
reliable | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
sleep wake | #3544 |
fact | #3544 |
cognitive behavioral therapy | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
preventive interventions | #3558 |
ecgs | #3558 |
neuronal function | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
mpfc | #3587 |
neurite outgrowth | #3587 |
crh | #3603 |
interrater reliability | #3604 |
cardio | #3606 |
major gene | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
methylation status | #3618 |
questions | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
posttraumatic stress | #3640 |
prior | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
neurotransmission | #3735 |
daily life | #3735 |
fifty | #3736 |
hapmap | #3737 |
depressed mood | #3737 |
population | #3738 |
therapy cbt | #3744 |
international | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
neurophysiological | #3758 |
333 | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
peers | #3787 |
promoter polymorphism | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
male marijuana | #3844 |
exchanger | #3844 |
developmental disorders | #3850 |
disease genes | #3850 |
children aged | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
208 | #3876 |
74 | #3876 |
influences | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
plasma membrane | #3898 |
neurology | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
specific factors | #3937 |
preexisting | #3937 |
frontal gyrus | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
factorial | #4000 |
categorization | #4000 |
preliminary evidence | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
diabetes risk | #4047 |
common variants | #4047 |
discussion | #4051 |
modeled | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
jointly | #4058 |
contextual factors | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
serotonin uptake | #4068 |
cag | #4068 |
magnetic resonance | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
heroin | #4090 |
study efficacy | #4090 |
clinical characteristics | #4096 |
lobe | #4098 |
temporal lobe | #4098 |
genetic variations | #4100 |
maternal depression | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
comprises | #4121 |
plausible | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
german | #4145 |
dosing | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
route | #4216 |
helpful | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
predict | #4253 |
gpcr | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
representative | #4263 |
trajectory | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
potential targets | #4315 |
adequacy | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
acute treatment | #4353 |
catechol | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
intolerance | #4378 |
mediate | #4378 |
066 | #4382 |
clarity | #4383 |
psychological adolescent | #4383 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
solving | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
diverse | #4413 |
survive | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
striatal dopamine | #4449 |
human studies | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
visits | #4516 |
valuation | #4516 |
disorders cognitive | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
considerable | #4540 |
postnatal day | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
higher level | #4553 |
employment | #4553 |
birth | #4564 |
preschool children | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
psd | #4587 |
neuronal differentiation | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
unmet | #4651 |
trouble | #4651 |
regression model | #4652 |
marriage | #4658 |
deliveries | #4660 |
centers | #4660 |
microsatellite | #4660 |
anterior cingulate cortex | #4661 |
243 | #4662 |
trajectories | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
vector machine | #4715 |
hazards models | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
unemployment | #4747 |
val | #4747 |
pons | #4753 |
cooperative | #4755 |
taiwan | #4757 |
drug | #4757 |
conflict | #4760 |
77 | #4760 |
tasks | #4762 |
portions | #4763 |
heavily | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
samples | #4791 |
noncarriers | #4791 |
sharing | #4795 |
publication administration | #4798 |
mp | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
modafinil | #4825 |
cognitive tests | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
cigarettes | #4881 |
subsamples | #4881 |
young age | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
hemispheric | #4949 |
delays | #4949 |
pooled analysis | #4951 |
powerful | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
selective attention | #5021 |
caucasians | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
probabilistic | #5039 |
discuss | #5039 |
distinguish | #5040 |
correct | #5040 |
auc | #5047 |
cingulate gyrus | #5047 |
anxiety depression | #5047 |
sga | #5050 |
convergent validity | #5051 |
marital | #5051 |
early | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
09 | #5101 |
reached | #5101 |
screening | #5104 |
103 | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
mediation | #5132 |
single nucleotide polymorphisms | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
difference | #5146 |
inherent | #5146 |
involves | #5147 |
pharmacogenomics | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
disability | #5193 |
238 | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
molecular biology | #5215 |
remains | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
trend | #5295 |
billion | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
individual level | #5345 |
social interactions | #5345 |
predictive tests | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
higher frequency | #5380 |
penetrance | #5380 |
lost | #5382 |
suicide attempts | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
label | #5403 |
37 | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
risk individuals | #5468 |
york | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
verbal fluency | #5525 |
promoter regions | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
modulate | #5547 |
155 | #5547 |
closely | #5549 |
elevated | #5549 |
prevention | #5551 |
flanking | #5552 |
restraint | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
baseline treatment | #5565 |
frontal cortex | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
mediators | #5579 |
240 | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
lower risk | #5663 |
perinatal | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
1999 | #5686 |
40 years | #5686 |
gene variants | #5687 |
vbm | #5688 |
markov | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
databases | #5696 |
normal | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
thirty | #5728 |
focused | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
nerve net | #5827 |
98 | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
council | #5910 |
imputation | #5910 |
appendix | #5916 |
characterizing | #5917 |
activity level | #5919 |
broad | #5919 |
ethics | #5923 |
parietal | #5925 |
linked | #5928 |
region | #5928 |
statement | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
moderating role | #6005 |
rois | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Rapport d'exécution | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Connu pour Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Connu pour Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Connu pour Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Connu pour Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Connu pour Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Connu pour Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Connu pour Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Connu pour Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Connu pour Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Connu pour Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Connu pour Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Connu pour Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Connu pour Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Connu pour Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Des personnes clés pour Hyperactivity Disorder
Stephen V Faraone∗:Impact expert
Concepts pour lesquelsStephen V Faraone∗a une influence directe:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:Impact de Kol
Concepts liés au travail d'autres auteurs pour lesquelsfor which Stephen V Faraone∗ a une influence:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
Est-ce votre profil? Réclamez votre profil Copier le lien ENCHED LIEN À VOTRE PROFIL |